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ABSTRACT 
The ability of dendritic cells (DC) to be either tolerogenic or immunogenic offers many 
opportunities to manipulate DC function and genetically modify DC to promote allograft 
acceptance. However, the greatest challenge in DC gene therapy is the difficulty of 
achieving successful transfection. At present, DC-targeting gene delivery strategies are 
hindered by the lack of DC-specific target molecules. Therefore, the essential aim of this 
study is to isolate and identify peptides capable of targeting immature DC (iDC), in 
particular those that internalise well as they are likely to be more effective in gene 
delivery. 
Phage library of short cyclic peptides expressed on pIII protein of M13 filamentous phage 
was used first in selection against streptavidin. Phage bearing HPQ and HPM motifs were 
successfully isolated indicating the feasibility of the library in selecting streptavidin-binding 
peptides through specific biotin interaction. In order to develop a method for in vitro 
selection on cell surfaces, the library was used against a cell line expressing αVβ3 integrin. 
One phage clone with encoded sequence of CLSSPALLC bound to the cell surface and 
was taken up by the cells expressing the αVβ3 integrin. 
Using methods established in the previous panning, the library was panned against iDC, 
after two subtractive pannings against PBMC and CD14+ cells. The phage isolated were 
characterised by using several methods including flow cytometric analysis and confocal 
microscopy. Two phage selected, DC4.25 and DC4.44 with encoded peptide sequences 
of CFPPTFPAC and CTPLLSPFC, respectively, have demonstrated the ability to bind to, 
and be internalised by, iDC. Soluble biotinylated peptides, which contain the encoded 
peptide sequences, were synthesised along with sequence-scrambled control peptides. 
Flow cytometric analysis detected non-specific binding of the monomeric peptides to iDC 
when used at high concentration. In an attempt to increase the binding avidity of the 
peptides to iDC, Streptavidin conjugated with Alexa-488® flurophore was used to form 
complexes with the peptides. However, flow cytometric analysis revealed that the 
complexes also bound non-specifically to iDC, as binding was also seen in control 
peptides. Streptavidin conjugated with HRP was then used to form complexes with the 
peptides, in order to increase the sensitivity of the binding assay. The results corroborated 
the previous findings, which showed that the peptides bound iDC non-specifically. 
The failure of the synthetic peptides to bind to iDC might be due to a number of reasons, 
including loss of cyclised conformation of the peptides during synthesis and insufficient 
incorporation of sequences that is essential and accountable for the binding, in the 
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synthetic peptides. However, this approach does offer the possibility of identifying cell 
binding peptides that may allow delivery of genes and other therapeutic or imaging 
agents. 
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1.0     INTRODUCTION 
1.1 Gene therapy 
Gene therapy is commonly defined as a treatment to correct defective genes 
responsible for disease development by transferring a functional normal copy of the gene 
into cells. Today, gene therapy has a broader definition i.e. the transfer of nucleic acids to 
treat or prevent a disease or reverse a pathological process by altering gene expression 
(Kay, 2011). For gene therapy to be successful, a therapeutic gene has to be delivered in 
an appropriate amount into target cells or tissues with no, or tolerable, side effects.  
From 1989 to 2011, the number of gene therapy clinical trials that have been 
approved worldwide is 1786, with 64% of the trials are conducted in the United States 
(Figure 1.1). Most of the trials are in Phase I, which designed to access the safety and the 
dosage level of a particular drug or approach in a small group of people. Apart from a 
small number being assessed in Phase IV, the rest of the trials are in Phase II and III 
where the assessment of efficacy and side effects are carried out in large group of people 
(Journal of Gene Medicine, © 2012 John Wiley and Sons Ltd, 
www.wiley.co.uk/genmed/clinical, updated in January 2012, accessed 1 April 2012).  
The field of gene therapy started to develop during 1960s and early 1970s 
(Friedmann, 1992). Gene therapy had a setback in 1999 when Jesse Gelsinger died 
within four days of receiving adenovirus-based gene therapy for treatment of partial 
ornithine transcarbamylase (OTC) deficiency (Hollon, 2000). OTC is a liver enzyme 
required for the safe removal of excessive nitrogen from amino acids and proteins 
(Thomas et al., 2003). Gelsinger death was due to multiple organ failure caused by 
anoxia and the autopsy report revealed that the adenovirus vector, which was injected 
into a hepatic blood vessel to reach liver, was found in other organs (Hollon, 2000; 
Sheridan, 2011).  
About a year later, what was first thought as a definitive cure of a disease by gene 
therapy turned out to be another hitch in the field. Two children who received treatment 
for X-linked severe combined immunodeficiency (SCID-X1) were reported to have a 
dramatic clinical improvement (Cavazzana-Calvo et al., 2000). In the period of 1999-2009, 
a total of twenty patients received treatment for SCID-X1. Unfortunately, between 23 and 
68 months later, five of them subsequently developed a T cell leukemic disease, caused 
by the activation of the LMO2 oncogene due to nearby -retroviral vector integration 
(Hacein-Bey-Abina et al., 2003; Hacein-Bey-Abina et al., 2010). Four patients recovered 
after chemotherapy, but one died (Fischer et al., 2010).   
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Figure 1.1 (A) Geographical distributions of gene therapy clinical trials (by country) and (B) 
Phases of gene therapy clinical trials. Most of the clinical trials of gene therapies are 
conducted in the United Stated (64%) followed by the United Kingdom (11.3%). Most of the 
trials are in Phase I, in which assessment on safety and dosage level of a particular approach 
is carried out in a small group of people. A small number of trials are being assessed in Phase 
IV (assessment of efficacy in various populations and side effects associated with long-term 
use carried out after marketing licence is granted). The rest of the trials are in Phase II and III 
where the assessment of efficacy and side effects are carried out in large group of people 
(Journal of Gene Medicine, © 2012 John Wiley and Sons Ltd, 
www.wiley.co.uk/genmed/clinical, updated in January 2012, accessed 1 April 2012).  
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For the past decade, gene transfer into cells or tissues has improved substantially 
due to many factors including refined vector systems and improved host-vector safety 
(Kay, 2011). Unfortunately, the safety of the vector is not the only concern in gene 
delivery as there are other hurdles that must be overcome to achieve successful gene 
delivery.  
 
1.2 Delivery barriers in gene transfer 
For successful delivery, vectors for gene delivery must be able to overcome a 
range of barriers. The first challenge in gene delivery is to ensure that the vectors are able 
to condense the DNA into a compact structure for cellular uptake and at the same time 
protect its cargo against rapid degradation by nucleases in the extracellular environment. 
Furthermore, as both DNA (due to phosphate groups within the backbone) and the 
plasma membrane are negatively charged, the vector/DNA complex must have a positive 
net charge to avoid electrostatic repulsion. To overcome these challenges, gene delivery 
vectors are commonly designed to be cationic. 
 However, in most cationic systems, aggregation of the complexes is a 
frequent problem when serum proteins, which are predominantly negatively charged, are 
present. Although serum reduction or complete removal from the media could solve this 
problem during in vitro transfection, this strategy is not applicable in an in vivo situation as 
presence of serum is inevitable. Covalent attachment of polyethylene glycol (PEG), a 
technique known as PEGylation, can provide a steric barrier against aggregation. It has 
also been reported that PEGylation increases water solubility (Parrott and DeSimone, 
2012) and reduce toxicity (Wang et al., 2009). Conversely, PEGylation obstructs positive 
charges resulting in a decrease in DNA binding and transfection efficiency (Oupicky et al., 
2002), and is associated with loss of biological activity (Veronese and Mero, 2008). 
Once taken up by the target cells, normally via endocytosis, the vector/DNA must 
disrupt the endosomal membrane and escape from the endosomes, or will face 
degradation in lysosomes. One strategy to accomplish endosomal escape is to buffer 
against the ATP-dependent proton pump located in the endosome membrane, an event 
popularly known as  the  “proton sponge effect” (Canton and Battaglia, 2012). A polymer 
such as polyethylenimine (PEI) has several unprotonated amines that can become 
protonated in the acidic environment of the endosomes (Boussif et al., 1995). As protons 
are pumped in, PEI absorbs the protons, which in turn trigger the influx of the negatively 
charged Cl- ions, causing osmotic overload within the endosomes (Won et al., 2009). This 
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leads to endosomal swelling, membrane rupture and the release of the contents into the 
cytosol (Yang and May, 2008). Another method to promote endosomal escape is by co-
incubation of cells with a lysosomolytic agent such as chloroquine (Yang et al., 2009). A 
more elegant approach to escape endosomes is by the creation of membrane disruptive 
peptides, which will be reviewed later.  
Ultimately, delivery of DNA to the nucleus must occur for transcription of the 
transgene to take place. Nuclear uptake has been demonstrated to be a substantial 
barrier to gene delivery. It has been reported that there are at least three possible routes 
of DNA transfer to the nucleus; either through the nuclear pores, DNA association with 
chromatin during mitosis or pass through the nuclear envelope (Wiethoff and Middaugh, 
2003). There have been several reports demonstrating the inclusion of specific sequence 
to the DNA to aid nuclear pore transport, including the attachment of nuclear localisation 
sequences (NLS) (Simeoni et al., 2003). Furthermore, it has been shown that nuclear 
targeting can be done in cell-specific manner. Vacik and his group have created reporter 
plasmids that are selectively expressed in smooth muscle cells by incorporating smooth 
muscle gamma actin gene promoter sequence in the plasmids. They have demonstrated 
that when these plasmids were injected into the cytoplasm, they localised in the nucleus 
of smooth muscle cells, but remain in the cytoplasm of fibroblasts and CV1 cells (Vacik et 
al., 1999).  
 Recent reports have revealed that less than 10% of plasmids delivered to the cell 
reach the nucleus for gene expression (Lam and Dean, 2010) and that nuclear delivery is 
a critical determinant of transgene expression level (Glover et al., 2010). Therefore, the 
ultimate challenge is to create a multifunctional vector that can conquer all barriers and 
yet, safe to use for therapeutic purposes. 
 
1.2.1  Vectors for gene therapy 
In the past several years, numerous attempts have been made to engineer various 
gene delivery vectors in order to increase the efficiency of gene and drug delivery. 
Vectors for gene therapy can be broadly divided into two categories, viral and non-viral 
vectors (Lundstrom and Boulikas, 2003). However, these vectors have their own risks and 
limitations that hamper the success of the delivery of therapeutic genes. 
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1.2.1.1 Viral vectors 
Viral vectors have been used in almost 70% of gene therapy clinical trials (Journal 
of Gene Medicine, © 2012 John Wiley and Sons Ltd, www.wiley.co.uk/genmed/clinical, 
accessed 1 April 2012) and can be classed into two main categories; integrating vectors 
and non-integrating vectors (Sheridan, 2011). Integrating vectors, such as lentiviral 
vectors, insert their genomes into the host genome, while non-integrating vectors, such as 
adenovirus, adeno-associated virus and herpes virus, replicates in the nucleus after 
infection and exist episomally as extra chromosomal genetic element (Kay et al., 2001; 
Thomas et al., 2003).  
Non-integrating vectors may not be suitable to be used in the treatment of genetic 
disorders that require long-term gene expression but may be appropriate in treating 
diseases where only transient gene expression is required (Young et al., 2006). 
Integrating vectors, conversely, are the preferred choices when long lasting transgene 
expression needs to be maintained in dividing cells (Kay, 2011). Yet, integration does not 
guarantee a stable transcription as transgene expression from integrated vector genomes 
can be gradually silenced over time (Pannell and Ellis, 2001). Table 2.1 gives an overview 
of the advantages and disadvantages of some of the viral vectors used for gene therapy. 
Adenoviruses represent the most prominent delivery system used in gene therapy. 
This vector has packaging capacity of 7.5 kb, can be purified to high titres relatively easily 
and is very efficient in transducing most tissues (Kay, 2011). Nevertheless, they are the 
most immunogenic of all viral vector groups. Adenovirus can induce severe toxicity at the 
dosage levels that are required for efficacy, especially in humans (Thomas et al., 2003), 
as they trigger strong immune response against vehicle (capsid) and a secondary 
antigen-dependent response (transgene) (Hartman et al., 2008). 
Retrovirus vectors, the second most used viral vector in gene therapy, have the 
ability to integrate stably into the host genome (Walther and Stein, 2000). Most of the 
retroviral vectors currently in clinical use are based on Moloney murine leukemia virus 
(MMLV) (Sheridan, 2011). However, a major disadvantage of conventional retroviral 
vectors is their inability to infect non-dividing cells whilst retrovirus vectors based on 
Moloney murine leukemia virus (MMLV) can cause insertional mutagenesis associated 
with the murine leukemia viral vector (Hacein-Bey-Abina et al., 2008).  
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Table 1.1: Overview of the advantages and disadvantages of viral vectors used for gene 
therapy. Source: Gene Therapy Net (http://www.genetherapynet.com/viral-vectors.html, 
accessed 1 April 2012) and Thomas et al., 2003. 
 Adenovirus 
 
Retrovirus / 
Lentivirus 
Adeno-associated 
virus 
Herpes virus 
Genome dsDNA ssRNA (+) ssDNA dsDNA 
Gene size 38 – 39 kb 3 – 9 kb 5 kb 120 – 200 kb 
Infection/ 
tropism 
Dividing and 
non-dividing 
cells 
Dividing cells / 
Lentivirus also 
infect non-
dividing cells 
Dividing and non-
dividing cells 
Dividing and 
non-dividing cells 
Host genome 
interaction 
Non-
integrating 
Integrating Non-integrating Non-integrating 
Transgene 
expression 
Transient Long lasting Potential long 
lasting 
Potential long 
lasting 
Packaging 
capacity 
7.5 kb 8 kb 4.5 kb  > 30 kb 
Main 
advantages 
Extremely 
efficient in 
transducing 
most tissues 
Persistent gene 
transfer in 
dividing cells 
(retrovirus) / 
most tissues 
(lentivirus) 
Non-inflammatory 
and non-
pathogenic 
Large packaging 
capacity 
Main 
limitations 
Capsid 
mediates a 
potent 
inflammatory 
response 
Integration 
might lead to 
oncogenesis in 
some 
applications 
Small packaging 
capacity 
Inflammatory, 
transient 
transgene 
expression in 
cells other than 
neuron  
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This has stimulated interest in using lentiviruses as vectors because lentiviruses 
are able to infect both proliferating and non-proliferating cells (Young et al., 2006). The 
ﬁrst  clinical  trial  with  lentiviral  vector  (HIV-1 based vector for anti-HIV therapy) was 
approved in 2002 (Sinn et al., 2005) and so far, there is no evidence of oncogenesis due 
to lentivirus integration (Sheridan, 2011). A recent success in gene therapy involved the 
use of lentivirus to transfer a functional -globin gene to an adult patient with severe -
thalassaemia disorder (Cavazzana-Calvo et al., 2010). Such patients require blood 
transfusion as a result of defective haemoglobin production in the body.  It was reported 
that after 33 months of the gene transfer, the patient who has been on a life-long 
transfusion requirement since early childhood, has converted to transfusion independent.  
Another viral vector that has been widely used in gene delivery is the adeno-
associated virus (AAV). It is a small, single stranded, non-pathogenic DNA virus that 
requires a helper virus, such as adenovirus (Muzyczka, 1992) or herpes simplex virus 
(Buller et al., 1981), to replicate and thus mediate a productive infection. The facts that 
AAV is an infectious human virus with no known disease association that is easily purified 
to high titres and can infect both dividing and non-dividing cells (Kay, 2011), have made 
AAV a very attractive candidate as viral vectors for gene therapy. However, AAV-based 
therapeutics have some limitations including low probability of integration and small 
packaging capacity that is restricted to just over 4 kb (Coura Rdos and Nardi, 2007). 
Although there have been many improvements in the design of viral vectors, which 
has led to more success in gene delivery, it is essential to find alternative non-viral 
vectors with equivalent efficiency, if not higher, but more importantly with safer profiles. 
 
1.2.1.2 Non-viral vectors 
Non-viral systems for gene delivery have several potential advantages over viral 
vectors. Non-viral vectors are easier, more amenable to large-scale production as they 
are less expensive to manufacture, and potentially safer for clinical use due to their ability 
to be repeatedly administered (Li and Huang, 2000). Non-viral vectors were once 
restricted by transient expression and low gene transfer efficiency (Ohlfest et al., 2005). 
However, in the past decade there have been substantial progress and improvements in 
the development and application of non-viral vectors in gene therapy. 
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Non-viral methods to transfer genes can be broadly categorised as using physical 
or chemical approaches. The simplest way of the former is the direct injection of naked 
plasmid DNA into cells (Herweijer and Wolff, 2003), however, the DNA expression has 
been very low in comparison to other methods of transfection. Therefore, various physical 
manipulations have been used to improve the efficiency including electroporation (Heller 
et al., 2005) and gene gun (Lin et al., 2000) . 
Electroporation uses short high-voltage pulses to induce a transient cell 
membrane permeabilised state, in which molecules could be loaded into the cells (Gehl, 
2003) whereas by using gene gun method, DNA is coated with gold particles and then  
shot into cells or tissues (Lin et al., 2000). These physical approaches allow direct 
penetration through the cell membrane, bypassing the endosomal compartment and into 
the cytoplasm, thus avoiding enzymatic degradation (Niidome and Huang, 2002). DNA 
may also directly reach the nucleus when introduced using a gene gun. Reports have 
demonstrated an efficient uptake of DNA into mouse muscle (Rizzuto et al., 1999) as well 
as in skin (Lin et al., 2000) and liver (Kuriyama et al., 2000) when these methods were 
employed.  
Cationic lipid- and polymer-based systems are the most extensively studied 
chemical based non-viral vectors. The use of cationic lipid in gene delivery was first 
reported by Felgner in 1987 (Felgner et al., 1987), and is still one of the major techniques 
for gene delivery into cells. Cationic lipids contain a cationic head group attached to a 
hydrophobic domain by a linker (Morille et al., 2008) and the positively charged head 
group is crucial for the binding of nucleic acid phosphate group. They can be classified 
into various subgroups such as N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
chloride (DOTAP), N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
(DOTMA), neutral  complement  lipid  (also  called  “helper  lipid”)  dioleoyl 
phosphatidylethanolamine (DOPE) and cholesterol-based lipids (Nishikawa and Huang, 
2001).  
Because of their high positive charge, cationic lipids are able to interact 
spontaneously with negatively charged DNA. The DNA is condensed and becomes 
encapsulated within a lipid bilayer. However, some reports have demonstrated that 
instead of encapsulating the DNA, cationic liposomes bind along the surface of the DNA 
(Even-Chen and Barenholz, 2000), maintaining its original size and shape. The liposome-
DNA complex, known as a lipoplex, interacts with the cell membrane, endocytoses and 
the DNA is released into the cytoplasm. The cationic lipids also protect against 
degradation of the DNA by the cell. Lipoplexes were proven to be safe when locally 
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delivered at relatively low doses, hence, have been used in several clinical trials for the 
treatment of cancer (Noble et al., 2004) and cystic ﬁbrosis (Bragonzi and Conese, 2002; 
Gautam et al., 2002).  
Polyethyleneimine (PEI) and dendrimers are some examples of polymer-based 
vectors that are widely used in gene delivery. PEI polymers have been used as a carrier 
for gene delivery, for example, in human adipose tissue-derived stem cells (Ahn et al., 
2008) and in human lymphoma cell lines (Guillem et al., 2002). They are different in 
lengths and can be branched or linear. Breunig and co-workers have shown that linear 
PEI with low molecular weight was more efficient in transfection and less toxic than higher 
molecular weight PEI (Breunig et al., 2005). PEI can form complex DNA molecules readily 
and provide high transfection efficiency in various cell types (Morille et al., 2008), making 
them increasingly popular as a gene delivery vector. Furthermore, PEI polymers protect 
DNA from lysosome degradation by escaping to the cytosol from endosomes via the 
“proton sponge effect” and promote nucleic acid delivery to the nucleus once the complex 
DNA molecule is inside the cell (Akinc et al., 2005). 
Dendrimers are repeatedly branched spherical molecules radiating from a central 
core (Morille et al., 2008) and their transfection efficiency depends largely on the size and 
diameter of the dendrimers used. Once the dendrimer-DNA complexes have formed, the 
complex, which has net positive charges, will bind to negatively charged receptors. Upon 
internalisation, the dendrimers buffer the endosomes (Thomas and Klibanov, 2003), thus 
ensure the stability of the complexes and allows the intact DNA to be transported to the 
nucleus. Examples of dendrimers used in gene delivery are polyamines, polyamides or 
polyesters and polyamidoamine (PAMAM). PAMAM dendrimer has high transfection 
efficiency and has been used to transfer gene to corneal endothelium (Hudde et al., 
1999), activated vascular endothelium (Theoharis et al., 2009) and many others. 
 
1.3 Peptide-mediated gene delivery 
Peptide-mediated non-viral gene delivery has obvious advantages over other gene 
therapy strategies. Unlike viral vectors, peptides have greater biodegradability, 
biocompatibility, the synthesis can be automated and susceptible to scaling up. More 
importantly, the use of peptides as gene delivery vectors is advantageous over some 
other non-viral agents in that they can be target specific, thus increase the chances of 
therapeutic genes to be delivered and remain functioned.  
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1.3.1  Tat 
The transactivator of transcription (Tat) is the key protein in the activation of viral 
transcription (Sodroski et al., 1985a; Sodroski et al., 1985b; Chen, 1986). HIV-1 Tat 
protein, which is made up by 101 amino acids, is encoded by two exons. The first exon is 
located between residues 1-72, and encodes two functional regions, i.e. the cysteine-rich 
region (residues 22-37) and the highly basic region (residues 49-57 with six arginine and 
two lysines) (Sodroski et al., 1985a). The second exon encodes residues 73-101, which is 
responsible for viral infectivity (Jeang et al., 1999).  
In 1988, two independent groups discovered that Tat can be rapidly taken up by 
cells and subsequently activate the viral promoter (Frankel and Pabo, 1988; Green and 
Loewenstein, 1988). It was then reported that a 35-amino acid Tat peptide (residues 37-
72), which retains the basic residues, preserves the cellular delivery function of the full-
length Tat protein. This peptide is able to deliver covalently bound proteins such as 
horseradish peroxidase, -galactosidase, RNase A and domain Ill of Pseudomonas 
exotoxin A (PE) to several cell lines and tissues (Fawell et al., 1994). 
Interestingly, it was later demonstrated that a shorter peptide, Tat-(48-60) is more 
efficient than the full-length protein in crossing through the plasma membrane (Vives et 
al., 1997). Substitution or deletion of any basic residue within the Tat-(48-60) reduces the 
membrane translocation activity, suggesting that the net positive charge of the peptide is 
crucial for cellular uptake (Schmidt et al., 2009). To date, two most popular Tat sequence 
used in many studies are Tat-(47-57) and Tat-(48-60). 
Tat peptides have been shown to be able to deliver an extensive list of cargoes 
into the cells. For example, Albarran and co-workers constructed TAT-streptavidin (TAT-
SA) fusion protein and demonstrated that TAT-SA is capable of delivering large 
biotinylated enzymes into Jurkat T cells and NIH 3T3 cells (Albarran et al., 2005) with no 
significant loss of enzymatic function. The group further elucidated the uptake mechanism 
of TAT-SA and established that macropinocytosis as a major internalisation pathway, 
while clathrin-mediated endocytosis is partially involved (Rinne et al., 2007). 
Tat peptides have also been used to deliver plasmid DNAs. Oligomers of the Tat-
(47-57) peptide have been shown to efficiently compact plasmid DNA and mediate gene 
delivery to cells in culture 6 to 8-fold more efficiently than control peptides (Rudolph et al., 
2003). In addition, when standard cationic transfection reagents such as 
polyethyleneimine (PEI), Superfect, and LipofectAMINE was added into DNA pre-
condensed with Tat peptides, the transfection efficiency was further improved as 
     
  26 
compared to the standard vectors. Besides proteins and plasmid DNAs, Tat peptides 
have also been reported to direct the uptake of liposomes (Torchilin et al., 2001; Torchilin 
et al., 2003), phage vectors (Eguchi et al., 2001) as well as nanoparticles (Lewin et al., 
2000).  
In the context of immunotherapy, Tat peptides have been incorporated with tumor 
antigenic peptides and delivered into antigen presenting cells for T cell activation. For 
example, Wang and colleagues transduced covalently fused Tat peptide with a tumor 
antigen TRP2 peptide into dendritic cells. They demonstrated that the transduction 
successfully provided continuous peptide presentation on the cell surface for a prolonged 
T cell activation. Moreover, the immunisation of mice with cells loaded with such peptide 
not only resulted in complete protective immunity against B16 tumor, but also 
demonstrated significant inhibition of lung metastases in a 3-day tumor model (Wang et 
al., 2002). Another study has also shown that when a recombinant Tat peptide with tumor 
antigen, OVA was transduced into dendritic cell, the tumor antigen could also be 
presented on dendritic cell surface and mediated cytotoxic T lymphocte (CTL) responses 
(Shibagaki and Udey, 2002). 
 
1.3.2  Poly­L­lysine (PLL) 
PLL is a synthetic repeat of the amino acid lysine, able to condense DNA and 
readily biodegradable. Although, higher molecular weight PLLs have a greater net positive 
charge, thus, able to bind DNA tighter, they are more toxic than their low molecular weight 
counterparts (Mannisto et al., 2002).  
Amongst earliest evidence of the use of PLL in delivering plasmid to receptor 
specific cells was demonstrated by Wu and colleague in 1987. They demonstrated that a 
conjugate, which was formed by coupling asialoorosomucoid (ASOR) with PLL, was able 
to bind a reporter plasmid (Wu and Wu, 1987) and the complex was successfully 
delivered to hepatoma cell line expressing the asiaIoglycoprotein receptor, Hep G2, but 
not in SK-Hep 1 cells, which is receptor negative control cell line. 
Cellular uptake of PLL/DNA polyplexes is effective and has been reported to have 
a similar way of internalisation as the PEI/DNA complexes (Morille et al., 2008), but the 
transfection efficiency is weak as subsequent escape from endosomes into the cytoplasm 
remains a problem (Meyer et al., 2008). Therefore, several modifications such as the 
attachment of poly(ethylene)glycol (PEG) (Park et al., 2006) to the polymer have been 
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made to increase the gene delivery efficiency.  
Histidine residues have been incorporated into PLL to induce endosomal escape. 
It has been reported that a histidine-substituted PLL increases transfection efficiency 
without addition of any membrane-disrupting agents (Midoux and Monsigny, 1999). This 
partially histidylated PLL is able to become cationic at endosomal pH and by substituting 
a number of amino acids with histidine residues, maximal transfection efficiency was 
achieved.  
Over the years, the addition of histidine to fusogenic peptide has become 
increasingly popular. It has been reported that a peptide containing histidine, CHK6HC, 
can deliver up to a 10-fold increase in gene expression when compared with a non-
histidine-containing control peptide (McKenzie et al., 2000). It was also noted that the 
presence of histidine in the peptide provides buffering capacity in the absence of 
chloroquine. Another example of histidine incorporation in oligolysine peptide is 
K(16)GRGDSPC peptide, which has the ability to form condensed complex with DNA and 
can be internalised into cells by targeting the integrin receptor on the cells surface (Haitao 
et al., 2007). 
 
1.3.3  Target specific peptide    
In general, targeting peptides consist of short sequences of essential amino acid 
from larger proteins that are required for receptor recognition. This enables the peptides 
to bind the receptor with strong affinity and be internalised by target cells via receptor-
mediated endocytosis. In instances where they contain sufficient positively charged basic 
residues, these peptides can also condense the DNA, although covalently attached 
condensing agent usually executes this function. Some of these peptides are called cell-
targeting peptides (Vives et al., 2008) mainly because of the strong and specific 
interaction between the peptides with the exclusively over-expressed receptor cell lines. 
Presently, integrins are the most targeted families of receptors and extensively 
studied in gene delivery. Most of these integrin-targeting peptides contain the conserved 
arginine-glycine-aspartic acid (RGD) sequence. Integrin binding peptides can either be 
specific for a single integrin or bind a wide variety of integrin receptors. 
 Earlier work on RGD peptide was described by Koivunen and co-workers 
(Koivunen et al., 1993), who reported that a cyclic peptide with RGD motif, 
GACRGDCLGA, is capable in inhibiting the binding of RGD-expressing phage to 51 
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integrin as well as the attachment of the integrin-expressing cells to fibronectin. The 
inhibition is 10-fold more efficient than any of the linear RGD-containing hexapeptides. 
The same group later discovered that a cyclic nonapeptide, CDCRGDCFC, homed to 
tumors when injected intravenously into tumor-bearing mice (Pasqualini et al., 1997), 
suggesting that V-directed peptides can be useful in diagnostic and therapeutic tumor 
targeting.   
The 51 integrin-specific sequence CRRETAWAC (Koivunen et al., 1994) has 
been used as a part of a synthetic delivery system consisting of cationic liposomes (L), 
the integrin-targeting peptide (I) and plasmid DNA (D), also known as LID vector particles 
(Writer et al., 2006). The peptide component of LID contains the integrin sequence 
together with a K16 peptide that mediates the condensation of the DNA with glycine-
alanine linker ([K]16GACRRETAWACG). It has been demonstrated that the peptides 
themselves are effective in transfection, however, the transfection efficiency is further 
enhanced by the incorporation of cationic lipids (Hart, 2010).  
Another example of the incorporation of integrin-targeting sequence in a peptide 
construct has been described recently. The RGD integrin-targeting sequence, which was 
incorporated into K16 peptide, along with an intracellularly cleavable PEG-lipid 
formulation was used to deliver plasmids into mice bearing subcutaneous tumors 
(Tagalakis et al., 2011). Transfection in tumors by integrin-targeting peptides was 2-fold 
more efficient compared to the non-targeted counterparts. When interleukin-2 (IL-2) and 
IL-12 genes were administered intravenously using the system, a reduction in tumor size 
in treated animals was observed with long-term survival in one third of treated mice. 
 Besides integrins, endothelial cell-specific LOX-1 receptor has also been 
targeted. Up-regulation of LOX-1 in endothelial cells has been associated with 
hypertension and atherosclerosis. The identification of peptides LSIPPKA, FQTPPQL, 
and LTPATAI, which mediate binding to the extracellular domain of LOX-1, may be useful 
for targeted gene transfer aimed at dysfunctional endothelium (White et al., 2001). 
Another example of targeted receptor in gene delivery is epidermal growth factor 
receptor (EGF-R). A novel EGF-R peptide ligand (Leu-Ala-Arg-Leu-Leu-Thr) was recently 
identified from a virtual peptide library of putative EGF-R binding peptides using a 
computer-aided design approach (Song et al., 2009). The ability of the peptide-conjugated 
liposomes to bind cells in vitro and be internalised was demonstrated using EGF-R high-
expressing cancer cells, H1299. When delivered intravenously, the peptide-conjugated 
liposomes accumulated in the EGF-R-expressing xenograft tumor tissues, suggesting the 
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specificity of the ligand and the prospect of it being developed as a peptide-directed drug 
delivery system. 
 
1.3.4  Self­assembly peptide 
Self-assembly peptides are another gene transfer vector that have been studied 
recently. Such peptides have key features responsible for DNA binding, membrane 
penetration and buffering capacity to escape endosomes. For example, Seow and co-
author have designed tri-block oligopeptides consist of an octaarginine block (R8) for 
DNA binding and membrane penetration, a block of four histidines (H4) for buffering 
capacity and endosomal escape and a hydrophobic block consisting 5 hydrophobic amino 
acids (W5, F5 or I5) to improve cellular uptake and DNA complex formation (Seow and 
Yang, 2009). They have demonstrated that all three peptides could bind and protect DNA 
from enzymatic degradation (Seow et al., 2009). Furthermore, F5H4R8 peptide was able to 
deliver luciferase and GFP reporter plasmids into mouse corneal endothelial cells (MCEC) 
with higher efficiency than the control commercial PEI used. More significantly, a 
therapeutic gene IDO, which has been previously shown to prolong corneal allograft 
survival (Beutelspacher et al., 2006), was successfully transfected and shown to be 
functionally active and capable of inhibiting T-cell proliferation. 
 
1.4 Phage display technology 
Phage display describes a selection technique in which a library of peptides or 
protein is genetically fused to a coat protein of a bacteriophage. This results in the display 
of the fused protein on the surface of the phage virion, while the DNA encoding the fusion 
exists within the virion (Smith, 1985; Brissette and Goldstein, 2007). 
The first established method for displaying polypeptides on the surface of 
filamentous M13-derived bacteriophage was reported in 1985 by Smith (Smith, 1985). 
Smith was able to create a fusion protein by inserting foreign DNA fragments into 
filamentous phage gene III, without disrupting the pIII function. The fusion protein was 
incorporated into the virion, which displayed the foreign peptide in a form accessible to 
specific antibody to the peptide. Since then, phage display has been used as a powerful 
method to study peptide/ligand binding and in many other applications, which some will 
be mentioned later on. 
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1.4.1  Structure of the bacteriophage and its genome 
Filamentous phage are bacterial viruses that infect many gram-negative bacteria. 
In contrast to most bacterial viruses, filamentous phage are produced and secreted from 
infected bacteria without killing the host cell (lysis). The most common phage used in 
phage display technology are Ff (F-pilus specific) filamentous phage. There are three 
types of Ff class phage, namely f1, fd and M13. The Ff phage particle is about 6.5 nm in 
diameter and 930 nm in length. The genomes of these three phage are more than 98% 
identical (Barbas, 2001). The phage genome, which is circular single stranded DNA 
(ssDNA) of about 6400 nucleotides, encodes for 11 proteins and the function of each 
protein is as listed in Table 1.2. In short, three proteins are required for phage assembly 
(pI, pXI, pIV), three proteins (pII, pX, pV) are involved in the replication of the ssDNA, 
whereas another five proteins (pIII, pVI, pVII, pVIII, pIX) are the structural proteins that 
make up the phage particle (Rakonjac et al., 2011). 
There are about 2700 copies of the pVIII major coat protein, which is a 50 amino 
acid protein encoded by gene VIII. The pVIII proteins form a hollow tube that 
encapsulates the ssDNA. The pVIII has been reported to be oriented at a 20° angle from 
the particle axis and are overlapped like helical ‘fish scale’ (Russel, 1991). 
At one end, the phage is capped by 5 copies of each of pIII and pVI coat proteins, 
while the other end contains 5 copies each of pVII and pIX proteins (Sidhu, 2001). Both 
pVII and pIX are small hydrophobic proteins encoded by only 33 and 32 amino acids, 
respectively, whereas the pIII and pVI proteins are encoded by 406 and 112 residue, 
respectively (Barbas, 2001).  
pVII and pIX are incorporated into the virion at the beginning of assembly. pIII and 
pVI, which are added to the virion at the end of assembly, are required for the structural 
stability of the virion and also for termination of assembly. In addition, pIII mediates entry 
of the phage into the host cell (Rakonjac et al., 1999).  
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Figure 1.2: The M13 bacteriophage particle. The single stranded DNA are encapsulated by 
approximately 2700 copies of pVIII capsid proteins. The phage is capped by 5 copies of each 
of pIII and pVI coat proteins at one end, while the other end contains 5 copies each of pVII 
and pIX proteins  
 
Table 1.2: F-specific filamentous phage genes, proteins and their functions. 
Gene Protein Function Location  
I I Assembly Inner membrane 
 XI Assembly Inner membrane 
II II DNA replication Cytoplasm 
 X DNA replication Cytoplasm 
III III Minor capsid protein Virion tip (end) 
IV IV Assembly (exit channel) Outer membrane 
V V Binding ssDNA Cytoplasm 
VI VI Minor capsid protein Virion tip (end) 
VII VII Minor capsid protein Virion tip (start) 
VIII VIII Major capsid protein Virion filament 
IX IX Minor capsid protein Virion tip (start) 
 
   pIII (5 copies) 
     pVI (5 copies) 
     pVIII (2700 copies) 
    pVII (5 copies) 
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1.4.2  The M13 life cycle 
The M13 phage use the tip of F pilus on E. coli as receptor or place of infection. 
Infection is initiated by the binding of phage pIII to the F pilus tip of E. coli (Deng et al., 
1999). The pilus then retracts, bringing the pIII end of the phage particle to the periplasm. 
Once the positive strand phage DNA enters the cytoplasm, the complementary strand is 
synthesised by bacterial enzymes and this formed a covalently closed, supercoiled, 
double-stranded DNA (dsDNA) called the parental replicative form (RF) (Barbas, 2001).  
By rolling-circle replication, in which two proteins, pII and pX are involved, a pool 
of progeny double-stranded RF are produced. The negative strand of the RF is used as 
template for transcription, and the mRNA are translated into all phage proteins. The only 
phage proteins residing in the cytoplasm are pII, pX and pV, while the rest of the proteins 
are synthesised and inserted into the outer membrane before being assembled into 
phage. 
 The synthesis of the RF DNA continues until pV reaches sufficient concentrations. 
At this point, pV coats the newly synthesised ssDNA and prevents its conversion to RF 
DNA (Kehoe and Kay, 2005). Only a small packaging signal (PS), which is involved in the 
initiation of assembly, is left free of pV. During assembly, pV dimers are removed from the 
ssDNA and the phage genome is coated with pVIII as it extruded through the membrane. 
pVII and pIX are incorporated into the end of the virion containing PS. As the virus is 
emerging from the infected cell, pIII and pVI are incorporated at the opposite end of the 
virion, while pIII also assists in the release of phage from the bacterial cell as completed 
virion (Russel, 1991). 
 
1.4.3  Display of peptides 
All five coat proteins have been used to display proteins or peptides (Sergeeva et 
al., 2006). However, the most commonly used coat proteins for phage display are the 
minor coat protein pIII (Smith, 1985; Kehoe and Kay, 2005) and the major coat protein 
pVIII (Felici et al., 1991). When pVIII and pIII are used for display, the sequence is usually 
inserted at the N-terminus, between the signal sequence and the start of the mature 
protein coding sequence (Lowman, 1997). The signal sequence, which is cleaved by 
signal peptidase during translocation, directs the N-terminus of the mature protein in the 
periplasm (Kehoe and Kay, 2005). Thus, in order for the peptide to be displayed on the 
surface, the sequence has to be inserted in frame, between the signal sequence and the 
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mature protein sequence. This has made the display of cDNA libraries as fusion to the N-
terminus of pIII and pVIII difficult, as there are stop codons in the full length cDNA. 
Moreover, direct fusion to the C-terminus of either coat protein is not feasible as C-
terminus of pIII is required for phage assembly while that of pVIII form the inside wall of 
the cylinder that encapsulates the phage genome (Barbas, 2001). 
An alternative approach is to fuse cDNA libraries to the C-terminus of pVI (Jespers 
et al., 1995; Jespers et al., 1996). Since pVI has no function in infectivity and the C-
terminus is thought to be exposed to the surface, the insertion of cDNA containing stop 
codons will not prevent display (Hufton et al., 1999). 
Another option to accommodate such cDNA or any large sequence, which could 
affect the function of the coat protein, is to use a phagemid/helper phage system. The 
fusion gene is inserted in a phagemid, which have a bacterial origin of replication and an 
antibiotic resistance marker that allow it to propagate as plasmid in E. coli (Mead and 
Kemper, 1988). In addition, it has a phage origin of replication and a phage packaging 
signal, which permits the production of ssDNA and packaging into phage particles 
(Georgieva and Konthur, 2011). 
Infection of bacterial host containing phagemid with helper phage activates the 
phage origin of replication. The helper phage provide the necessary phage proteins but 
are less efficient in packaging (Barbas, 2001). This resulted in the single-stranded 
phagemid DNA, which contain optimal packaging signal, being packaged in preference 
into phage particles using helper phage proteins. The display protein may be either wild 
type (derived from the helper phage) or recombinant (derived from the phagemid). 
Recently, a helper plasmid that expresses phage packaging proteins have been 
constructed, thus, eliminating the need for a helper phage in phage display (Chasteen et 
al., 2006). 
 
1.4.4  Valency of display 
There are two basic formats of peptide display in phage libraries, i.e. polyvalent 
and monovalent, and are related to the choice of display vector used. When the fusion 
gene is inserted directly into the N terminus of pIII or pVIII in the phage genome, every 
five copies or up to 2700 copies of the coat proteins, respectively, display the peptide 
(Smith, 1985; Barbas, 2001). This is termed as polyvalent display, in which the peptide is 
being displayed at each copy of the coat protein (Sergeeva et al., 2006). When the pIII-
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peptide fusion gene is incorporated into a phagemid, approximately one copy of the coat 
protein displays the fusion peptide and this is referred to as monovalent display (Rakonjac 
et al., 2011). However, when phagemid vectors are used for pVIII display, the peptide can 
be displayed polyvalently as the number of copies of the coat protein incorporated into the 
virion is usually more than one copy (Lowman, 1997). In general, polyvalent display is 
limited for small peptides as larger inserts interfere with the function of the coat proteins 
and reduce, if not abolish, the infectivity of the virus (Gad, 2005).  
The valency of display is important as it can discriminate binders of different 
affinities. For example, in polyvalent display, the phage has multiple-point attachment to 
the target molecule and this increases the chances of it binding to the target (Lowman, 
1997). Therefore, polyvalent display is suitable in selecting weak binder or low affinity 
target. On the other hand, monovalent display purely allows selection based on one-to-
one binding affinity (Lowman et al., 1991) and thus, avoids potential avidity effect 
observed in polyvalent display. Hence, monovalent display is more applicable in selecting 
the tightest binder from a library (Gad, 2005). 
 
1.4.5  Application of phage display 
The application of phage display technology has been seen to progress 
considerably in the past decade. By using different methods of screening, identification 
and characterisation of specific peptides bind to different target molecules in vitro as well 
as in vivo have successfully been made, such as in epitope mapping/vaccine 
development (Itoh et al., 2007; Li et al., 2008), receptors ligands (Lee et al., 2002; Du et 
al., 2006; Gasanov et al., 2006) as well as in drug discovery (Landon et al., 2004). This 
section will be discussed in more detail later. 
 
1.5 Dendritic cells 
Steinman and Cohn (Steinman and Cohn, 1973) first identified cells of dendritic 
morphology within murine spleen in 1973. Dendritic cells (DC) are professional antigen-
presenting cells that are critically involved in controlling the immune response. DC can be 
derived from bone marrow haematopoietic stem cell (CD34+), thus, termed myeloid (DC1) 
and from lymphoid (DC2) precursors (Pan et al., 2008), and can be classed as either 
immature (iDC) or mature (mDC). Maturation can be stimulated by different products, 
such as, bacterial lipopolysaccharide (LPS), interleukin (IL)-1β,  tumor  necrosis  factor 
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(TNF)-α,  pro-inflammatory cytokines granulocyte/macrophage-colony-stimulating factor 
(GM-CSF), IL-4 and interferon (IFN)-γ (McCurry et al., 2006). 
mDC express high levels of MHC class II and co-stimulatory molecules and are 
responsible for activating naïve T cells. Thus, mDC can be used to induce immunity to 
pathogens (Raftery et al., 2001; Castelli et al., 2004) or tumor-related antigens ((Pan et 
al., 2008). In contrast, iDC express lower levels of MHC class II and co-stimulatory 
molecules and are capable of inducing anergy (Wakkach et al., 2003) and regulatory T 
cells (Mahnke et al., 2007). Hence, iDC play a role in controlling autoimmune disease or 
transplantation (Nouri-Shirazi and Thomson, 2006; Morelli and Thomson, 2007). 
 
1.5.1  Dendritic cells and transplantation 
Organ transplant is the only form of treatment for most end-stage organ failure. To 
date, successful organ transplants depend largely on the use of potent 
immunosuppressive drugs to suppress the host immune responses in order to prevent 
rejection. Although the use of such drugs has been successful in preventing acute graft 
rejection, a long-term usage increases the risk for life-threatening infections and cancer, 
and chronic graft rejection still happen (Tan et al., 2006). The ability of DC to become 
tolerogenic has made it possible to use DC as therapeutic tools to improve or prevent 
graft rejection or graft-versus-host disease (GVHD). Tolerogenic DC present antigen to 
antigen-specific T cells, but unable to deliver sufficient co-stimulatory signals for effector 
T-cell activation and proliferation, thus promote tolerance in graft rejection (Morelli and 
Thomson, 2007).  
Graft rejection occurs after transplantation due to DC’s ability to present antigen to 
T cell through direct, indirect and semi-direct allorecognition pathways (van Kooten et al., 
2011). Direct allorecognition pathway has been strongly associated with acute graft 
rejection, which usually takes place over a period of days to week after transplantation, 
whereas the indirect pathway, which predominates at later times after transplantation, is 
the major cause of chronic graft rejection (Lechler and George, 2006). 
After transplantation, donor DC can migrate out of the graft and interact with 
recipient T cell by presenting intact donor MHC molecules through direct pathway. Under 
the influence of pro-inflammatory signals provoked by transplantation procedure, donor 
DC travel to secondary lymphoid tissue of the recipient (Lakkis et al., 2000). In the lymph 
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node, donor DC prime recipient T cells, causing migration of activated T cells to the graft 
and initiation of immune response, which bring about graft rejection.  
In addition, donor alloantigen can be picked up, processed by recipient DC and 
presented as a peptide on self MHC molecules to recipient T cells through indirect 
pathways. Indirect alloantigen results in alloresponses that are dominated by CD4+ T 
cells. However, the response is relatively delayed when compared with the direct pathway 
as longer time is needed for antigen processing (van Kooten et al., 2011).  
Harshyne and colleagues have reported that DC, especially immature DC, can 
physically extract plasma membrane and intracellular proteins from other live APC and 
lymphocytes in a cell contact-dependent manner (Harshyne et al., 2001). In addition, DC 
are capable of shedding soluble MHC molecules and membrane vesicles called 
exosomes that can be captured by other DC (Thery et al., 2002). Consequently, the ability 
of DC in acquiring antigen from other live cells has put forward the third allorecognition 
pathway i.e. the semi-direct pathway, in which recipient T cells could recognise donor 
MHC molecules after being transferred, intact, from the surface of donor cells to the 
surface of recipient DC (Herrera et al., 2004; Morelli and Thomson, 2007).  
Among  the  first  evidence  of DC’s  role  in  promoting  tolerance  in  transplantation, 
was a study by Fu and colleagues, whom demonstrated a single injection of immature 
donor-derived DC, 7 days before cardiac allograft transplant results in prolonged allograft 
survival in mice (Fu et al., 1996). Similarly, another group (Lutz et al., 2000) demonstrated 
that DC generated in low doses of granulocyte macrophage-colony stimulating factor 
(GM-CSF) in the absence of IL-4 are phenotypically and functionally resistant to 
maturation stimuli and they also demonstrated that pre-treatment with these DC 7 days 
before transplantation induced prolonged cardiac allograft survival.  
Apart from using donor DC that are rendered tolerogenic to prolong allograft 
survival, techniques involving recipient DC have also been developed. Interestingly, a 
significant prolongation of heart allograft survival in rats was reported when immature DC 
generated from recipient bone marrow progenitors were administered to recipients 1 day 
before transplantation (Peche et al., 2005). It has also been demonstrated that a 
combination of recipient-derived immature DC administration and suboptimal 
immunosuppression produced a striking synergistic effect in donor-specific allograft 
tolerance in rats (Beriou et al., 2005).  
Tolerogenic DC can also be generated through exposure of immunosuppressive 
agents such as rapamycin and aspirin. Rapamycin inhibits DC maturation by 
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lipopolysaccharide (LPS) in murine bone marrow-derived DC and impairs DC mobilisation 
and function in vivo (Hackstein et al., 2003). Furthermore, rapamycin-conditioned myeloid 
DC are impaired in IL-12p70 production and resistant to maturation following CD40 
ligation (Turnquist et al., 2007). It has also been reported that human DC when treated 
with aspirin have reduced expression of co-stimulatory molecules (CD40, CD80, and 
CD86), which are maintained even when challenged with cytokine or LPS (Buckland and 
Lombardi, 2009).  
Besides using immunosuppressive drugs exposure to generate toloregenic DC, 
DC have been genetically engineered to express immunosuppressive molecules. One 
example is indoleamine 2, 3 dioxygenase (IDO), which is an enzyme that catalyses the 
depletion of tryptophan (Kwidzinski and Bechmann, 2007), resulting the inhibition of T cell 
proliferation. IDO expression is inducible by the pro-inflammatory cytokine IFN-γ and to a 
lower extent by IFN-β in several cell types including macrophages, DC, and fibroblasts 
whereas in the brain, murine and human microglia have been shown to express IDO upon 
treatment with IFN-γ (Kwidzinski and Bechmann, 2007). 
Several studies have confirmed the role of this tryptophan-catabolising enzyme in 
the maintenance of immune tolerance. A study by Munn et al (Munn et al., 1998) revealed 
an early association between IDO and immune tolerance as they found out that inhibition 
of IDO during pregnancy in mice triggered tolerance breakdown and fetus rejection. Since 
then, many studies have been carried out to confirm the role of IDO in maintaining 
immune tolerance. One of such studies has demonstrated that IDO-expressing DC inhibit 
T cell proliferation via the local depletion of Trp or by synthesis of apoptotic kynurenine 
metabolites (Mellor and Munn, 2004). In addition, another group has shown that over 
expression of IDO, by genetically engineered DC, modulate T cell alloresponses in vitro 
and IDO gene transfer prolongs cardiac allograft survival (Li et al., 2007). These findings 
suggest that regulation of tryptophan catabolism by means of IDO over expression may 
be a useful approach in transplantation. 
Another example of genetically engineered DC to express immunosuppressive 
molecules is by inducing the expression of the cytotoxic T lymphocyte antigen 4 (CTLA-
4). Co-stimulatory molecules are essential for T cell activation. The most potent co-
stimulatory molecules known are B7, which are constitutively expressed on DC and exist 
as homodimers on the cell surface (Male et al., 2006). T cells express CD28, which 
ligates CD80/CD86 whereas its homolog CTLA-4 competes with CD28 for ligation of B7 
on DC. Binding of CTLA-4 to CD80/CD86 down regulates T cells and can lead to anergy. 
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It has also been shown that CD80/CD86-CTLA-4 interaction enhances the production of 
functional IDO (Morelli and Thomson, 2007). 
Tan and co-authors have reported the use of a modified CTLA-4 molecule, CTLA-
4-KDEL, to knock out the expression of B7 co-stimulatory molecules on DC (Tan et al., 
2005c). They demonstrated that there is no expression of CD80/86 on the surface of DC 
expressing this construct and this B7-deficient DC are tolerogenic in vitro. Moreover, they 
also found that the transfected DC do not up-regulate IDO, unlike cells treated with 
soluble CTLA-4-immunoglobin (Ig).  
All these methods of DC modification render its tolerogenicity, a key characteristic 
that has made DC an attractive target in promoting tolerance in transplantation. 
 
1.6 Gene delivery into dendritic cells 
Gene therapy has large potential in preventing graft rejection. Amongst many 
methods of modifying DC functions to favour tolerance induction is to use gene therapy to 
genetically engineer DC to prevent co-stimulatory molecule expression (Ehser et al., 
2008). However, gene delivery into DC was found to be difficult, regardless different 
methods, viral and non-viral, being employed to deliver a gene. At present, gene transfer 
into DC favours the use of viral vectors as they exhibit higher efficiency of gene transfer 
compared to that of non-viral gene delivery systems (Tan et al., 2005a).  
 
1.6.1  Virus­based delivery 
Adenovirus (Ad) vectors are so far the most efficient gene delivery system for DC. 
CD34+ or CD14+ derived DCs have been successfully transfected with Ad with efficiency 
ranging from 30% to more than 90%. Viral dose and the stage of DC maturation influence 
the expression level of the gene transferred (Timares et al., 2004).   
It has been well documented that the entry of Ad into target cells occurs in a two-
step event. First, the fiber knob of Ad particles attaches to the Coxsackie-adenovirus 
receptor (CAR) on the cell surface (Bergelson et al., 1997). The Arg-Gly-Asp (RGD) motif 
in the Ad-penton base then interacts with V3 or V5 integrins and allows virus–receptor 
complexes to enter clathrin-coated pits via endocytosis (Wickham et al., 1993). As DC is 
deficient in the expression of CAR (Tillman et al., 1999), several approaches have been 
developed to improve the Ad-mediated gene delivery into the cells. 
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Okada and co-workers modified the Ad-fiber knob to target the integrin on DC 
such that the Ad-RGD-LacZ could bind to murine DC in a CAR independent manner 
(Okada et al., 2001). The fiber mutant containing Ad-RGD-LacZ was reported to be more 
efficient in delivering the LacZ gene compared to that by conventional Ad vector, resulted 
in high gene expression in murine DC lines and normal human DC. It was further 
demonstrated that the AdRGD vector increased transduction efficiency significantly in 
mouse bone marrow-derived DC and caused more maturation in DC than conventional 
Ad infection (Okada et al., 2003). 
Ad vector has also been modified to target CD40 marker expressed on DC 
surface. The CD40-targeted Ad mediated high efficiency luciferase gene transfer into 
monocyte-derived human DC and induced DC maturation as demonstrated by the 
increased expression of CD83, MHC and co-stimulatory molecules (Tillman et al., 1999). 
The same results were detected when murine DC were used (Tillman et al., 2000), 
exhibiting an attractive prospect of CD40-targeted Ad in gene delivery into DC. 
Besides adenovirus, lentivirus has also been used as a vector to transfer gene into 
DC. HIV-1-based lentiviral vector expressing enhanced green fluorescent protein (EGFP) 
has been shown to efficiently integrate and express the marker gene in monocyte-derived 
human DC without altering DC cellular phenotype (Chinnasamy et al., 2000). Other group 
has demonstrated the ability of third-generation self-inactivating (SIN) lentiviral vectors to 
deliver the GFP and CD40L genes into immature monocyte-derived human DC with an 
average transduction efficiency of 70% (Koya et al., 2003). It has been shown that the 
expression of the CD40L transgene promoted DC maturation as shown by the 
upregulation of cell surface markers expression, which was not seen in cells transduced 
with control vector carrying GFP gene, indicating CD40L as the cause of the DC 
activation rather than the lentiviral transduction itself. 
Recently, another study was published which further corroborated the efficiency of 
SIN lentiviral vector in transducing monocyte-derived DC without inciting significant 
activation (Metelo et al., 2011). In specific, the group compared the transducing ability of 
several lentivectors pseudotyped with different envelopes [vesicular stomatitis virus G 
glycoprotein (VSVG), Ross River Virus glycoprotein (RRV), MLV-A, glycoprotein from the 
Ebola Zaire Virus (EboZ) and glycoprotein from the insect fusion virus Autographica 
californica (gp64)]. It was demonstrated that VSVG viral envelope is the most efficient 
pseudotype at transducing immature DC and their precursor monocytes. It was 
established that DC transduced with this pseudotype lentivector on days 0 and 2 of 
culture, preserved the immature phenotype and function, regardless the viral load, 
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suggesting that efficient transduction can be achieved at all stages of DC differentiation 
from monocytes. Conversely, other studies have shown that lentiviral transduction caused 
maturation of human and murine myeloid DC, via dose-dependent ligation of the Toll-like 
receptor (TLR) 3,7 and 8 pattern recognition receptors (Breckpot et al., 2007; Breckpot et 
al., 2010).  
 
1.6.2  Non­viral delivery 
 The fact that viral vectors can cause potent antiviral immune response limits its 
application in medical therapy. Moreover, viruses can activate iDC to become mDC (Tan 
et al., 2005b), making the effort to promote tolerance in preventing allograft rejection to be 
futile.  
 At present, non-viral delivery system gains growing interests from many 
researchers to be developed as a safer alternative to the viral system. However, most of 
the non-viral transfer methods have been proven to be rather inefficient. It has been 
reported that in general, physical transfection methods are more efficient in delivering 
nucleic acids into DC than the chemical transfection methods, although the former are 
potentially toxic to DC (Kikuchi, 2006). Examples of physical approaches in delivering 
gene into DC that are worth mentioned are electroporation and nucleofection.  
mRNA electroporation was used to transfect different types of human DC, 
including monocytre-derived DC, CD34 progenitor-derived DC and Langerhans cells while 
retaining their phenotype and maturation potential  (Van Tendeloo et al., 2001). More 
importantly, the expression level of transgene was higher compared to that transfected 
with lipofectin and the mRNA-transfected monocyte-derived DC was able to process and 
present the antigen, and induced antigen specific CTL response. 
A relatively new electroporation method, termed nucleoporation, was described by 
Lentz and co-workers, with up to 60% of reporter gene transfection efficiency been 
reported (Lenz et al., 2003). Nucleoporation is an electroporation-based method, which 
uses a combination of specific nucleofector solution and patented specific electrical 
parameters, was developed by Amaxa Biosystems (Cologne, Germany) (Gresch et al., 
2004). DC subjected to nucleoporation preserved most of the phenotypic characteristic 
and were able to secrete inflammatory cytokine when stimulated but were short-lived. 
Despite the fact that cells transfected using this method have limited survival over 48 
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hours, this system remains the only successful method to date in transferring gene into 
DC.  
 
1.6.3  Receptor­mediated delivery 
Receptor-mediated gene delivery represents an appealing approach in targeting 
gene into DC as it exploits the presence of specific receptors that are expressed on DC. 
Many receptors have been investigated, including mannose receptors, DEC-205, and 
CD11c. 
 
1.6.3.1 Mannose receptor 
Mannose receptors and mannose-receptor-related receptors are expressed 
abundantly on macrophages and dendritic cells (Jordens et al., 1999). They recognise 
carbohydrates such as mannose, glucose, fucose, N-acetylglucosamine and maltose, on 
the cell wall of infectious agents (Diebold et al., 2002). Upon ligand binding, the 
receptor/ligand complex is taken up by the cells by endocytosis and phagocytosis 
(Ezekowitz et al., 1990). The receptor then releases its cargo and is recycled and 
transported back to the cell surface, allowing another ligand to be internalised (Stahl, 
1992).  
Mannose PEI (ManPEI) conjugate is an example of a gene carrier exploiting 
mannose receptor in targeting gene into DC. It has been reported that in transfection of 
luciferase reporter gene, ManPEI delivered more than 50-fold more efficiently compared 
to using PEI alone (Diebold et al., 1999b). Control experiments using mannosylated 
bovine serum albumin (ManBSA) showed that ManBSA reduced luciferase expression by 
Man/PEI and that the binding of ManBSA and targeted gene delivery by ManPEI 
conjugated are receptor specific (Diebold et al., 1999a). 
It has been reported that the use of DOTMA/Man-C4-Chol/cholestreol liposomes 
(Man liposomes) has successfully induced a significant increase in gene transfection into 
DC compared to unmodified liposomes and naked DNA (Lu et al., 2007). Intraperitoneal 
administration of DNA condensed with this liposome demonstrated higher gene 
expression, with 3.5- and 12.5-fold more expression in macrophages and DC than 
injection of non-mannosylated lipoplexes, respectively (Hattori et al., 2006). 
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1.6.3.2 DEC-205 
DEC205, also known as C type-lectin endocytic receptor CD205, is an integral 
membrane protein homologous to the macrophage mannose receptor and binds 
carbohydrates (Jiang et al., 1995).  Upon ligand binding, the receptor/ligand complex is 
rapidly endocytosed by formation of coated pits and is delivered to multivesicular 
compartment that resembles the MHC class II containing vesicles.    
In mice, DEC-205 is expressed on cortical thymic epithelium, thymic medullary DC 
and subsets of peripheral DC (Shrimpton et al., 2009). In humans, DEC-205 is expressed 
at relatively high levels on myeloid blood DC, but in contrast to mice, expression is also 
present on monocytes and B lymphocytes, and at low levels on NK cells, plasmacytoid 
blood DC, and T lymphocytes (Kato et al., 2006). 
It has been shown that ovalbumin protein coupled to DEC-205 antibody was 
efficiently delivered to DC, presented on both MHC class I and II products of lymph node 
DC and led to CD4+ and CD8+ T cell tolerance rather than activation (Bonifaz et al., 
2002). It has also been shown that antigen-specific immune response was mediated 
when antibody-antigen fusion proteins combined with maturation stimuli were used to 
target DEC-205 in mice (Bonifaz et al., 2004). Mahnke and co-authors have demonstrated 
that delivery of melanoma tumor antigen tyrosinase-related protein-2 (TRP-2) and gp100, 
which target DEC-205, cured 70% of tumor-bearing mice (Mahnke et al., 2005).  
In human system, Tan and co-authors have demonstrated an improved delivery of 
plasmid DNA into monocyte-derived human DC by targeting the CD205 receptor on DC 
(Tan et al., 2005a). They have shown an increase in the binding of the immunolipoplexes 
containing anti-CD205 monoclonal antibodies as well as their internalisation compared to 
uncomplexed liposomes. The transfection efficiency of pCMV-EGFP plasmid by the 
immunolipoplexes was improved in both iDC and mDC when compared to commercially 
available liposomes, i.e. Tfx-50, Lipofectin and LipofectAMINE.   
Recently, DEC-205 was targeted using an anti-DEC-205scFv fused with MAGE-
A3 peptide (Birkholz et al., 2010). MAGE-A3 is a cancer-testis antigen, which is highly 
expressed in malignant melanoma, multiple myeloma, head and neck squamous cell 
carcinoma, lung carcinoma, and breast carcinoma, but not in normal tissues, except for 
testis (Gaugler et al., 1994). They have demonstrated that not only DC from healthy 
donors can be targeted, but also more importantly DC from malignant melanoma patients 
were efficiently loaded with the construct, suggesting possible clinical application of DEC-
205-targeting for the treatment of melanoma. 
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1.6.3.3 CD11c 
CD11c, which is present at high levels on DC, is a type I transmembrane protein, 
also known as integrin X and forms the complement receptor 4 with integrin 2 (CD18) 
(Kurts, 2008). In recent years, CD11c has been studied as a target molecule mainly in 
delivering antigen into DC.  In a study carried out by Castro et al., in vivo targeting of DC 
with autoantigen OVA coupled to Fab fragments of a hamster antibody specific for murine 
CD11c resulted in efficient antigen processing and presentation of MHC Class I and II and 
subsequently, robust CD4 and CD8 T cell responses (Castro et al., 2008).  
Others have shown that recombinant fusion protein, ScFv(CD11c)-TRP2, 
consisting of mouse tyrosine-related protein 2 (TRP2) peptide and CD11c-specific single-
chain fragment variable (scFvCD11c) has specific binding ability to DC and is capable of 
stimulating TRP2 peptide-specific T-cell activation and proliferation in vitro (Kou et al., 
2007). In addition, it has been established that recombinant CyaA toxoid can specifically 
target CD11c+CD8–CD11bhigh DC through CD11b integrin on the cell surface, in vivo and 
able to prime CTL response (Guermonprez et al., 2002). All these evidence substantiate 
the feasibility of using CD11c as a target molecule to drive the transfer of gene into DC. 
 
1.6.4  DC binding peptides 
DC binding peptides have been identified by using phage display techniques. To 
date, there have been limited reports on the use of phage display technology in isolating 
peptide against DC. Writer and co-workers have chosen two peptides isolated from 
panning of a random constrained 7-mer peptide phage display library against immature 
dendritic cells (DC) and integrated them into non-viral and viral vectors (Writer et al., 
2003). One of the peptides, which were synthesised in the form of [K]16GAC[X]7CG, 
increased the transfection percentage of human dendritic cell line when compared to a 
vector bearing an integrin-binding peptide. However, these peptides also increased gene 
delivery into other cell types rendering their non-specificity towards DC. The adenovirus 
bearing peptide vector on the other hand, demonstrated an increase in the percentage of 
positive DC for GFP over wild type virus.  
Another example is the work carried out by Curiel group using 12-mer peptide 
phage display library to select dendritic cells peptides (Curiel et al., 2004). The peptides 
were isolated after series of panning against several cell types prior to DC. The peptides 
were then fused to hepatitis C virus (HCV) non-structural protein 3 (NS3), which is an 
antigen proposed for HCV vaccines (Eckels et al., 2000). It was demonstrated that the 
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fusion peptides were able to bind to DC without altering the cells phenotype, efficiently 
presented to CD4 and CD8 T cells derived from HCV-positive blood cells and in turn, 
induced T cell activation and proliferation. 
 
1.7 Aims of this study 
At present, gene delivery into DC favours the use of viral vectors as they exhibit 
higher efficiency of gene transfer compared to that of non-viral gene delivery systems. 
However, these vectors are potentially immunogenic, hence, limiting their application in 
medical therapy. On the contrary, with non-viral gene delivery into DC reported so far, 
transfer genes with low efficiency and often without cell type specificity.  
The ability of DC to become tolerogenic has made it possible to use DC as a 
target in promoting tolerance in transplantation. At present, immunosuppressive drugs are 
used to suppress the host immune responses in order to prevent graft rejection. Thus, the 
ultimate goal in organ transplantation is to maintain immune tolerance and prevent graft 
rejection without or with minimal use of immunosuppressive drugs. 
The essential aim of this study was to develop a non-viral gene transfer strategy 
that target immature DC. Phage display was used as a strategy approach to identify 
peptides that target molecules capable of internalising on immature DC surface as such 
peptides are likely to be more efficient in gene delivery. 
The first aim of this study was to validate the phage library and the system by 
panning phage libraries of short cyclic peptides expressed on pIII protein of M13 
filamentous phage against streptavidin, which consensus motif are well known. The 
specificity of the selected streptavidin clones was then tested. 
The second aim was to develop a feasible and effective method for in vitro 
selection on cell surfaces. This step was important as this would test whether phage 
bearing specific binding motifs could be selected using whole cells as target. This aim 
was achieved by carrying out an in vitro selection of peptide phage against MCF7-αVβ3 
cell line, which stably expressed αVβ3 integrin, using the phage libraries. The ability of the 
phage selected to bind to and be internalised by the target cells were inspected. 
The third objective was to identify peptide phage capable of targeting immature 
DC using methods established in the previous aim. The ability and the specificity of the 
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selected phage to bind immature DC were assessed. The internalising property of the 
phage was also investigated. 
Lastly, the encoded peptide sequence of the phage that had been identified in the 
third objective were synthesised as free soluble synthetic peptides. The ability of these 
peptides to bind to immature DC was assessed as a prelude to their use in targeting gene 
therapy vectors. 
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2.0  MATERIALS AND METHODS 
2.1 Cell culture: cell lines, human dendritic cells and reagents 
2.1.1  Cell lines and reagents 
 All cell culture reagents and cell lines used in this study are summarised in Table 
2.1 and Table 2.2 below. 
Table 2.1: Cell culture reagents used in cell culture. 
Cell culture reagents Purchased from 
RPMI-1640  Invitrogen, Paisley, UK 
Dulbecco’s modified Eagle’s medium (DMEM)  Invitrogen, Paisley, UK 
Fetal calf serum (FCS) PAA, Pasching, Germany 
L-glutamine Cambrex, Workingham, UK  
Penicillin-Streptomycin Bio-Whittaker Lonza, Basel, Switzerland 
Trypsin-EDTA solution (0.05% Trypsin, 
0.02%EDTA) 
Invitrogen, Paisley, UK 
Bovine pancreas insulin  Sigma-Aldrich, Dorset, UK 
Plastic tissue culture flasks and plates Helena Biosciences, Sunderland, UK  
 
Table 2.2: Cell lines used in this study. MCF7‡ and MCF7-αVβ3‡ were kind gifts from Professor 
Costantino Pitzalis (Barts and The London School of Medicine and Dentistry). Others were 
obtained from American Tissue Culture Collection (ATCC). 
Cell line Description Culture medium 
MCF7‡  Human breast carcinoma epithelial cells. 
Adherent. (ATCC) 
DMEM  
MCF7-αVβ3‡ MCF7 cell line stably expressing  αVβ3 
integrin. Adherent. (Pereira et al., 2004) 
DMEM  
THP-1  Human leukemia monocytic cells. 
Suspension. (ATCC) 
RPMI-1640  
HEK293 Human embryonic kidney 293. 
Adherent. (ATCC) 
DMEM 
U-937 Human lymphoma monocytic cells. 
Suspension. (ATCC) 
RPMI-1640  
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 All growth medium was supplemented with 10% (v/v) heat-inactivated (56ºC, 30 
min) FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/ml streptomycin. Growth 
medium for MCF7 and MCF7-αVβ3 cells was also supplemented with 0.01 mg/ml bovine 
pancreas insulin. All cultures were maintained at 37oC in a humidified atmosphere 
containing 5% (v/v) CO2 in air. Trypsin-EDTA was used routinely when subculturing 
adherent cells and harvesting cell monolayers. Adherent cells were subcultured every 3-4 
days at 1:4 ratio while suspension cells were maintained by addition of fresh medium. 
 
2.1.2  Human dendritic cells 
2.1.2.1 Separation of PBMC from buffy coats 
 Peripheral blood mononuclear cells (PBMC) were isolated from blood donated by 
healthy volunteers (NHS Blood and Transplant, London, UK). Blood was extracted from 
the bag and diluted in sterile PBS with a ratio of 1:3. The blood was then layered slowly to 
avoid mixing over Lymphoprep (Axis-Shield, Scotland, UK) in 2:1 ratio, in 50 ml Falcon 
tubes (usually 30 ml blood to 15 ml Lymphoprep). The tubes were centrifuged at 800 g for 
20-30 minutes with no or low brakes. 
Using Pasteur pipette, the lymphocyte layer was collected from the interface layer, 
transferred to 50 ml Falcon tubes and topped up with sterile PBS. The tubes were 
centrifuged at 300 g for 20 minutes with brakes and the supernatant was discarded. The 
wash and centrifugation steps were repeated at 300 g for 20 minutes with brakes.  
When red blood cells were present in the pellet, 5 ml red lysis buffer (15 mM 
NH4CL, 10 mM NaHCO3, 0.1 mM EDTA, in water, pH 7.0) was added in and the mixtures 
were incubated at room temperature for 5 minutes. The mixtures were topped up with 
PBS and centrifuged at 300 g for 10 minutes at 4ºC. The addition of red lysis buffer was 
repeated when the pellet was still red in colour. The pellet was re-suspended fully in either 
medium or MACS buffer (PBS containing 0.5% [v/v] FCS, 2 mM EDTA). The PBMC were 
counted and either used immediately to subsequently generate CD14+ cells or frozen in 
filter-sterile freezing media (90% [v/v] FCS and 10% [v/v] dimethyl sulfoxide (Sigma-
Aldrich, Dorset, UK)) and kept at -80ºC for further use. 
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2.1.2.2 Generation of monocyte derived dendritic cells (DC)  
PBMC pellet, which had been washed once with MACS buffer, was re-suspended 
in 2 ml MACS buffer and 20 μl of CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) was added per 107 total cells. The cells and beads were mixed well and 
incubated on a roller for 20 minutes at 4ºC. Next, the cells were centrifuged and the 
pellets were washed twice with cold MACS buffer and subjected to centrifugation at 300 g 
at 4ºC for 10 minutes. The cells pellet was re-suspended  in 500 μl  of MACS buffer  for 
every 108 cells.  
Meanwhile, a Miltenyi column (MiltenyiBiotec, Bergisch Gladbach, Germany) of 
appropriate size was prepared by placing it in the magnetic field of a suitable MACS 
Separator and the column was rinsed with cold MACS buffer. Then, the cell suspension 
was passed through a pre-separation Miltenyi filter (MiltenyiBiotec, Bergisch Gladbach, 
Germany) to get rid of any cell clumps before passing through the column. 
The column was washed with MACS buffer three times and the total effluent was 
collected and labelled as CD14- cells. The column was then removed from the magnetic 
field. An appropriate volume of complete RPMI-1640 medium was added into the column 
(depending on the size of the column used) and immediately the column plunger was 
applied and pushed firmly to flush out the magnetically labelled cells fraction known as 
CD14+ cells. 
Subsequently, the CD14+ cells were counted and about 1 to 2 x 107 cells were 
plated in a T75 flask in 6 ml complete RPMI-1640 media supplemented with 20 ng/ml of 
granulocyte monocyte colony stimulating factor (GM-CSF) (First Link, Birmingham, UK) 
and 20 ng/ml of interleukin-4 (IL-4) (Invitrogen, Paisley, UK) to stimulate the differentiation 
of the monocyte to dendritic cells. The cells were added with 1 ml of complete media 
containing the required amount of GM-CSF and IL-4 every other day until day 5. 
 
2.2 Phage display 
Ph.D.-C7C™ Phage Display Peptide Library Kit was purchased from New England 
Biolabs (Ipswich, MA, USA) and consisted of disulpfide constrained heptapeptide phage 
display library (2 x 1013 pfu/ml), 1.5 mg/ml streptavidin, 10 mM biotin, E.coli ER2738 host 
strain and sequencing primers. The supplied E.coli host strain was plated and propagated 
on tetracycline-containing media while the cultures for infection were grown either in LB or 
LB-Tetracycline media. Other reagents used in phage display work are listed in Table 2.3. 
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Table 2.3: Reagents used in phage display work. 
Reagents Composition Purchased from 
LB medium Per liter: 10 g Bacto-Tryptone, 5 g 
yeast extract, 5 g NaCl 
 
Sigma-Aldrich, Dorset, UK 
LB agar 1 liter LB medium + 15 g/l agar 
IPTG/Xgal stock 1.25 g IPTG (isopropyl--galactoside) 
and 1 g Xgal (5-Bromo-4-chloro-3-
indolyl--galactoside) in 25 ml DMF 
(dimethyl formamide) 
IPTG and Xgal from Merck 
KGaA, Darmstadt, 
Germany 
DMF from Sigma-Aldrich, 
Dorset, UK 
PEG/NaCl  20% (w/v) polyethylyne glycol-8000, 
2.5 M NaCl 
 
 
 
All components from 
Sigma-Aldrich, Dorset, UK 
except ethanol from Merck 
KGaA, Darmstadt, 
Germany 
 
Tetracyclin stock 20 mg/ml in 1:1 ethanol:water 
Iodide buffer  10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 4 M NaI, stored at room 
temperature in the dark 
Top agar Per liter: 10 g Bacto-Tryptone, 5 g 
yeast extract, 5 g NaCl, 7 g agarose  
LB/IPTG/Xgal plates 1 liter LB medium + 15 g/l agar, 1 ml 
IPTG/Xgal added in when cooled 
NA 
RGD peptide phage  Peptide phage isolated from 
selection on αVβ3 integrin with 
CSPRGDHPC amino acid sequence 
(Lee et al., 2002) 
NA 
TE buffer  10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA 
 
All components were from 
Sigma-Aldrich, Dorset, UK TBS 50 mM Tris-HCl (pH 7 .5), 150 mM 
NaCl 
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2.2.1  Streptavidin Panning  
Streptavidin panning was carried out according to the manufacturer’s protocols. In 
general, 100 µg/ml streptavidin prepared in 0.1 M NaHCO3 (pH 8.6) was added into each 
well of a 96-well plate and incubated overnight at 4ºC with gentle agitation in a humidified 
container. The next day, the coating solution was poured off and each well was filled with 
blocking buffer (0.1 M NaHCO3, 5 mg/ml BSA, 0.02% [v/v] NaN3) and incubated at least 1 
hour at 4ºC. The blocking solution was then discarded and each plate was washed rapidly 
six times with TBST (TBS, 0.1% [v/v] Tween-20).  
Subsequently, 2 x 1011 phage (from the original library) that was pre-diluted in 100 
µl TBST was added into the coated plate and the plate was rocked gently for 1 hour at 
room temperature. The non-bound phage was discarded and the plate was washed ten 
times with TBST. Finally, the bound phage was eluted with 100 µl 0.1 mM biotin. The 
plate was rocked gently for 1 hour at room temperature and the eluate was transferred 
into a clean micro centrifuge tube. 
A small amount of the eluate was later titrated as described in section 2.2.3 and 
amplified as depicted in section 2.2.4. The amplified phage was used as the input phage 
in the subsequent round of panning. 
 
2.2.2  Panning against whole cells 
2.2.2.1 Plate panning 
 Panning against MCF7-αVβ3 cells was performed by using two approaches, i.e. 
plate panning and solution panning, which will be described in section 2.2.2.2 below. In 
plate panning, about 5 x 105 MCF7-αVβ3 cells were plated in a 24-well plate a day before 
and incubated at 37ºC in a humidified atmosphere containing 5% [v/v] CO2 in air. On the 
day of panning, the cells were washed twice with PBS, fixed with 4% [v/v] 
paraformaldehyde and incubated at room temperature for 20-30 minutes. After sufficient 
washes, the cells underwent similar routine of blocking and washing steps as described 
previously in section 2.2.1 streptavidin panning.  
 2 x 1011 phage (from the original library) was panned against the cells at 4ºC with 
gently agitation. The non-bound phage were removed from the plate and the cells were 
washed with TBST. Then, 400 µl of 0.2 M Glycine-HCl (pH 2.2), 1 mg/ml BSA was added 
to the cells and the plate was rocked gently for no more than 10 minutes. The eluate was 
     
  51 
transferred into a micro centrifuge tube and neutralised with 200 µl of 1 M Tris-HCl (pH 
9.1). 
A small amount of the eluate was later titrated as described in section 2.2.3 and 
amplified as depicted in section 2.2.4. The amplified phage was used as the input phage 
in the subsequent round of panning. 
 
2.2.2.2 Solution panning 
  Solution panning was carried out against MCF7-αVβ3 cells and DC in tubes that 
were pre-blocked with blocking buffer prior to panning step. 2 x 1011 phage was panned 
against 1 x 106 MCF7-αVβ3 cells for 2 hours at 4ºC on a roller to ensure good mixing. The 
cells were centrifuged at 800 g at 4ºC for 5 minutes and the pellets were washed six times 
with TBST before the elution of bound phage using 400 µl of 0.2 M Glycine-HCl (pH 2.2), 
1 mg/ml BSA. The elution mixture was incubated with the cells for no more than 10 
minutes on a roller and neutralised with 200 µl of 1 M Tris-HCl (pH 9.1). The cells were 
centrifuged and the supernatant was transferred into a clean micro centrifuge tube. 
 In panning experiment against DC, two subtractive panning against PBMC and 
CD14+ cells were included. Initially, 2 x 1011 phage from the library kit were panned 
against 108 PBMC for 1 hour at 4ºC. Then, the non-bound phage from this panning 
experiment were removed and used as the input phage to be panned against 107 CD14+ 
cells. Subsequently, after 1 hour, the non-bound phage from this selection were used to 
pan against DC. The phage and the cells were incubated at 4ºC for 2 hours. The rest of 
the procedures were as described in the previous paragraph. 
The eluate (unamplified phage) was titrated as described in section 2.2.3 and 
amplified as described in section 2.2.4. The amplified phage were titrated and used as the 
input phage for subsequent round of panning. 
 
2.2.3  Phage titering 
5-10 ml of LB was inoculated with a single colony of the supplied host cells and 
incubated with shaking until mid-log phase (OD600~ 0.5). Meanwhile, Top agar was melted 
in a microwave, 3 ml was then dispensed into 15 ml Falcon tube (one per expected phage 
dilution) and kept at 45ºC until use. 10-fold serial dilutions of phage were then prepared in 
LB. Once the E. coli  cultures reached mid-log phase, 200 µl culture was dispensed into 
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micro centrifuge tubes (one for each phage dilution). Subsequently, 10 µl of each dilution 
was added to each tube containing E. coli culture. Then, the infected cells were 
transferred into a culture tube containing Top agar, vortexed briskly, and immediately 
poured onto a pre-warmed LB/IPTG/Xgal plate, spreading the top agar evenly. The plates 
were left to cool, then inverted and incubated overnight at 37ºC. 
The next day, the plates were inspected, blue plaques were counted on plates 
having less than 200 plaques and the phage titer was determined. In order to get phage 
titer in plaque forming units (pfu) per 10 µl, each number of plaque counts was multiplied 
by the dilution factor for that plate. This value was then used to calculate an input volume 
corresponding to 2 x 1011 pfu for subsequent panning.  
  
2.2.4  Phage amplification 
An overnight culture of ER2738 in LB-Tet was diluted 1:100 in 30 ml LB in a 250 
ml flask and the unamplified phage was added into it. The culture was shaken at 37ºC, at 
200 rpm for 4.5 hours. Then, the culture was transferred to a centrifuge tube and spun for 
10 minutes at 4ºC at 12,000 g. The supernatant was transferred to a fresh tube and re-
spun. Next, the upper 80% of the supernatant was transferred into a fresh tube and 1/6 
volume of PEG/NaCl was added into. Phage was left to precipitate at 4ºC, on a roller, 
overnight.   
The overnight phage in PEG/NaCl solution was spun for 15 minutes at 12,000 g at 
4ºC, the supernatant was decanted and the residual supernatant was removed 
completely using a pipette. The pellet was then re-suspended in 1 ml TBS, transferred 
into a micro centrifuge tube, spun for 5 minutes at 4ºC to pellet residual cells. The 
supernatant was transferred into a new tube and re-precipitated with 1/6 volume 
PEG/NaCl. The tube was incubated on ice for 1 hour before subjected to centrifugation at 
4ºC for 10 minutes. The tube was re-spun after removal of the supernatant to eliminate 
any residual supernatant. Finally, the pellet was re-suspended in 200 µl TBS, spun for 1 
minute to pellet any insoluble matter. The supernatant (amplified phage) was transferred 
into a new tube and stored at 4ºC. 
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2.3 Characterisation of Binding Clones 
2.3.1  Plaque amplification and rapid purification 
 Plaques from the 3rd, 4th and 5th round of panning were selected to be 
characterised, as clones from the third round were reportedly sufficient to detect 
consensus binding sequence (Ph.D.-C7C™ Phage Display Peptide Library Kit manual, 
New England Biolabs). 2 ml of diluted ER2758 overnight culture (1:100 in LB) was 
dispensed into 15 ml Falcon tubes, one for each clone to be characterised. A blue plaque 
was stabbed using a sterile wooden stick or a pipet tip and transferred to a tube 
containing diluted culture. The tubes were incubated at 37ºC with shaking at 200 rpm, for 
4.5 to 5 hours. Then, the culture was transferred to a micro centrifuge tube and spun for 
30 seconds. 500 µl of the upper supernatant was transferred into a fresh tube while the 
remaining supernatant was transferred into another fresh tube and re-spun. Next, the 
upper 80% of the supernatant was transferred into a fresh tube and kept at 4ºC for 
several weeks as amplified phage or kept at -20ºC as glycerol stock (1:1 dilution with 
sterile glycerol). 
 200 µl PEG/NaCl was added into the 500 µl supernatant that was removed after 
the first centrifugation, mixed properly and left at room temperature for 10 minutes. Then, 
the tube was centrifuged for 10 minutes at 12,000 g, the supernatant was discarded and 
the tube was re-centrifuged to eliminate any remaining supernatant. Next, the pellet was 
thoroughly re-suspended in 100 µl iodide buffer and 250 µl ethanol was added into the 
mixture. The tube was then centrifuged for 10 minutes and the supernatant was 
discarded. 
Finally, the pellet was washed in 70% ethanol and dried briefly before being re-
suspended in 30 µl TE buffer. 5 µl of the re-suspended template was sent for sequencing. 
The sequence of the -96 primer, which was used in the sequencing, is shown in Table 
2.4. The amino acid sequence of the clones isolated was then determined using the 
genetic code shown in Figure 2.1. 
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Table 2.4: The sequence of primers used in phage DNA sequencing and PCR. 
Primer Sequence (5’-3’) 
-96 sequencing primer 5´- CCC TCA TAG TTA GCG TAA CG –3´ 
Forward PCR phage 5-TTA TTC GCA ATT CCT TTA GTG GTA CCT TTC-3’ 
Reverse PCR phage 5´-GCC CTC ATA GTT AGC GTA ACG ATC TAA AG-3´ 
 
   
Fi
rs
t P
os
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Second Position  
Third P
osition 
 T  C  A  G 
T 
Phe (F) 
Leu (L) 
Ser (S) 
Ser (S) 
Tyr (Y) 
Gln* (Q) 
Cys (C) 
Trp (W) 
T 
G 
C 
Leu (L) 
Leu (L) 
Pro (P) 
Pro (P) 
His (H) 
Gln (Q) 
Arg (R) 
Arg (R) 
T 
G 
A 
Ile (I) 
Met (M) 
Thr (T) 
Thr (T) 
Asn (N) 
Lys (K) 
Ser (S) 
Arg (R) 
T 
G 
G 
Val (V) 
Val (V) 
Ala (A) 
Ala (A) 
Asp (D) 
Glu (E) 
Gly (G) 
Gly (G) 
T 
G 
Figure 2.1: The genetic code used to determine the amino acid sequence of the clones 
isolated. 
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2.3.2  Polymerase Chain Reaction (PCR) 
 PCR was carried out using phage DNA that was isolated and purified in section 
2.3.1 as template to confirm the presence of peptide in the clone(s) isolated before the 
DNA was sent for sequencing. PCR reaction contained 1.5 µl of template (phage DNA), 
2.5 mM MgCl2 (Bioline, MA, USA), 100 nM dNTPs (Bioline, MA, USA), 0.5 µM of each 
forward and reverse primers, and 0.04 U of Taq DNA Polymerase (Bioline, MA, USA) in 
1X reaction buffer (25 µl final volume). The sequences of the forward and reverse primers 
used are as shown in Table 2.4. 
The reaction was then run for the following cycles; initial denaturation of 94ºC for 5 
minutes followed by 25-30 cycles of denaturation step carried out at 94ºC for 30 seconds, 
annealing step at 50ºC for 30 seconds, extension step at 72ºC for 40 seconds. Finally, 
additional extension step was carried at 72ºC for 5 minutes for 1 cycle.  
The PCR product was run on 2% [w/v] agarose gel containing ethidium bromide 
along with DNA Hyper ladder IV (Bioline, MA, USA) and viewed under UV 
transilluminator.  
 
2.3.3  Enzyme­Linked Immunosorbent Assay (ELISA) 
 ELISA was carried out in order to establish the binding ability of the selected 
phage clones towards the target protein/cells and to determine whether the selected 
clones were specific to the target or merely plastic binders.  
 
2.3.3.1 ELISA for streptavidin binding 
 To achieve this purpose, one row of ELISA plate wells (one row for each clone to 
be characterised) was coated with 200 µl of 100 µg/ml streptavidin prepared in 0.1 M 
NaHCO3 (pH 8.6). Additionally, another one row of wells was coated with 200 µl of 35 
mg/ml BSA prepared in 0.1 M NaHCO3 (pH 8.6) to test for binding of phage clones to 
BSA-coated plastic. The ELISA plate was incubated overnight at 4ºC with gentle agitation 
in an air-tight humidified box.  
On the day of experiment, streptavidin and BSA solution were shaken out of the 
plate and the plate was slapped face-down onto a paper towel. Each well was filled with 
blocking buffer, incubated at 4ºC with gentle agitation, for 1-2 hours. The blocking buffer 
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was shaken out of the plate and the plate was then washed 6X with TBST, slapped face-
down onto a clean paper towel each time.  
Four-fold serial dilutions of the phage were carried out in 100 µl TBST per well and 
the diluted phage were transferred into the wells. The plate was incubated at room 
temperature with agitation for 1 hour. The plate was washed 6X with TBST as before and 
100 µl of diluted mouse anti-M13-HRP conjugate antibody (1:5000 in blocking buffer) (GE 
Healthcare, Munich, Germany) was added into each well. The plate was incubated at 
room temperature with agitation for 1 hour. After subsequent washes, 100 µl of TMB 
solution was added to each well. Once the blue colour appeared at the required intensity, 
the reaction was stopped by addition of 50 µl of 0.1 N HCl. The plate was read at 450 nm 
absorbance. 
 
2.3.3.2 Cell-based ELISA 
 Cell-based ELISA was carried out in order to assess the binding ability of phage 
clones selected against MCF7-αVβ3 cells. In this method, approximately 2 to 4 x 104 
MCF7-αVβ3 cells were seeded in a row of wells of a flat bottom 96-well culture plate a day 
before. The cells were then washed, fixed with 4% [v/v] paraformaldehyde for 20-30 
minutes at room temperature and washed with TBST prior for blocking. The serially 
dilution of phage, phage incubation with the cells and the rest of ELISA procedures were 
carried out as described previously in section 2.3.3.1. 
 
2.3.4  Single clone panning 
 Single clone panning experiments were carried out in order to further confirm the 
binding ability of selected phage clones towards the target cells. In this experiment, single 
phage clones were incubated with the target cells for 2 hours at 4ºC on a roller to ensure 
good mixing. The cells were centrifuged at 800 g, at 4ºC for 5 minutes and washed three 
times with PBS. The bound phage were eluted using 200 µl 0.2 M Glycine-HCl (pH 2.2), 
left at room temperature for no more than 10 minutes before subjected to centrifugation. 
The supernatant was transferred into a micro centrifuge tube and neutralised with 100 µl 
1 M Tris-HCl (pH 9.1). The neutralised phage were then titrated as described in section 
2.2.3. 
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2.4 Flow cytometry 
 In this study, flow cytometry was used to determine the expression level of cell 
surface receptor of cells before the cells were used in panning selection. In addition, it 
was also used as a method to confirm the binding ability of phage clones and later the 
biotinylated synthetic peptides towards target cells.  
Staining of cell surface receptors was done either by direct staining in which, cells 
were stained with antibody conjugated with specific fluorescence, or by indirect staining 
by using unlabelled primary and fluorescently labelled secondary antibodies. Appropriate 
isotype controls were also included to validate the results. 
In general, approximately 1 x 106 cells were plated in a V-bottomed 96-well plate 
(Nunc, Roskidle, Denmark) and incubated with 2-3 µg/ml of fluorescently labelled or 
unlabelled primary antibody, diluted in PBS. The plate was wrapped in an aluminium foil 
and incubated on ice for 45 minutes. Then, the plate was subjected to centrifugation at 
800 g at 4ºC for 3 minutes to pellet the cells. The cells were washed 3 times with PBS 
and the plate was flicked to remove the supernatant. When direct staining protocol was in 
use, the cells were directly collected after antibody incubation and wash. 
Subsequently, in experiments using indirect staining protocol, the cells were 
stained with 1-3 µg/ml of fluorescently labelled secondary antibody diluted in PBS. The 
cells were incubated on ice for 30 minutes and then centrifuged at 800 g at 4ºC for 3 
minutes. After three times wash, the cells were finally collected, re-suspended in FACS 
buffer or PBS and transferred to a FACS tube for immediate analysis or re-suspended in 
cold FACS fixative buffer (PBS containing 5% [v/v] heat inactivated FCS, 0.1% [v/v] 
sodium azide, 1% [v/v] paraformaldehyde) and wrapped in an aluminium foil for later 
analysis. 
 Flow cytometry was carried out using FACS Calibur (Becton Dickinson 
Immunocytometry Systems, California, USA). FITC and AlexaFluor 488 were detected on 
FL-1 channel and PE was detected on FL-2. The data were analysed using FlowJo 
version 8.4.5 software (Tree Star, Oregon, USA) and the data were expressed in form of 
percentage of positivity or Mean Fluorescence Intensity (MFI). 
 In experiments where flow cytometry was used to determine the binding ability of 
isolated phage towards target cells, 5 x 105 cells were firstly mixed with 1 x 1011 phage in 
a tube. The mixture was incubated at 4ºC on a roller for 2 hours to facilitate binding, then 
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centrifuged at 800 g at 4ºC for 5 minutes and washed several times with cold-PBS prior to 
incubation with antibodies.  
 In experiment where flow cytometry was used to determine the binding ability of 
biotinylated synthetic monomeric peptides towards DC, 5 x 105 DC were incubated with 
various concentrations of monomeric peptides for 45 minutes at 4ºC on a roller to ensure 
good mixing. The cells were centrifuged at 800 g at 4ºC for 3 minutes, washed with PBS 
and incubated with 1 µg streptavidin conjugated with Alexa 488® fluorophore (strep488) 
(Invitrogen, Paisley, UK) for 20 minutes at 4ºC. The cells were washed once with cold-
PBS before collection for flow cytometric analysis.  
 In experiments carried out to establish the binding of peptide-strep488 complexes 
towards DC, various concentrations of the complexes were mixed with 5 x 105 DC and the 
mixture was incubated at 4ºC for 45 minutes. The mixture was centrifuged at 800 g at 4ºC 
for 3 minutes, washed once with cold-PBS and immediately analysed using flow 
cytometry. 
 
2.5 Coating cover slips with poly-L-lysine 
Cover slips were pre-treated with poly-L-lysine to facilitate the attachment and 
adhesion of cells, especially suspension cells, to cover slips surface. Cover slips were first 
cleaned with ethanol by soaking them for 5 minutes and air-dried. Once dried, the cover 
slips were soaked in poly-L-lysine for 10-15 minutes. The cover slips were thoroughly 
rinse with sterile tissue culture grade water and allowed to dry at least 2 hours before 
used.  
 
2.6 Immunostaining and confocal microscopy 
Since MCF7-αVβ3 cells are adherent cells, panning selection using these cells as 
target is probably best carried out when they are grown as monolayer. Nevertheless, it is 
crucial to ensure that in monolayer form, the antigen site on the cell surface remain 
undisturbed and free for interaction. Therefore, staining of cells grown on cover slips with 
anti-αVβ3 antibody was carried out and visualised under a confocal microscope.  
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Table 2.5 Primary antibodies (including isotype control antibodies) used in flow cytometry (FC) 
and confocal microscopy (CM). 
Antibody Concentration used Purchased from 
Mouse anti-αVβ3, clone LM609  2 g/100 l (FC),  
1:100 (CM) 
Millipore, CA, USA 
Mouse anti-M13  GE Healthcare, 
Munich, Germany 
Rabbit anti-EEA1 (Early Endosome 
Marker) 
1:100 (CM) Abcam, MA, USA 
Mouse IgG1 isotype control  2 g/100 l (FC),  
1:100 (CM) 
R&D System, MN, USA 
Mouse IgG2a,  isotype control  1:100 (CM) eBioscience, CA, USA 
 
Table 2.6 Secondary antibodies used in flow cytometry (FC) and confocal microscopy (CM). 
Antibody Concentration used Purchased from 
Alexa Fluor® 488 F(ab')2 fragment of goat 
anti-mouse IgG 
1 g/100 l (FC) 
1:100 (CM) 
Molecular Probes, 
Oregon, USA 
Alexa Fluor® 594 donkey anti-rabbit IgG 1:100 (CM) 
 
Table 2.7 Fluorophores-conjugated antibodies used in flow cytometry to determine DC profile. 
Antibody Conjugate Concentration 
used 
Purchased from 
Mouse anti-human CD14  
 
      PE 
 
 
         
 
           2 g/ml 
 
 
Caltag Laboratories, 
Buckingham, UK 
Mouse anti-human CD80  
Mouse anti-human CD86 
Mouse IgG1, isotype control 
Mouse IgG2a, isotype control 
Mouse anti-human CD11c           
     FITC 
DAKO Cytomation, 
Glostrup  Denmark 
Mouse IgG1,  isotype control eBioscience, CA,USA 
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Briefly, about 1 x 105 MCF7 control cells and MCF7-αVβ3 cells were plated on 
cover slips placed in a 24-well plate and incubated at 37ºC overnight. The next day, cells 
on cover slips were washed twice with PBS, fixed with 4% [v/v] paraformaldehyde and 
incubated at room temperature for 20-30 minutes. The cells were then washed three 
times with PBS and blocked with blocking buffer at room temperature for 1 hour. After 
sufficient washing, the cells were stained with the anti-αVβ3 antibody including the relevant 
isotype control. The cells were washed several times before incubation with the 
secondary antibodies and subjected to further wash afterwards.  
The cover slips were left at room temperature to dry and once dried, the cover 
slips were placed face down on a microscope slide, one cover slip for each slide. The 
edges of the cover slips were sealed with nail varnish and visualised under confocal 
microscope using Alexa 488 fluorochrome channel.  
Immunostaining and confocal microscopy were also carried out in order to assess 
phage internalisation. 2 x 105 cells were plated on a cover slip placed in a 12-well plate 
and grown overnight at 37ºC in a humidified incubator. When DC were used in the 
experiment, the cells were plated on poly-L-lysine treated cover slips (described in section 
2.5) and incubated for a few hours at 37ºC incubator to let the cells settled and adhered 
on the slips.  
Next, the medium was removed and the cells were washed with ice-cold PBS 
twice. Cold PBS was added into the well and 1 x 1011 phages were added into. The plate 
was incubated at 4ºC for 2 hours and then further incubated at 37ºC or at 4ºC for 1 hour. 
The cells were then washed with ice-cold PBS three times and fixed with 4% [v/v] 
paraformaldehyde at room temperature for 10 minutes. Next, the cells were washed three 
times with PBS, permeabilised with cold acetone at -20ºC for 3 minutes and washed with 
PBS three times for 5 minutes. The cells were then incubated with blocking buffer, which 
consisted of PBS, 1% [v/v] FCS, and 0.1% [w/v] gelatine, for 30 minutes at room 
temperature to block unspecific binding of the antibodies. 
After blocking, the cells were washed again twice with PBS and incubated with a 
mixture of two primary antibodies, either an isotype control (1:100) or a mouse anti-M13 
antibody (1:100) together with rabbit anti-EEA1 antibody (1:100) overnight at 4ºC. The 
next day, the cells were washed three times in PBS for 5 minutes each wash, incubated 
with a mixture of two secondary antibodies (1:100, each), which were raised in different 
species and with two different fluorophores, for 1 hour room temperature in the dark and 
washed again three times with PBS for 5 minutes each. 
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The cover slips were mounted with mounting media with DAPI, placed on a slide 
and sealed with nail varnish. The slide was analysed using Leica DMI5000 microscope 
and LAS AF version 2.4.1 build 6384 software.  
 
2.7 Recovery and titration of cell lysate 
This method was employed in order to assess the internalisation of phage by the 
target cells. This approach involved the recovery and titration of cell surface bound as well 
as endocytosed phage from within the cells. The cell surface bound phage were 
recovered in the stripping fraction after being stripped with stripping buffer. The cell 
lysates were also collected and titrated as they represent the endocytosed phage. 
In this experiment, 1 x 1011 single phage clones were incubated with 1 x 106 cells 
at 4C for 2 hours and subsequently at 37C for 1 hour to allow internalisation. The 
supernatant were removed from the cells and in experiment where DC were used, the 
cells were centrifuged at 800g for 5 minutes and the supernatant were removed. 200 μl of 
stripping buffer was added to the cells and incubated at room temperature for 10 minutes. 
The stripped fraction was recovered from the cells and 100 μl 1M Tris-HCl, pH 9.1 was 
added to neutralise the buffer. These fractions were kept at 4C until titrated.  
The cells were then lysed using 1X Lysis Buffer according to protocol described in 
section 2.8. Finally, the stripped fractions and the cell lysates were titrated as described in 
section 2.2.3. 
 
2.8 Preparation of cell lysates 
Cell lysates were prepared by using 1X Lysis Buffer (LB) (Promega, WI, USA) with 
some modification. 5X Lysis Buffer (LB) is a mild lysis agent and requires a single freeze-
thaw cycle to achieve complete cell lysis. However, in this study, the protocol has been 
optimised and two freeze-thaw cycles were carried out. 
In specific, 5X LB was diluted with PBS to 1X strength prior to use. 200 μl 1X LB 
was added into cell pellets, mixed well and incubated at -80C for 30 minutes, before left 
thawed at room temperature for 15 minutes. The cells were then re-incubated at -80C for 
another 20 minutes, and then left thawed at room temperature. The cells were kept on ice 
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for 2 minutes, then vortexed for 15 seconds. The cells were centrifuged at 12,000 g, for 2 
minutes at 4C. The cell lysates were transferred into clean tubes for further use. 
 
2.9 Peptide-strep488 complex making 
 In quest of establishing the ability of biotinylated synthetic peptides to bind iDC, 
peptides were used to form complexes with streptavidin conjugated with Alexa Fluor® 488 
(strep488) (Invitrogen, Paisley, UK) and streptavidin conjugated with horseradish 
peroxidase  (strepHRP) (Invitrogen, Paisley, UK). This was done to increase peptides 
binding avidity to the target cells.  
 Peptide-strep488 and peptide-strepHRP complexes were made by using ratio 
determined from HABA-Avidin assay described in section 2.10. In specific, the peptides 
were mixed with strep488 or strepHRP and incubated at room temperature, on a roller for 
30 minutes in dark. The complexes were kept cooled until use. 
 
2.10 HABA-Avidin  
 HABA-Avidin has been widely used as a standard assay to determine the level of 
biotin incorporation in a protein. The assay is based on the ability of the HABA dye to bind 
to avidin and of biotin to displace the dye. Free HABA dye (4'-hydroxyazobenzene-2-
carboxylic acid) has an absorption peak at 348 nm. When HABA binds to avidin, a yellow-
orange colored complex is produced, which has a strong absorption at 500 nm. Biotin 
binds non-covalently to avidin with high affinity (Kd=1x10-15 M). Since the affinity between 
HABA and avidin is relatively weak (Kd=5.8x10-6 M) compared to the affinity between 
biotin and avidin, biotin can easily displace HABA from HABA-Avidin complex. This 
results in a decrease of absorption at 500 nm and this change is directly proportional to 
the level of biotin in the sample. 
 Based on this principle, HABA-Avidin assay was used to optimise the formation of 
biotinylated peptide-streptavidin complex. Avidin was used instead of strep488 to simulate 
the complex making because the yellow colour of strep488 (due to Alexa 488 fluorophore) 
interfered with the absorption readings at 500 nm.  
 In this experiment, HABA solution (10 mM) was first made by adding 24.2 mg 
HABA (Thermo Fisher Scientific, Massachusetts, USA) to 9.9 ml of ultrapure water. To 
this mixture, 0.1 ml of 1 N NaOH was then added and stored at 4oC. 20 ml HABA-Avidin 
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solution was prepared by adding 10 mg Avidin to 600 µl HABA solution and PBS. The 
concentration of Avidin in this complex solution is 7.4 µM and was considered as 1 ratio 
concentration throughout the study.  
180 µl of HABA-Avidin solution was added into each well of a flat bottom 96-well 
plate. Increasing ratio concentration of biotinylated peptides (with respect to the ratio 
concentration of Avidin in the HABA-Avidin solution i.e. 1 ratio concentration = 7.4 µM) 
were added into the well and the total volume was adjusted to 200 µl with PBS. 
Increasing ratio concentration of biotin and DMSO were also included in the assay as 
positive and solvent controls, respectively. The plate was incubated at room temperature 
for 15 minutes on a reciprocal shaker and was read using a plate reader at 500 nm 
absorbance.  
 
2.11 Assessing peptide-strepHRP complex binding to DC 
 The binding of peptide-strepHRP complexes to DC was assessed by using a 
modified ELISA protocol. In specific, 1 x 105 DC were incubated with different 
concentration of cooled peptide-strepHRP complex (whose formation was as described in 
Section 2.9) at 4°C for 45 minutes on a reciprocal shaker to facilitate equal mixing. The 
cells were centrifuged at 800 g at 4°C for 3 minutes and washed twice with PBS. After the 
last washing, the cell pellets were re-suspended in 100 µl TMB substrate (Cell Signaling, 
MA, USA). After the desired signal was achieved, 100 µl STOP solution (Cell Signaling, 
MA, USA) was added into the well. The plate was centrifuged briefly to pellet the cells, 
150 µl of the supernatant was transferred into a clean plate and the plate was read at 450 
nm absorbance. 
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RESULTS 
3.0  CHAPTER 3 
3.1 In vitro phage display selection with streptavidin (control panning 
experiment) 
In 1990, Devlin et al. used libraries of random peptide sequences to isolate phage 
bearing specific binding molecules and found nine different streptavidin-binding 
sequences with a core consensus sequence of His-Pro-Gln (HPQ) (Devlin et al., 1990). 
They also found that biotin inhibited the binding of these phage to streptavidin, indicating 
the specificity of the phage towards the biotin binding site of streptavidin. Another group 
identified the consensus amino acid sequence motif EPDW using streptavidin as the 
target protein, also using phage display library. Binding inhibition experiment revealed that 
'streptag' peptide sequence (AWRHPQGG) inhibited phage with the EPDW consensus 
sequence binding to streptavidin (Caparon et al., 1996). 
The work in this chapter mainly described the ability of phage libraries of short 
cyclic peptides expressed on pIII protein of M13 filamentous phage (Ph.D.-C7C™ Phage 
Display Peptide Library Kit, New England Biolabs) in selecting peptide phage specific for 
known target and thereby validating the phage library and the system used. The selection 
against streptavidin was carried out to test its capacity to isolate streptavidin-binding 
peptide phage through specific biotin interaction site. 
 
3.1.1  Selection of HPQ bearing phage clones by streptavidin panning 
  The phage library was panned against streptavidin-coated plate for 2 hours and, 
after extensive washes, the bound phage was eluted using biotin and titered. The eluted 
phage were amplified and used in successive round of panning. Altogether, four round of 
pannings were carried out. It was found that the number of eluted phage increased about 
1-log fold from the 1st panning to the 2nd panning and 2-log fold from the 2nd panning to 
the 3rd panning, suggesting enrichment had taken place. Table 3.1 summaries the 
number of phage used for panning (input phage), phage recovered after panning 
(recovered phage) and phage amplified after every round of panning (amplified phage).  
After three rounds of selection, 10 clones were randomly picked from a plate that 
has less than 200 plaques and were amplified. The DNA of all 10 clones was extracted. 
Each clone was then characterised by PCR using forward and reverse PCR phage 
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primers (Table 2.1) and sent for DNA sequencing. All of the clones chosen had peptide 
sequence fused to the pIII gene sequence of the M13 phage except clone 7 as indicated 
by DNA electrophoresis gel (Figure 3.1) and DNA sequencing results (Table 3.2).  
The peptide sequence that has been inserted in the library has a sequence of Ala-
Cys-Xxx7-Cys-Gly-Gly-Gly (ACX7CGGG) with a DNA sequence of 5’-GCT TGT (NNK)7 
TGC GGT GGA GGT-3’. The sequence GGG is the short linker sequence between the 
displayed peptide and pIII, in which the first amino acid after the linker is Ser (the DNA 
sequence is TCG). In the case of clone 7, the flanking sequences which precede the 7-
mer insert (AC) and after the insert (CGGG) are not present in its sequence, suggesting 
that a wild-type M13 contaminant had been selected and sequenced. 
Sequencing analysis (Table 3.2) of the selected phage DNA showed a common 
sequence pattern except in clone 3strep, 7strep and 8strep. The analysis of other 7 
clones revealed a sequence pattern of G-X-[F/Y]-X-H-P-[Q/M], whereby X denote a 
different amino acid residue of either S, T, P, V, F, or A. It can be seen that the G amino 
acid residue is found in the first position after N-terminal cysteine in all the clones. In the 
second position, amino acid T is found in 4 out of the 7 clones (clone 1strep, 2strep, 
4strep and 10strep) while amino acid S, P and V is found in clone 5strep, 6strep and 
9strep, respectively. In the third position is amino acid F in all clones except in clone 
2strep, which has Y instead of F. In the fourth position, amino acid S is found in 4 clones 
(1strep, 2strep, 4strep and 10 strep) while amino acid F, V and A is found in clone 5strep, 
6strep and 9strep, respectively. 
Besides the HPQ motif, which is the most strongly conserved sequence for 
streptavidin-binding peptides (Devlin et al., 1990), HPM is also another consensus 
sequence commonly identified when using streptavidin as a target (Lam et al., 1991). All 
clones except 3strep, 7strep and 8strep, contain either the HPQ or the HPM consensus 
motif sequence for streptavidin binding. Clone 1strep, 4strep, 5strep and 10strep contain 
the HPM motif while three others have the HPQ motif i.e. clone 2strep, 6strep and 9strep. 
The clones with the HPQ motif were then amplified and purified for further analysis.  
3strep and 8strep do not contain any consensus motif and could be “carry 
through” of non-binding phage clones. However, it is also debatable that both clones are 
streptavidin binding clones but with a different motif. In addition, although it has been 
documented that plastic binders have distinct characteristics with aromatic amino acids 
especially W, P and F (Vodnik et al., 2011), it is still possible that both 3strep and 8strep 
clones bind plastic or components of blocking buffer. 
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Table 3.1: The number of input phage, recovered phage and amplified phage in every round 
of streptavidin panning. The library was panned against a streptavidin-coated plate and the 
bound phage was eluted using biotin. The eluted phage was then amplified and used as the 
input phage in the next round of panning. The number of recovered phage was found to 
increase in every successive round of panning, suggesting enrichment had occurred. 
Panning Input phage Recovered phage  Amplified phage  
1st pan 2 x 1011  1.36 x 103 6.75 x 1010 
2nd pan 2 x 1010 1.40 x 104 9.00 x 1010 
3rd pan 2 x 1010 3.60 x 106 6.00 x 1010 
4th pan 2 x 1010 5.90 x 106 NA 
 
 
 
                             
Figure 3.1: PCR amplification of DNA of 10 clones chosen after three rounds of selection 
against streptavidin. Forward and reverse PCR phage primers were used and water was used 
as the negative control template. The PCR product was run on 2% [w/v] agarose gel 
containing ethidium bromide along with DNA Hyper ladder IV and viewed under UV 
transilluminator. The PCR product of about 190 kb in size in clone 1 to 10 except 7 indicated 
that all chosen clones had peptide sequence fused to the pIII gene of the M13 phage except 
clone 7.   
Hyper 
ladder 
IV 
1         2         3         4         5         6         7         8         9        10 Negative 
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Table 3.2: Sequencing analysis of 10 clones selected after 3 rounds of selection panning 
against streptavidin. DNA of each clone was extracted and sent for sequencing. The amino 
acid sequence of the clones was determined using genetic code. His-Pro-Gln (HPQ) motif 
was found in three clones and is shown in bold. 
Clones DNA sequence 5’-3’ Peptide sequence 
1strep GCT TGT GGG ACT TTT TCG CAT CCT ATG TGC  ACGTFSHPMC 
2strep GCT TGT GGT ACT TAT TCT CAT CCT CAG TGC ACGTYSHPQC 
3strep GCT TGT CTT AAT GCT CAT CGG GCG TCT TGC ACLNAHRATC 
4strep GCT TGT GGG ACT TTT TCG CAT CCT ATG TGC ACGTFSHPMC 
5strep GCT TGT GGG TCT TTT TTT CAT CCT ATG TGC ACGSFFHPMC 
6strep GCT TGT GGT CCT TTT GTG CAT CCT CAG TGC ACGPFVHPQC 
7strep No signal N/A 
8strep GCT TGT TCT GGG GCG GGT ATT TTG AAG TGC ACSGAGILKC 
9strep GCT TGT GGT GTT TTT GCT CAT CCG CAG TGC ACGVFAHPQC 
10strep GCT TGT GGG ACT TTT TCG CAT CCT ATG TGC ACGTFSHPMC 
Clone sequence pattern: G-X- [F/Y]-X-H-P- [Q/M], with X=either S, T, P, V, F, or A 
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3.2 ELISA confirms the binding capacity of streptavidin phage clones 
towards streptavidin 
ELISA was carried out to further characterise these clones in order to assess their 
binding capacity towards streptavidin. An ELISA plate was coated with streptavidin and 
BSA was used as a protein control. Phage binding was detected using HRP-conjugated 
anti-M13 antibody and the TMB substrate. The reaction was stopped by addition of 
hydrochloric acid prior to the colorimetric measurement at 450 nm. 
ELISA results (Figure 3.2) show the binding pattern of the three streptavidin phage 
clones that contain the HPQ motif, i.e. 2strep, 6strep and 9strep, towards streptavidin and 
BSA. All streptavidin phage have a high binding affinity for streptavidin. The OD 450 nm 
of all streptavidin phage clones in BSA coated plate is below 0.4, which is very much 
lower than that of streptavidin coated plate, indicating the specificity of the selected clones 
towards streptavidin. 
 
 
Figure 3.2: The ELISA results of three streptavidin phage clones containing HPQ motif (clone 
2strep, 6strep and 9strep). Serially diluted phage were added to ELISA plates coated with 
streptavidin or BSA (as protein control), and detected using HRP-conjugated anti-M13 
antibody. The reaction, which was stopped by the addition of hydrochloric acid, was read at 
450 nm. All three clones were shown to have high affinity for streptavidin. This graph is a 
representative of two independent experiments. 
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4.0  CHAPTER 4 
4.1 In vitro selection of phage binding to MCF7- αVβ3 cells 
 Integrins are adhesion molecules expressed on the cell surface that mediate the 
interaction between cells and the extracellular matrix (van der Flier and Sonnenberg, 
2001). Each integrin exists as a heterodimer consists of an alpha subunit and a beta 
subunit, joined noncovalently. To date, there are 18 alpha subunits and 8 beta subunits 
(Kinashi, 2005) in which 24 combinations have been described, and αVβ3 is one of them.  
 MCF7-αVβ3 cells are human breast carcinoma epithelial cells stably expressing 
αVβ3 integrin (Pereira et al., 2004). In previous chapter, it has been shown that the phage 
libraries are capable of selecting peptide phage specific for streptavidin. Since the 
ultimate aim of this work is to identify peptides that target internalising molecules on DC, it 
is therefore crucial to develop a feasible and effective method for in vitro selection on cell 
surfaces. It is also important to test whether phage bearing specific binding motifs could 
be selected using whole cells as target. This section described the in vitro selection of 
peptide phage bound to MCF7-αVβ3 cell line using phage libraries. 
  
4.1.1  Immunostaining of MCF7 cells with anti­αVβ3 antibody 
Before MCF7-αVβ3 cells were used in panning selection, the level of αVβ3 
expression of the cells was first determined by antibody staining. Both washed MCF7-
αVβ3 and MCF7 (used as control cells) cells were resuspended in FACS tubes, stained 
with anti-αVβ3 antibody and subsequently relevant secondary antibody. An appropriate 
isotype control was also included and the cell surface expression of αVβ3 of these cells 
was determined by flow cytometric analysis.  
As indicated in Figure 4.1, MCF7-αVβ3 cells showed a high level of αVβ3 expression 
(A) whereas MCF7-control cells expressed a low level of αVβ3 integrin (B). It was first 
thought that the wild type MCF7 cells could be used as a target in subtractive panning 
strategy. However, this approach was not feasible as the wild type cells (i.e. the MCF7-
control cells) are weakly αVβ3 positive. 
Since MCF-7 cells are adherent cells, panning selection using these cells as target 
is probably best carried out when they are grown as monolayer. Nevertheless, it is crucial 
to ensure that in monolayer form, the antigen site on the cell surface remain undisturbed 
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and free for interaction. Therefore, staining of cells grown on cover slips with anti-αVβ3 
antibody was carried out and visualised under a confocal microscope.  
Figure 4.1(F) shows MCF7-αVβ3 cells stained with anti-αVβ3 antibody. The cells 
were strongly stained compared to the isotype control (Figure 4.1(D)), suggesting a high 
level of αVβ3 expression. The MCF7-control cells were also stained with the antibody and 
as indicated in Figure 4.1(H), these cells were faintly stained compared to the MCF7-αVβ3 
cells. This observation is parallel with the flow cytometric analysis results, which showed 
that the control cells have a low expression level of αVβ3 integrin. 
 
4.1.2  Panning against MCF7­αVβ3 cells 
Although MCF7-αVβ3 cells are adherent cells, both plate and solution panning was 
carried out simultaneously in order to establish which technique was better for future 
studies with DC. In plate panning, cells were grown overnight in a 24-well plate, fixed with 
4% [v/v] paraformaldehyde and blocked using blocking buffer before the addition of 
phage. In solution panning, the phage was panned against cells in suspension in a tube 
that were previously blocked with blocking buffer. The panning was carried out at 4oC and 
after extensive wash, the bound phage were eluted using 0.2 M Glycine-HCl (pH 2.2) 
buffer. The eluted phage were then amplified and used in subsequent panning rounds.  
Table 4.1 summaries the details of the panning, the number of input phage, 
recovered phage and amplified phage in every round of selection. Between 103 and 105 
total phage were eluted off in every round of panning while the total number of phage 
amplified after being eluted was between 109 and 1011 phage in every panning. This 
suggest that the efficiency of amplification is between 104 to 107-fold per round. 
After the third and fifth round of panning, 20 clones were randomly selected from 
plates with less than 200 plaques, amplified and phage DNA was extracted. Each clone 
was then characterised by PCR using forward and reverse PCR phage primers (Table 
2.1) and sent for DNA sequencing. Figure 4.2 shows the PCR products of about 190 bp in 
size of all 20 clones selected with (A) showing the PCR product of phage selected from 
plate pannings while (B) showing the PCR product of phage selected from solution 
pannings.  
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Figure 4.1: Staining of MCF7-αVβ3 and MCF7-control cells with anti-αVβ3 antibody and isotype 
control antibody. (A) and (B) showed flow cytometry analysis of the cells staining. Washed 
cells were resuspended in a 96-well plate and stained with antibodies. The red lines represent 
the isotype control used and the green lines represent the staining with anti-αVβ3 antibody. 
There is a high level of αVβ3 expression on MCF7-αVβ3 cells (A) and a low level of αVβ3 
integrin expression on MCF7-control cells (B). Figure (C-H) are images of the cells visualised 
under a confocal microscope using bright field and Alexa 488 fluorochrome channel. (C,D) 
shows MCF7-αVβ3 cells stained with an isotype control antibody, (E,F) MCF7-αVβ3 cells 
stained with anti-αVβ3 antibody, and (G,H) MCF7-control cells stained with anti-αVβ3 antibody. 
Cells were grown on cover slips overnight, washed, fixed with 4% paraformaldehyde and 
incubated with antibodies. MCF7-αVβ3 cells were well stained (F) compared to the isotype 
control (D), suggesting a high αVβ3 expression level. MCF7-control cells (H) were faintly 
stained compared to the MCF7-αVβ3 cells, suggesting a low expression level of the integrin on 
the cell surface of MCF7-control cells. 
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Table 4.1: Plate and solution panning against MCF7-αVβ3 cells. The cells were grown 
overnight in a 24-well plate, fixed with 4% paraformaldehyde and blocked with blocking buffer 
(in plate panning) prior to panning step while in solution panning, the phage was panned 
against cells in suspension. 0.2 M Glycine-HCl (pH 2.2) was used to elute the bound phage 
and all phage were titrated, amplified and used as the input phage in the next round of 
panning.  
Panning Input 
Phage 
Plate Solution 
Recovered 
phage 
Amplified 
phage  
Recovered 
phage  
Amplified 
phage  
1st pan 2 x 1011 1.20 x 105  8.80 x 109  1.35 x 104 7.40 x 109 
2nd pan 2 x 1010 3.60 x 103 7.60 x 1010  3.00 x 105 1.00 x 1011 
3rd pan 2 x 1011 1.60 x 103  2.70 x 1010  2.30 x 104 5.00 x 1010  
4th pan 2 x 1011 1.62 x 104  2.90 x 1011 1.37 x 104 4.70 x 1011 
5th pan 2 x 1011 1.46 x 104 NA 1.23 x 103 NA 
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Table 4.2(A) shows the peptide sequence of each phage clone selected from the 
third and fifth plate pannings as well as that of solution pannings. Four clones were found 
to have the same DNA sequence encoded for peptide CNLSSSWIC (1ap, p4a, a10s and 
av3s clone) and CSPWSSLAC (10ap, p7a, a6p and av6p clone), respectively. The 
repetitive clones are shown in circle and rectangle lines. Phage clones with encoded 
peptide sequence which are shown in bold, were chosen to be further characterised 
based on the consensus motif of SS and VGY. Motif SS happens to be shared among the 
repetitive clones and also with 4p clone (CLSSPALLC). Two other phage clones chosen 
to be further characterised were 5as clone (CSLVGYPIC) and 8as clone (CVGYSPSLC) 
based on the motif VGY shared between them. The DNA sequence of all the peptides is 
shown in Table 4.2(B). 
All peptide sequences were scanned through a web server named Scanner And 
Reporter Of Target-Unrelated Peptides (SAROTUP) (Huang et al., 2010), as well as two 
other peptide databases, MimoDB (Ru et al., 2010) and PepBank (Shtatland et al., 2007) 
for identification of known/published peptide sequences. MimoDB and PepBank are freely 
accessible databases that contain large numbers of peptides selected by using phage 
display on different targets, while SAROTUP, also a free accessible server, contains data 
of phage display selections on antibodies. By using these databases, a comparison 
analysis between peptide sequences selected in this study and the published sequences 
in the databases can be done. 
Peptide sequence NLSSSWI has been reported to bind C179 monoclonal 
antibody (Zhong et al., 2011) in an experiment using Ph.D. -C7C peptide phage-display 
library. This phage-displayed peptide is a dominant sequence that has been selected 9 
times over 12 clones sequenced and is considered as a mimotope of the influenza A 
virus/Okuda/57 strain. 
In this study, the same peptide sequence (CNLSSSWIC) appeared four times in 
independent experiments, suggesting that the repetitive peptides, which bind to receptors 
on the surface of MCF7-αVβ3 cells, may also bind C179 monoclonal antibody. Another 
phage peptide selected in this study from the fifth plate panning, with the sequence of 
CTHEPSGRC, was also selected against anti-influenza A H3N2 polyclonal antibody IgG 
by the same authors with the frequency of 1 over 12, also using the cyclic 7-mer phage 
peptide library.  
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Figure 4.2: PCR product of all 20 clones selected after the third and fifth round of panning 
against MCF7-αVβ3 cells. Water was used as template for negative control. The PCR product 
was run on 2% [w/v] agarose gel along with DNA Hyper ladder IV. The PCR product of about 
190 kb in size in all clones except the negative control indicates the presence of a sequence 
encoding phage peptide on the phage clones selected. (A) PCR product of phage selected 
from plate pannings. (B) PCR product of phage selected from solution pannings. 
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Table 4.2: (A) Peptide sequence of 20 clones selected after 3rd and 5th panning against 
MCF7-αVβ3 cells from both plate and solution pannings. Four clones were found to have the 
same DNA sequence encode for each peptide CNLSSSWIC and CSPWSSLAC. The 
repetitive clones are shown in circle and rectangle lines, respectively. Phage clones that are 
shown in bold were chosen to be further characterised based on two consensus motifs, SS 
and VGY (underlined). SS motif was shared among the repetitive clones and with 4p clone 
while VGY motif was shared between 5as and 8as clones. (B) shows the DNA sequence of all 
the peptides. 
Panning  Plate  Solution 
Third pan  1ap   CNLSSSWIC  4as  CPAPHLFTC 
  10ap   CSPWSSLAC  5as CSLVGYPIC 
      7as CLRAQSVLC 
      8as  CVGYSPSLC 
      9as   CTLRNLALC 
Fifth pan  p4a  CNLSSSWIC  a1s  CNPISLHLC 
  p7a  CSPWSSLAC  a4s   CVPSTPLAC 
  p9a  CPLEHRPMC  a10s  CNLSSSWIC 
  a3p  CTHEPSGRC  av5s  CPGLATNFC 
  a4p  CSLHFPPTC  av3s  CNLSSSWIC 
  a6p  CSPWSSLAC     
  4p  CLSSPALLC     
  av6p  CSPWSSLAC     
(A) 
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Clone Peptide 
sequence 
DNA sequence 5’-3’ 
1ap, p4a,  
a10s, av3s  
CNLSSSWIC TGT AAT CTT TCG TCT TCA TGG ATT TGC 
10ap, p7a,  
a6p, av6p 
CSPWSSLAC TGT TCG CCG TGG TCT TCT CTT GCG TGC 
4p CLSSPALLC TGT CTG TCG TCT CCT GCT TTG CTG TGC  
8as CVGYSPSLC TGT GTG GGG TAT TCT CCT TCT CTT TGC 
5as CSLVGYPIC TGT TCT CTG GTG GGG TAT CCT ATT TGC 
4as CPAPHLFTC TGT CCG GCT CCT CAT CTG TTT ACT TGC 
7as CLRAQSVLC TGT CTT CGT GCT CAG TCT GTG CTT TGC 
9as CTLRNLALC TGT ACG CTG CGT AAT TTG GCG CTT TGC 
p9a CPLEHRPMC  TGT CCG TTG GAG CAT CGG CCT ATG TGC  
a3p CTHEPSGRC TGT ACT CAT GAG CCT TCT GGG CGT TGC 
a4p CSLHFPPTC TGT AGT CTT CAT TTT CCT CCT ACT TGC  
a1s CNPISLHLC TGT AAT CCT ATT TCT CTT CAT TTG TGC  
a4s CVPSTPLAC TGT GTT CCG TCG ACT CCT CTG GCG TGC 
av5s CPGLATNFC TGT CCT GGT CTT GCG ACT AAT TTT TGC  
 
 
 
 
(B) 
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The -C7C peptide phage library used in this study contain 3.7 x 109 independent 
clones, sufficient to encode all of the 207 = 1.28 x 109 possible 7-residue sequence. 
Therefore, there is a high probability to isolate the same peptide sequence in different 
independent experiments. This also suggest that any peptide phage that emerged 
repetitively in different experiments is either a strong binder of the target or that the 
peptide phage present in high frequency in the library used, thus making it more likely to 
be selected during panning.  
Similarly, peptide sequence CSPWSSLAC, which emerged four times in 
independent experiments, has a match pattern of SS(I/L) which has been shown by other 
groups as a binder to immunoglobulin Fc region. Ehrlich and Bailon used Fc of 
humanised anti-Tac (HAT) as target in phage display and, among multiple sequences, 
found the motif SS(I/L) (Ehrlich and Bailon, 1998). Krook and co-authors isolated clones 
bearing the sequence SSI, by screening a decapeptide library with a commercial 
preparation of human IgG Fc and eluting with protein A (Krook et al., 1998). One clone 
containing the SSI motif was found to compete with protein A for binding to the screening 
Fc, suggesting that it interacts with the protein-A-binding site on human IgG Fc. These 
evidences suggest the possibilities that have been discussed previously or that the 
epitopes are cross-reactive and thus, the peptide phage CSPWSSLAC that has been 
isolated is a true target binder. 
Comparing both panning approaches, CNLSSSWIC sequence appeared twice in 
both solution and plate pannings. However, in plate panning 4 out of 10 clones selected 
are the repetitive CSPWSSLAC sequence. From these observations and findings, it can 
be concluded that solution panning is a better approach as more diverse clones were 
selected compared with clones from plate panning. This could be due to more cell surface 
receptors available for interaction in suspension state as compared to that of cells grown 
as monolayers in plate panning. 
 
4.2 Characterisation of phage clones selected after panning against 
MCF7-αVβ3 cells 
As previously demonstrated in the last section, five phage clones contain either 
SS or VGY motifs in their peptide sequences. This section described different binding 
ability of the clones towards MCF7-αVβ3 cells despite sharing certain motifs. By using 
methods like flow cytometry analysis, ELISA and single clone panning, which involved the 
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recovery and titration of bound phage on MCF7-αVβ3 cells, one clone was found to be 
superior in binding MCF7-αVβ3 cells. 
 
4.2.1  Determination of phage clone with high binding capacity towards MCF7­αVβ3 
cells 
Flow cytometry analysis was first carried out in order to assess the binding ability 
of the phage clones selected against MCF7-αVβ3 cells. This was done by first incubating 
the phage with the cells for 2 hours at 4°C to facilitate binding. Subsequently, the cells 
with bound phage were stained with anti-M13 phage antibody and an isotype control 
antibody. One of the streptavidin clones (2strep) that were isolated earlier in Section 3.1.1 
was used as a negative control clone in this experiment.  
Flow cytometry analysis in Figure 4.3 revealed that 2strep clone can bind to 
MCF7-αVβ3 cells and the degree of binding is similar to that of 5as, 8as, av3s and av6p. 
4p clone, on the other hand, shows a higher binding ability to the cells compared to other 
clones. Since 2strep clone was used as an irrelevant phage control, its degree of binding 
was considered as the point of reference for non-specific binding. Therefore, within the 
limit of flow cytometric assay, it is deduced that 4p phage is the only phage clone whose 
binding to MCF7-αVβ3 cells could be detected and confirmed as significant compared to 
others. 
Subsequently, cell-based ELISA was carried out in order to verify the flow 
cytometry analysis findings. This was done by seeding the cells in a flat bottom 96-well 
culture plate a day before. The cells were then washed, fixed with 4% paraformaldehyde 
and washed with TBST prior for blocking. The rest of ELISA procedure was done as 
discussed previously and 2strep clone was included as a negative control. ELISA results 
(Figure 4.4) showed that 4p clone has the strongest ability in binding to MCF7-αVβ3 cells 
compared to other clones. 2strep has a low level of binding to the cells and it is similar to 
that of 5as, 8as and av3s. av6p has the lowest level of binding compared to others. This 
finding is consistent with the previous flow cytometry analysis results and indicates that 4p 
phage clone can bind MCF7-αVβ3 cells.  
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Figure 4.3: Flow cytometry analysis of five peptide phage clones that were selected during 
panning against MCF7-αVβ3 cells. The respective phage were mixed with the cells to facilitate 
binding and stained with anti-M13 phage antibody. Streptavidin clone (2strep) was used as 
negative control clone. As indicated, 4p clone is shown to have the highest binding ability 
towards MCF7-αVβ3 cells among all five peptide phage clones. These data are representative 
of three independent experiments. 
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 anti-M13 antibody 
5as  8as 
av3s  av6p 
4p  2strep 
     
  80 
 
 
 
 
 
 
 
 
 
Figure 4.4: MCF7-αVβ3 cell-based ELISA showing 4p clone as the highest cell binder among 
four other peptide phage clones. 2strep clone was used as a negative control. Cell-based 
ELISA was carried out by growing the cells in a flat bottom 96-well culture plate one day 
prior to the experiment day. The cells were washed, fixed with 4% formaldehyde and 
washed again with TBST prior for blocking. The bound phage were incubated with diluted 
HRP-conjugated anti-M13 antibody and the plate was read at 450 nm. Based on the pattern, 
it is clear that 4p clone has the strongest ability to bind to MCF7-αVβ3 cells compared to 
other clones. This is parallel with the findings of flow cytometry analysis earlier, thus, 
corroborating 4p clone ability to bind to the cells. This result is a representative of three 
independent experiments carried out. 
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4.2.2  Determination of binding ability of 4p phage towards other cells 
Having shown that 4p phage has an ability to bind to MCF7-αVβ3 cells, a flow 
cytometric analysis was carried out to determine whether 4p phage could also bind to 
other cells. Prior to this, the level of αVβ3 expression in HEK-293, U-937 and THP-1 cells 
was first determined by using flow cytometric analysis. Figure 4.5 shows the level of αVβ3 
expression on the cell surface of the cells. U-937 and THP-1  cells  have  no  αVβ3 
expression whereas HEK-293 has a low level of αVβ3 expression.  
Next, 4p phage and streptavidin phage (as control) were incubated with the cells 
at 4°C for 2 hours, and then stained with anti-M13 antibody prior to flow cytometry 
analysis. Figure 4.6 shows the flow cytometry profile of the binding of 4p phage and 
streptavidin phage towards MCF7-αVβ3 , HEK-293, THP-1 and U-937 cells. It is clearly 
demonstrated that 4p phage can bind MCF7-αVβ3 cells but not THP-1, U-937 and HEK-
293 cells. 2strep phage also bound to MCF7-αVβ3 cells but much lower than that seen 
with 4p phage, agreeing with the previous findings. 
 
4.2.3  Confirmation of binding ability of 4p phage in comparison to an irrelevant 
phage towards MCF7­αVβ3 cells 
In order to further confirm the binding ability of 4p phage towards MCF7-αVβ3 cells, 
single phage clone binding experiment was carried out. In this experiment, the RGD 
phage with encoded CSPRGDHPC peptide sequence, which had previously been 
isolated after three rounds of selection on αVβ3 (Lee et al., 2002) was also included. The 
RGD, 4p and 2strep phage were incubated with MCF7-αVβ3 cells and MCF7-control cells 
at 4°C for 2 hours. After several washes, bound phage were eluted using 0.2 M Glycine-
HCl (pH 2.2) buffer and titrated.  
Figure 4.7 shows the number of the phage eluted after incubation with MCF7-αVβ3  
cells and MCF7-control cells. The highest number of phage eluted from MCF7-αVβ3 cells 
was RGD phage, followed by 4p phage. The streptavidin phage eluted was about 10-fold 
less than the 4p phage. Interestingly, the number of phage eluted from MCF7-control cells 
was about the same as that of the streptavidin phage eluted from MCF7-αVβ3 cells. This 
shows that RGD and 4p phages can also bind to MCF7-control cells and suggests that 
the increase in the binding ability of RGD and 4p phages towards MCF7-αVβ3 cells might 
be due to the αVβ3 integrin. 
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Figure 4.5: Staining of HEK-293, THP-1 and U-937 cells with anti-αVβ3  antibody. The red 
lines represent the isotype control and the green lines represent staining with the antibody. 
There is no expression of αVβ3 on the cell surface of U-937 and THP-1 cells. HEK-293 cells, 
however, showed a low level expression of the integrin. 
  
  
Figure 4.6: 4p and 2strep phage were incubated with HEK-293, THP-1, U-937 and MCF7-
αVβ3 cells at 40C for 2 hours. Cells were then washed and stained with anti-M13 phage 
antibody. Streptavidin (2strep) phage clone was used as a control. Flow cytometry analysis 
revealed that 4p phage can bind to MCF7-αVβ3 cells. In other cells, the phage either have 
no binding capacity or little binding to the target cells. This experiment was carried out more 
than twice and this data is a representative of all. 
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Figure 4.7: Number of phage eluted from MCF7-αVβ3 and MCF7-control cells. 1 x 1011 of 
phage from a single clone were mixed with MCF7-αVβ3 cells and MCF7-control cells, 
respectively, allowed to bind at 40C for 2 hours, washed and eluted using 0.2 M Glycine-HCl, 
pH 2.2. With MCF7-αVβ3 cells, the RGD phage was eluted about 6-fold more than the 4p 
phage while the control 2strep phage was eluted the least among all clones. With MCF7-
control cells, about the same number of phage was eluted from the cells. This outcome further 
confirmed the binding ability of the RGD and the 4p phage towards the MCF7-αVβ3 cells 
compared to the strep clone. This is a representative of two independent experiments which 
data trends are similar. 
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5.0  CHAPTER 5 
5.1 Generation of dendritic cells 
PBMC were isolated from healthy donor blood and the CD14+ cells were 
separated from PBMC using CD14 MicroBeads and a MACS column. The CD14+ cells 
were incubated with GM-CSF and IL-4 for 5 days, to allow differentiation of the cells to 
immature dendritic cells. 
The CD14+ cells (taken on the day of isolation) and DC (5 days after incubation 
with cytokines) were stained with antibodies against cell surface markers and flow 
cytometric analysis was carried out. Figure 5.1 illustrates the flow cytometric analysis 
profile of the CD14+ cells on the day of isolation (A) and immature DC (B).  
On the day of isolation, more than 90% of the monocytes population gated was 
CD14 positive, indicating the purity of the population isolated from PBMC. After 5 days 
culturing with the presence of the cytokines, the high expression of the CD14 surface 
marker of the monocyte dropped to about less than 3% indicating that the monocytes had 
differentiated into immature DC. Furthermore, the level of CD11c, a marker for immature 
DC, was almost 100% and the low expression level of co-stimulatory marker of CD80 and 
CD86 further confirmed that the monocytes had fully differentiated into immature DC.  
 
5.2 In vitro selection of phage binding to immature dendritic cells (iDC) 
In vitro selection of phage binding to iDC was carried out in order to identify novel 
peptides specific to DC. In this study, live suspension iDC were used rather than fixed or 
immobilised cells for panning in an attempt to maintain the integrity of the surface 
antigens in their native state. Furthermore, it has been shown previously in the MCF7-
αVβ3 cells panning experiments that more diverse clones can be selected from solution 
panning compared with clones from plate panning. 
  In this experiment, subtractive panning strategy was also employed to increase 
binding specificity. Subtractive panning is a dual selection process, which involves the 
depletion of phage of undesired specificities and selection of phage of desired target. The 
former step is carried out by preadsorbing the libraries on unwanted target and the latter 
by panning the depleted phage pool against target molecules. 
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Figure 5.1: The flow cytometry profile of CD14+ cells on the day of isolation and DC after 5 
days incubation with the cytokine. CD14+ cells were separated from PMBC while DC were 
generated from CD14+ cells by addition of GM-CSF and IL-4. A high expression of CD14 
marker of CD14+ cells on the day of isolation indicate the purity of the monocyte population 
whereas a high level of CD11c expression and low expression of CD14, CD80 and CD86 
markers of DC after 5 days culture show that the monocytes had differentiated into immature 
DC. 
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 Two subtractive pannings were carried out initially against PBMC and 
subsequently CD14+ cells. In these two experiments, phage from the library were panned 
against 108 PBMC and the non-bound phage were then used as the input phage panned 
against 107 CD14+ cells. Subsequently, the non-bound phage from this selection were 
used to pan against iDC. The eluted phage from the first round of selection against iDC 
was amplified and used as the input phage for subsequent panning. Overall, four 
independent pannings against iDC have been carried out. Table 5.1 summaries the 
number of phage used in the panning experiment, those that were eluted after the 
selection and amplified after every round of panning.  
 Figure 5.2 shows the PCR product of DNA of randomly selected phage clones 
after third and fourth round of pannings. Nine phage clones from the third round of 
panning (Figure 5.2A) and eight clones from the fourth round of panning (Figure 5.2B) of 
about 190 bp in size were sent for DNA sequencing. Table 5.2 shows the DNA and 
deduced peptide sequences of all 17 clones sent for sequencing. Three peptide 
sequences that emerged repetitively are CFTLSPFSC (five times), CFGTAFPAC (three 
times), and CPRPTALQC (three times). Finally, nine clones with unique peptide sequence 
were chosen to be further investigated. 
As described in Section 4.1.2, all peptide sequences obtained from panning 
against iDC were also scanned through SAROTUP, MimoDB and PepBank peptide 
databases. Peptide phage (DC4.43) with the sequence of CLGALSHTC, which was 
isolated during fourth round of panning against immature DC, has been reported to be 
selected 8 times out of 12 clones isolated against anti-influenza A H3N2 polyclonal 
antibody IgG using Ph.D. -C7C peptide phage-display library (Zhong et al., 2011). It was 
reported that the phage library was first incubated with goat IgG (100 g/ml) as 
subtractive biopanning approach, the non-bound phage were subsequently transferred to 
H3N2 polyclonal antibody-coated wells (30 g/ml) and finally the binding phage were 
eluted with H3N2 polyclonal antibody. The peptide phage library used in this study might 
have bind to receptors on the surface of iDC that can also bind influenza A H3N2 virus. 
The peptide sequences of the rest of the phage selected against iDC do not match 
any of the published peptides in the databases. 
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Table 5.1: Panning against immature dendritic cells. The phage library was panned against 
PBMC and CD14+ cells initially in two subtractive pannings. The non-bound phage from the 
second subtractive panning were subsequently used as the input phage and panned against 
iDC. 0.2 M Glycine-HCl (pH 2.2) buffer was used to elute the DC-bound phage. The eluted 
phage were amplified and used as input phage in subsequent panning. A total of four 
pannings have been carried out. The number of phage recovered after panning is between 
1x103 to 1.5x104 pfu.  
Panning Input phage Recovered phage  Amplified phage  
1st pan 2x1011  3.3x103 1.58x1011 
2nd pan 2x1011 1.15x104 2.65x1011 
3rd pan 2x1011 1.83x103 6.0x1010 
4th pan 2x1011 3.75x103 NA 
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Figure 5.2: PCR product of selected phage clones after the third and fourth round of panning 
against immature DC. The PCR products were run on 2% [w/v] agarose gel containing 
ethidium bromide. PCR products of about 190 bp in size, in nine phage clones from the third 
round of panning (A) (i.e. clone DC3.1, DC3.2, DC3.4, DC3.5, DC3.6, DC3.9, DC3.14, DC3.19 
and DC3.20) and eight clones from the fourth round of panning (B), indicate the presence of a 
sequence encoding phage peptide in the phage clones selected. However, in (B) only the 
positive clones out of all clones selected from the forth panning were shown (i.e. DC4.10, 
DC4.14, DC4.22, DC4.25, DC4.31, DC4.43 and DC4.44). [HL IV: Hyper Ladder IV] 
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Table 5.2: The DNA and deduced peptide sequences of 17 clones sent for sequencing. The 
repetitive peptides are CFTLSPFSC (in oval box), CFGTAFPAC (in rectangle box), and 
CPRPTALQC (in hexagon box). Nine clones with unique peptide sequence were chosen to be 
further investigated and are highlighted in bold. 
 
Third round of panning against immature DC 
CLONE DNA SEQUENCE PEPTIDE SEQUENCE 
DC3.1 TGT TTT GGT ACG GCT TTT CCG GCG TGC  CFGTAFPAC 
DC3.2 TGT CCT GGT CTT CAT TCT GCG GCG TGC  CPGLHSAAC 
DC3.4 TGT CCG CGT CCT ACT GCT TTG CAG TGC  CPRPTALQC 
DC3.5 TGT TTT GGT ACG GCT TTT CCG GCG TGC  CFGTAFPAC 
DC3.6 TGT TTT GGT ACG GCT TTT CCG GCG TGC  CFGTAFPAC 
DC3.9 TGT TTT ACT CTG AGT CCT TTT TCG TGC  CFTLSPFSC 
DC3.14 TGT CCG CGT CCT ACT GCT TTG CAG TGC  CPRPTALQC 
DC3.19 TGT CCG CGT CCT ACT GCT TTG CAG TGC  CPRPTALQC 
DC3.20 TGT ATG TCG CAT CGT CCT CAT CAG TGC  CMSHRPHQC 
 
Fourth round of panning against immature DC 
DC4.10 TGT CAG GCG CCG TTT CTG TTT GCT TGC CQAPFLFAC 
DC4.14 TGT TTT ACT CTG AGT CCT TTT TCG TGC  CFTLSPFSC 
DC4.22 TGT TTT ACT CTG AGT CCT TTT TCG TGC  CFTLSPFSC  
DC4.25 TGT TTT CCT CCG ACT TTT CCT GCG TGC  CFPPTFPAC 
DC4.31 TGT TTT ACT CTG AGT CCT TTT TCG TGC  CFTLSPFSC 
DC4.40 TGT TTT ACT CTG AGT CCT TTT TCG TGC  CFTLSPFSC 
DC4.43 TGT CTG GGT GCT CTT TCG CAT ACG TGC  CLGALSHTC 
DC4.44 TGT ACG CCT CTT CTT TCT CCT TTT TGC  CTPLLSPFC 
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5.3 Characterisation of phage clones selected after panning against iDC  
In previous section, nine phage clones, each with unique peptide sequence 
encoded, have been identified after selection against iDC. This section mainly described 
the difference in binding ability of all the clones towards iDC by using methods like flow 
cytometry analysis and single phage clone binding experiment, which involve the recovery 
and titration of the eluted bound phage. Two potential phage clones, which have high 
binding preference towards iDC, were later identified. 
 
5.3.1  Establishing phage clones with high binding capacity towards iDC 
 Flow cytometry analysis was carried out on nine peptide phage clones selected 
against iDC in order to establish the binding capacity of all clones. The phage were 
incubated with iDC for 2 hours at 4°C and after several washes, the cells with bound 
phage were stained with anti-M13 phage antibody prior to flow cytometric analysis. Cells 
incubated with phage were also stained with an isotype control antibody. 2strep phage 
was included in this experiment as an irrelevant phage control. Thus, the degree of cell 
binding of 2strep was considered as the point of reference for non-specific binding. Any 
binding that is similar to the binding of 2strep to DC is considered as non-specific.  
 Figure 5.3 show the flow cytometric analysis profile of all nine clones and 2strep 
clone as irrelevant phage control. Two phage clones identified from the fourth round of 
panning, i.e. DC4.25 (with encoded peptide sequence CFPPTFPAC) and DC4.44 (with 
encoded peptide sequence CTPLLSPFC) have high binding ability towards iDC compared 
to other phage. Other phage clones showed similar binding capacity towards iDC as that 
of the streptavidin control, and thus are considered as non-specific binding.  
 
5.3.2  Determination of cell­specific binding of DC phage clones towards iDC 
 Having shown that DC4.25 and DC4.44 phage clones have a significantly high 
binding capacity towards iDC, the specificity of the binding was further investigated. In 
order to achieve this goal, the phage were incubated with iDC and the two cell types 
which were used in the previous subtractive pannings, CD14+ and PBMC. In addition, the 
phage were also incubated with other several cell lines to determine cell specificity of the 
DC phage. The phage were incubated with respective cells at 4oC for 2 hours, stained 
with anti-M13 antibody and assessed by flow cytometric analysis. 
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Figure 5.3: Flow cytometry analysis profile of DC phage clones bind to iDC. iDC were 
incubated with DC phage clones at 4ºC for 2 hours and stained with anti-M13 antibody (green 
line) and also isotype control antibody (red line). It is clearly shown that DC4.25 and DC4.44 
clones have a higher binding ability towards iDC compared to other DC phage clones and 
streptavidin control phage. Other DC phage clones have binding ability similar to that of 2strep 
control phage. As 2strep was used as an irrelevant phage control, any binding similar to its 
binding is considered as non-specific. 
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 Figure 5.4 shows the binding profile of DC4.25 and DC4.44 phage towards iDC, 
CD14+ and PBMC. Streptavidin phage was used as a control phage. It can be seen 
clearly that there is a high binding of both DC phage to iDC compared to that of 
streptavidin phage as previously demonstrated. There is also very little binding of the 
phage towards CD14+ cells and no evidence of phage bind to PBMC, indicating the 
success of subtractive panning in removing most of the phage with undesired specificities.  
 Figure 5.5 shows the flow cytometry analysis profile of the binding of DC4.25 and 
DC4.44 phage clones towards iDC, human monocytic cell lines THP-1 and U-937, as well 
as other human cell lines HEK293 and MCF7-αVβ3 cells. Streptavidin phage was 
included as control phage. It is clearly demonstrated that DC4.25 and DC4.44 phage bind 
to iDC and do not bind to THP-1, U-937, HEK293 and MCF7-αVβ3 cells. 
 
5.3.3  Confirmation of the binding ability of DC phage towards iDC in comparison 
with an irrelevant phage  
In order to further confirm the binding ability of DC phage clones towards iDC, 
single phage clone binding experiment was carried out. In this experiment, DC phage and  
streptavidin phage were incubated with iDC at 4°C for 2 hours, washed and then eluted 
using 0.2 M Glycine-HCl (pH 2.2) buffer. The recovered phage were titred and plated on 
IPTG/Xgal plates and the blue plaques formed were counted the next day. The number of 
eluted phage in each sample is then used as an indicator to determine binding ability of 
such phage towards iDC. The higher the number of eluted phage indicates a higher 
binding ability towards the cells. 
Figure 5.6 shows the number of recovered phage after incubation with iDC. The 
highest number of phage eluted was DC4.44 phage (2 x 105 pfu), followed by DC4.25 
phage, which was 1X less than that of DC4.44 phage. In addition, streptavidin phage was 
eluted the least amongst the phage. This confirms that the DC phage have a high binding 
ability towards DC and corroborates the previous data. 
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Figure 5.4: Flow cytometry profile of binding of DC4.25, DC4.44 and streptavidin phage 
towards iDC, CD14+ cells and PBMC. The phage were incubated with the cells for 2 hours at 
4oC and stained with anti-M13 antibody. Isotype control antibody staining and streptavidin 
phage were also included as controls. There is evidence of high binding of both phage 
towards iDC, very little binding towards CD14+ cells and no binding of both phage towards 
PBMC. This binding experiment was carried out three times and the data trends were similar 
in all experiments. 
  
  
Figure 5.5: DC phage clones binding profile to iDC. The phage were incubated with iDC, THP-
1, U-937, HEK293 and MCF7-αVβ3 cells at 4oC for two hours before subjected to antibody 
staining and assessed by flow cytometry analysis. Both DC4.25 (blue line) and DC4.44 (green 
line) phage are shown to bind to iDC but not to THP-1, U-937, HEK293 and MCF7-αVβ3 cells. 
2Strep phage was included as a control phage (brown line). This is a representative of three 
independent experiments.  
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Figure 5.6: Number of phage eluted from iDC. 1 x 1011 of single clone phage were mixed with 
iDC, respectively, allowed to bind at 40C for 2 hours, washed and eluted using 0.2 M Glycine-
HCl, pH 2.2, buffer. The DC4.44 phage eluted is 2 times more than that of DC4.25 phage 
whereas the number of 2strep phage eluted is around 1x104 pfu . This further confirmed that 
both DC phage clones can bind to iDC with a higher capacity than that of streptavidin phage. 
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6.0  CHAPTER 6 
6.1 Assessing the internalisation of selected phage  
 In previous chapters, it has been demonstrated that 4p phage has the ability to 
bind to MCF7-αVβ3 cells while both DC4.25 and DC4.44 phage have high binding ability 
towards iDC. Both DC phage have unique peptide sequences with no common motif 
shared between them. Having shown that they could bind the cells, it is important to 
investigate whether the selected phage could be internalised by the target cells. This is 
because internalising phage indicates an interaction between phage bearing peptide with 
molecules capable of internalising on target cells and such internalising peptides are likely 
to be more efficient in gene delivery. 
 To establish the internalisation property of the selected phage, two different 
approaches were utilised. The first method involves the recovery and titration of cell 
surface bound and internalised phage. This approach requires the use of stripping buffer 
to remove any phage that bind to target cells (cell bound phage) after cells and phage 
incubation. This is then followed by the use of lysis buffer to lyse the cells and allow the 
recovery of phage from within the cells (endocytosed phage). Immunostaining and 
colocalisation of the phage with endosomes were subsequently studied to further 
demonstrate the internalisation of phage by the target cells.  
Several reports have demonstrated that internalisation is significantly reduced at 
4°C as compared to at 37°C as low temperature slows the endocytic process (Nakase et 
al., 2004). Some reports have also described cessation of cell uptake when cells were 
incubated at 4°C (Tomoda et al., 1989) since all energy-dependent pathways are inhibited 
(Madani et al., 2011). Therefore, in this chapter, the internalisation of the selected phage 
by their target cells is assessed at 37°C while 4°C is used as control temperature. 
 
6.2 Optimisation of buffers 
 Some optimisation works were carried out first by using 4p phage and MCF7-αVβ3 
cells in attempt to establish reliable methods in determining the internalisation property of 
such phage.  
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6.2.1  Optimisation of stripping buffers   
 In order to identify stripping buffer that could remove most of cell bound phage off 
the cell surface, two stripping buffers, i.e. buffer 1 (S1) and buffer 2 (S2) were chosen to 
be tested. S1 consists of 0.2 M Glycine-HCl (pH 2.2), 1mg/mL BSA, while S2 is made of 
50 mM glycine (pH 2.8), 0.5 M NaCl, 2 M urea, 2% polyvinylpyrrolidone (Becerril et al., 
1999). S1 has been previously used as a general buffer for nonspecific disruption of 
binding interactions in eluting bound phage in panning experiments in Chapter 4 and 5. 
S2, on the other hand, has been used as stripping buffer in many phage display work.  
 The stripping efficiency of the buffers was first assessed by flow cytometry. In this 
experiment, MCF7-αVβ3 cells were incubated with 1 x 1011 phage at 4C for 2 hours to 
allow binding before subjected to treatment with the buffers for 10 minutes at 4C to 
remove the cell bound phage off the cells surface. Some samples were not subjected to 
this stripping step. The cells were then stained with anti-M13 phage antibody and 
subsequently with Alexa-488 conjugated secondary antibody. The fluorescence signal 
obtained in flow cytometric analysis corresponds to the number of phage left, bound and 
intact on the cell surface and, if the stripping was efficient, the signal should be less than 
that of the samples without the stripping step.  
 Figure 6.1 shows the flow cytometric analysis results of the experiment. (A) shows 
the distribution of the MCF7-αVβ3 cells population in an ungated FSC (forward scatter) 
against SSC (side scatter) dot plot. It is clear that S1 and S2 buffers altered the size and 
the granularity of the cells population. Therefore, all cell populations were taken into 
consideration when making the analysis (no gating performed).  
 Figure 6.1(B) shows the fluorescence signals obtained from cells with bound 
phage, which have been treated with or without stripping buffers. Cells alone without any 
phage also went through the same treatment as other samples. As indicated by the blue 
line, there is evidence of 4p and RGD phage binding to the cells. Streptavidin phage also 
bind the cells but with fewer phage binding compared to that of 4p and RGD phage. This 
is consistent with previous data. When S1 and S2 buffers were used to strip the bound 
phage off the cells’ surface, the fluorescence signals seemed to be amplified. This 
outcome was not seen when cells alone (without any bound phage or antibody staining) 
underwent the same stripping step. This suggests that both stripping buffers might have 
increased the non-specific fluorescence signal, perhaps making the cells stickier that 
enables the antibody to bind non-specifically. It is therefore, impossible to measure 
stripping efficiency using flow cytometric analysis. 
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Figure 6.1: Flow cytometry analysis of the use of two buffers, S1 and S2 to remove cell bound 
phage off the MCF7-αVβ3 cells surface. The cells were incubated with or without phage for 2 
hours at 4C for 2 hours, the bound phage were either stripped using the buffers or not, and 
stained with anti-M13 antibody and subsequent Alexa-488 conjugated secondary antibody. (A) 
shows the distribution of the cells population in a FSC against SSC dot plot graph. Both 
buffers altered the size and granularity of the cells population; hence, no gating was 
performed on the population in the analysis. (B) shows the fluorescence signal obtained from 
the experiment. The blue line shows phage binding to the cells. In samples where either of the 
buffers was used, the fluorescence signal seemed to be amplified (green and grey lines) but 
not in samples where the cells were without any bound phage. This suggests an increase in 
non-specific fluorescence signal, possibly by non-specific binding of the antibody to the cells, 
whenever the stripping buffers were used, thus, making it unfeasible to use flow cytometric 
analysis in measuring the efficiency of stripping buffers. 
 MCF7-αVβ3 cell population - untreated 
 MCF7-αVβ3 cell stripped with S1 buffer 
 MCF7-αVβ3 cell stripped with S2 buffer 
 MCF7-αVβ3 cells without any phage  
 MCF7-αVβ3 cells incubated with phage 
without stripping 
 MCF7-αVβ3 cells stripped with S1 buffer 
 MCF7-αVβ3 cells stripped with S2 buffer 
Cells only RGD phage 
Streptavidin phage 
(A) 
(B)  4p phage 
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 Two other buffers i.e. 0.05% Trypsin-EDTA (Gibco, Life Technologies, NY, USA), 
which is used widely for dissociation of cell monolayers, and S3 buffer containing 1.5% 
[w/v] glycine, 0.1% [w/v] SDS, 1% [v/v] Tween-20, pH 2.2, which is usually used for 
stripping membrane in western blot work had also been tested. When S3 buffer was used, 
none of the samples gave out any fluorescence signal, suggesting cell death due to harsh 
components of the buffer. Conversely, 0.05% Trypsin-EDTA was only able to remove 
50% of the bound phage off the cells surface, which is not adequate, as the remaining 
bound phage would also be recovered in the cell lysate after cell lysis and contributed to 
the actual number of endocytosed phage. 
 As a result, a single phage clone panning experiment was carried out to identify 
which buffer has better ability in removing cell surface bound phage. In this experiment, 1 
x 1011 phage were incubated with MCF7-αVβ3 cells grown overnight in a 6-well plate, 
incubated at 4°C for 2 hours. After three washes, the cell surface bound phage were 
eluted using S1 and S2 buffers. The stripped fractions were then titrated and plated on 
IPTG/XGal plates. 
 Figure 6.2 shows the number of phage stripped using both buffers. Overall, S2 
buffer was shown to be able to remove more 4p and RGD phage from the cell surface, i.e. 
about 2-fold more than S1 buffer. Both buffers stripped about the same number of 
streptavidin phage. From this observation, it can be concluded that S2 buffer is more 
efficient in removing bound phage from cell surface, thus, was chosen to be used in 
successive experiments. 
 
6.2.2  Optimisation of lysis buffers  
 In order to recover endocytosed phage from within the cells, the lysis buffer must 
be able to lyse the cells without killing the phage. Three lysis buffers were tested, i.e. a 
mild lysis agent 1X Lysis Buffer (LB, from Promega), 1% Triton X-100 and lysis buffer C, 
which consists of 10 mM Tris-HCl, pH 7.4, 10 mM NaCl and 10 mM EDTA, containing 
0.5% SDS. 
 The first optimisation experiment was carried out to test whether the buffers could 
kill the phage. 100 l of individual buffer was mixed with 1.5 x 1011 phage in a tube and 
the tubes were subjected to the simulated lysis step as described in section 2.8. The 
phage were titrated at the end of the procedures. PBS and PBS-Tween 0.1% were used 
as control buffers. Table 6.1 shows the number of phage titrated after each simulated 
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lysis procedures. The number of phage remains the same as the initial phage used after 
the procedures in control buffers. In samples in which 1% Triton X-100 and 1X LB were 
used, the number of phage dropped slightly from 1.5 x 1011 to 1.2 x 1011 and 7.75 x 1010 
per 100 l samples, respectively. There was no plaque formed when lysis buffer C was 
used indicating the death of phage by this buffer. 
Next, the ability of the buffers to lyse cells was assessed. In this experiment, 5 x 
105 MCF7-αVβ3 cells were plated per well in a 6-well plate and cultured overnight. 100 l 
of buffer was added into a well and lysis procedure was carried out as described before. 
An observation under a microscope revealed that 1% Triton X-100 could not lyse the cells 
and the cells remained attached firmly on the plate. When a drop of trypan blue reagent 
was added into the well, the cells did not take up the stain, indicating the integrity of the 
cells. In contrast, lysis buffer C lysed all cells instantly when the buffer was added and 
only debris were seen under the microscope. Cells which were lysed using 1X LB 
appeared to have detached from the plate and were blue in colour indicating that they 
have taken in the trypan blue dye and that lysis had taken place. Thus, 1X LB was 
selected as the lysis buffer to be used in following experiments. 
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Figure 6.2: The number of phage recovered after being stripped off MCF7-αvβ3 cells using 
stripping buffer S1 and S2. Phage were incubated with MCF7-αvβ3 cells grown overnight, 
incubated at 4°C for 2 hours, stripped using S1 or S2 buffers and the stripped fractions were 
titrated. S2 buffer was able to remove about 2-fold more 4p phage and RGD phage off the 
cells surface than S1 buffer. Both buffers seemed to have removed the same number of 
streptavidin phage off the cells surface. S2 buffer was chosen to be used in subsequent work 
as stripping buffer. 
 
Table 6.1: The number of phage titrated after simulated lysis procedure using lysis buffers and 
control buffers. The number of phage remained the same as the initial number used in control 
buffers. When 1X LB and 1% Triton X-100 were used, a slight reduction in the number of 
phage titrated after the procedure was observed but the loss is not significant. However, no 
plaque was formed when lysis buffer C was used, indicating the phage was killed by the 
buffer.   
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6.3 Determination of internalising property of 4p phage 
6.3.1  Recovery and titration of cell surface bound and internalised phage in 
  MCF7­αVβ3 cells  
 Having chosen the optimised stripping and lysis buffers, the first method employed 
in assessing the internalisation of 4p phage in MCF7-αVβ3 cells was to recover and titrate 
cell surface bound as well as endocytosed phage from within the cells. In this experiment, 
single phage clones were incubated with the cells at 4C and subsequently at 37C for 1 
hour to allow internalisation. The cell surface bound phage were either stripped using S2 
stripping buffer or not, and the cells were then lysed using 1X LB. Finally, the cell lysates 
were titrated, plated on IPTG/Xgal plates and plaques formed were counted the next day. 
 The data table in Figure 6.3 summaries the number of phage titrated for each 
phage clone under different incubation temperature and conditions. TBP fractions are the 
number of phage from cells samples that were lysed after incubation without any stripping 
step and represent the total number of cell surface bound phage. EP fractions are the 
number of phage from cells samples that were stripped using S2 buffer prior to cell lysis 
and represent the number of phage recovered from within the cells following stripping. 
Figure 6.3 shows that the highest number of phage titrated from each sample condition is 
RGD phage, followed by 4p phage and streptavidin phage.  
 Figure 6.4 shows the percentage of internalisation of each phage clones at 4C 
and 37C. The percentage was calculated by dividing the number of phage recovered 
from within the cells (EP fraction) with the total number of cell bound phage (TBP 
fractions).  
 It was found that at 37C, the highest percentage of phage internalised by MCF7-
αVβ3 cells was RGD phage followed by 4p phage, with about 25% and 15% of the total 
cell bound phage internalised, respectively. 7% of the total cell bound streptavidin phage 
also internalised. Meanwhile, at 4C, the percentage of internalisation is below 5% for all 
phage clones.  
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Figure 6.3: Number of total bound phage and internalised phage recovered in MCF7-αVβ3 
cells. 4p, RGD and streptavidin phage were incubated with MCF7-αVβ3 cells at 4oC for 2 hours 
and then at 37oC for another hour, washed and either stripped with S2 buffer or not prior to 
addition of 1X LB lysis buffer. The cell lysates were then titrated. The number of 4p phage is 
higher than streptavidin control clone, whereas RGD clone has the highest titer value in all 
sample conditions.  
 
  
Figure 6.4: Percentage of internalisation of phage in MCF7-αVβ3 cells. The percentage of 
internalisation was calculated by dividing the number of phage recovered from within the cells 
(EP fraction) with the total number of cell bound phage (TBP fractions). At 37oC, 4p phage 
internalised about 2 times more efficient than streptavidin phage. RGD clone phage has the 
highest internalisation efficiency compared with the rest of the phage. At 4oC, the percentage 
of internalisation of all phage is below 5%. 
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6.3.2  Co­localisation of 4p phage with endosomes in MCF7­αVβ3 cells  
 Previous experiments in section 6.3.1 have shown that 4p phage can be 
internalised by MCF7-αVβ3 cells. Although the fraction is not very high, it is important to 
validate the finding. Therefore, immunostaining and confocal microscopy was carried out 
to verify the previous evidence of 4p phage internalisation in the cells.  
 In this experiment, MCF7-αVβ3 cells grown overnight on coverslips were incubated 
with 4p phage for 2 hours at 4°C, washed and further incubated at either 4°C or 37°C for 
another hour. The cells were then fixed, permeabilised, blocked and stained with either an 
isotype control antibody or anti-M13 antibody and anti-EEA1 antibody, and subsequent 
Alexa-488 and Alexa-594 conjugated secondary antibodies, respectively. Sequential 
scanning of the multiple channel fluorescence was used in order to reduce cross talk 
(bleed through). 
 Figure 6.5 shows the confocal images of cells incubated with 4p phage and 
stained with isotype control antibody. The top panels shows the isotype control cells 
incubated at 4°C whereas the bottom panels show cells incubated at 37°C. The 
endosome panels show images of endosome staining denoted by red punctate 
surrounding the nuclei, which can be seen clearly in the merge panels (right panels). 
There was no Alexa 488 fluorescence signal detected in cells incubated at both 
temperatures (phage panel), indicating the machine has been calibrated correctly to have 
minimal background signal. 
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Figure 6.5: The confocal images of the isotype control of MCF7-αVβ3 cells. The cells were 
incubated with 4p phage at 4°C (top panels) and 37°C (bottom panels), fixed and 
permeabilised, and stained with an isotype control antibody and anti-EEA1 antibody, and 
subsequent Alexa 488- and Alexa 594-conjugated secondary antibodies. The left panels 
(endosome) show endosomal staining denoted by red punctate images, which can be seen 
localised around the DAPI stained nucleuses (pseudo blue) on the merge panels (right 
panels). The middle panels (phage) show no detection of the Alexa 488 fluorophore, 
confirming that the isotype control antibody is working. This also indicates that the machine 
has been set up correctly.  
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 Figure 6.6 shows the confocal images of cells incubated with 4p phage and 
stained with anti-M13 antibody and anti-EEA1 antibody, and subsequent Alexa 488 and 
Alexa 594 conjugated secondary antibodies, respectively. The top panels show images of 
cells incubated with 4p phage at 4°C whereas the bottom panels show cells incubated at 
37°C. The nuclei were stained with DAPI and are denoted by the pseudo colour blue 
(merge panels). The red speckled images that can be seen in endosome panels at both 
4°C and 37°C incubation represent the endosomal staining of the cells. The presence of 
4p phage is indicated by the green punctate appearance in phage panels. 
 In order to demonstrate the co-localisation of the phage and the endosomes inside 
the cells, the analysis software was set to produce white specks at all area where the two 
respective fluorescence channels overlapped. As observed in the co-localisation panels, 
the presence of white spots is obvious and more noticeable in 37°C panel than that in 
4°C. There are also more green punctate images that remain green in colour when the 
channels are overlapped at 4°C compared to that at 37°C. These observations indicate 
that 4p phage not only binds MCF7-αVβ3 cells but also are able to be internalised and co-
localise with the endosomes. 
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Figure 6.6: The confocal images of immunostaining of 4p phage and MCF7-αVβ3 cells. The cells were incubated with the phage at 4°C (top panels) 
and 37°C (bottom panels), fixed and permeabilised and then stained with anti-M13 antibody and anti-EEA1 antibody, and subsequently with 
secondary antibody conjugated with Alexa 488 and Alexa 594, respectively. The Endosome panels show the staining of endosomes denoted by red 
dotted images, which can be seen surrounding the nucleuses (merge panels). The green punctate images observed in Phage panels indicate the 
presence and the staining of 4p phage. The co-localisation of 4p phage and endosome is represented as white spots images in the co-localisation 
panels. The presence of white spots is more evident in 37°C than in 4°C, implying that internalisation of 4p phage is more efficient at 37°C.
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6.4 Determination of internalising property of DC phage 
6.4.1  Recovery and titration of cell surface bound and internalised phage in iDC 
 The ability of DC4.25 and DC4.44 phage to bind to iDC was previously shown in 
Chapter 5. The next aim was to determine whether these phage could be internalised by 
iDC. To achieve this goal, single phage clones were incubated with iDC at 4C and 
subsequently at 37C. Cell surface bound phage were either stripped using stripping 
buffer S2 or not, prior to cell lysis using 1X LB. The cell lysates were then titrated and 
plated on IPTG/Xgal plates. 
 Figure 6.7 shows the number of DC4.25, DC4.44 and streptavidin phage 
recovered at the end of the experiment. The TBP fractions are the amount of phage 
titrated from cell lysates of cells samples without stripping step and represent the total 
number of cell surface bound phage. The EP fractions correspond to the number of phage 
recovered from within the cells of samples that undergone stripping step prior to cell lysis. 
The number of DC phage recovered in all samples is higher than that of streptavidin 
phage, with the number of DC4.44 phage being the highest of all.  
 From these values, the internalisation percentage was calculated. This was done 
by dividing the EP fractions with the respective TBP fractions. Figure 6.8 shows the 
percentage of internalisation of each phage clones at 4oC and 37oC. At 37oC, about 68% 
of the total cell surface bound DC4.25 phage internalised, followed by DC4.44 and 
streptavidin phage at the rate of 36% and 8% internalisation, respectively. At 4oC, the 
percentage of phage internalisation is below 8%.  
 
6.4.2  Co­localisation of DC phage with endosomes in iDC 
 It has been shown in the previous section that DC phage can be recovered from 
within the dendritic cells and this fraction may represent the phage that had been 
internalised by cells. To verify this finding, immunostaining and confocal microscopy was 
carried out to determine the locality of the phage and thus, validate the previous evidence 
of phage internalisation in the cells.  
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Figure 6.7: Number of total bound phage and internalised phage recovered in iDC. DC4.25, 
DC4.44 and 2strep phage were mixed with iDC, incubated at 4oC for 2 hours and 
subsequently at 37oC for an hour, washed and either stripped with stripping buffer or not prior 
to addition of lysis buffer. The cell lysates were then plated on IPTG/Xgal plates. The TBP 
fractions represent the total number of cell surface bound phage whereas the EP fractions 
represent the internalised phage. The number of DC phage recovered are higher than the 
streptavidin control clone, in all sample conditions, with the number of DC4.44 phage being 
the highest recovered in all samples. 
 
  
Figure 6.8: Percentage of internalisation of phage in iDC. The percentage of internalisation 
was calculated by dividing the number of phage recovered from within the cells (EP fraction) 
with the total number of cell bound phage (TBP fractions). The graph showed 67.6% 
internalisation of DC4.25 phage at 37oC followed by DC4.44 phage and streptavidin phage, at 
the rate of 36% and 8%, respectively. The percentage of internalisation at 4oC is below 8%.  
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 iDC were aliquoted onto poly-L-lysine treated coverslips and left in the 37°C 
incubator to allow the cells to adhere to the coverslips. The cells were then incubated with 
DC4.25 and DC4.44 phage for 2 hours at 4°C and further incubated for another hour at 
either 4°C or 37°C. The cells were then fixed, permeabilised, blocked and stained with 
either isotype control antibody or anti-M13 antibody and anti-EEA1 antibody, and 
subsequent Alexa 488- and Alexa 594-conjugated secondary antibodies. Sequential 
scanning of the multiple channel fluorescence was used in order to reduce cross talk 
(bleed through). 
 Figure 6.9 shows the isotype control cells incubated at 4°C (top panels) whereas 
the bottom panels show cells incubated at 37°C. The endosome staining was shown in 
the first panel and denoted by red spotted images. The red spots were localised around 
the nucleuses (stained with DAPI), which can be seen clearly in the merge panels (right 
panels). There was no Alexa 488 fluorescence signal detected in cells incubated at both 
temperatures (phage panel), indicating the machine has been calibrated correctly to have 
minimal background signal. 
 Figure 6.10 shows the confocal images of iDC incubated with DC4.25 phage (A) 
and DC4.44 (B) at 4°C and 37°C, stained with anti-M13 antibody and anti-EEA1 antibody 
and Alexa 488- and Alexa 594-conjugated secondary antibodies. The top panels show 
images of cells incubated at 4°C whereas the bottom panels show cells incubated at 
37°C. The nucleuses were stained with DAPI and are denoted by the pseudo colour blue 
(merge panels). The red speckled images that can be seen in the left panels at both 4°C 
and 37°C incubation represent the endosomal staining of the cells (endosome panel). The 
presence of the phage is indicated by the green spotty appearance in the second panels 
(phage panel). At 4°C, green spots appeared to be concentrated around the cells, 
whereby at 37°C they appeared to be more spread-out all over the cells.  
 During analysis, the Alexa 594 and Alexa 488 fluorescence channels were 
overlapped in order to demonstrate the co-localisation of the phage with the endosomes 
inside the cells. The white specks images show the phage co-localisation with the 
endosomes. As observed in the co-localisation panels, the presence of white specks is 
obvious and more noticeable in 37°C panel than that in 4°C. These observations indicate 
that DC phage can be internalised and co-localised with endosomes. 
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Figure 6.9: The confocal images of iDC isotype control at 4°C and 37°C. iDC were incubated 
with DC phage at 4°C (top panels) and 37°C (bottom panels), fixed and permeabilised and 
then stained with an isotype control antibody and anti-EEA1 antibody, and subsequent 
secondary antibody conjugated with Alexa 488 and Alexa 594 fluorophores. The left panels 
show endosomal staining denoted by red punctate images, which can be seen localised 
around the DAPI stained nucleuses on the merge panels (right panels). The middle panels 
show no staining of the phage. This indicates that the machine has been set up correctly.  
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Figure 6.10: The confocal images of iDC incubated with DC4.25 phage (A) and DC4.44 (B). iDC were incubated with the phage at 4°C (top panels) 
and 37°C (bottom panels), fixed and permeabilised and then stained with anti-M13 antibody and anti-EEA1 antibody, and subsequent secondary 
antibody conjugated with Alexa 488 and Alexa 594, respectively. The first left panels (endosome) show the staining of endosomes denoted by red 
dotted images, which can be seen surrounding the nucleuses (merge panels). The green punctate images observed in phage panels indicate the 
presence of DC phage on iDC. At 4°C, the phage were more concentrated around the cells whereby at 37°C, they appeared to be more spread out all 
over the cells. The co-localisation of the DC phage and the endosomes are presented as white speckled images in the co-localisation panels. The 
presence of white spots is more evident in 37°C than in 4°C, implying that there is more cell uptake of the DC phage at 37°C than at 4°C.
Endosome
   
Phage  Merge 
Co-localisation (all 
channels overlap) 
 
 
Co-localisation 
(white colour only) 
 
 
4°C 
 
37°C 
 
(B) DC4.44 phage  
     
  113 
7.0  CHAPTER 7 
7.1 Peptide design 
DC4.25 and DC4.44 phage have encoded peptide sequences of CFPPTFPAC 
and CTPLLSPFC, respectively. In previous chapters, it has been shown that these phage 
are able to bind to and be internalised by the target cells, iDC. Based on those 
characteristics, both peptide sequences have great potential to be developed into 
targeting molecules in gene delivery. The encoded peptide sequences of the phage were 
synthesised as free soluble peptides to enable more detailed studies to be carried out 
without the avidity artifacts associated with pentavalent display on such phage.  
Figure 7.1 shows a schematic diagram of the peptides. The peptides were 
synthesised as cyclised peptides as the library used in panning was a loop-constrained 
heptapeptide (Ph.D.-C7C) library. The randomised segment is flanked by a pair of 
cysteine residues (C) and formed disulfide bond (represented as SS) that resulted in the 
loop structure of the peptides. The first randomised position is preceded by Ala-Cys (AC) 
followed by 7 random residues (denoted as X). The Gly-Gly-Gly-Ser spacer (GGGS) was 
also included in the peptide sequence as the short linker sequence was also present 
between the displayed peptide and the pIII of the phage library used.  
For assay detection, a lysine (K) was added right after the spacer to enable biotin 
conjugation at the C-terminus of the peptides. The C-terminus of the synthetic peptides 
was amidated to block the negative charge. This is because during panning, the C-
terminal residue of the displayed sequence did not have a free negatively charged 
carboxylate. No modification was made at the N-terminus of the peptides. 
Pep-4.25 and Pep-4.44 are free synthetic peptides of the encoded peptide 
sequences of DC4.25 and DC4.44 phage. Pep-4.25-control and Pep-4.44-control were 
also synthesised and contain scramble-displayed sequence of DC4.25 and DC4.44, 
respectively. The peptide sequence of all four peptides was as shown in Figure 7.1 
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Figure 7.1: The design of the peptides. Ala-Cys (AC) preceded the randomised displayed 
sequence (XXXXXXX), followed by another Cysteine residue (C) and a Gly-Gly-Gly-Ser 
(GGGS) spacer. A Lysine (K) was added after the spacer to enable biotin conjugation at the 
C-terminus of the peptides. The Cysteine pair form disulfide bond causing the peptide to be in 
a cyclised form. There was no modification made at the N-terminus while the C-terminus was 
amidated to block the negative charge. Pep-4.25 and Pep-4.44 contained the encoded 
peptide sequence of DC4.25 and DC4.44 phage, respectively, while Pep-4.25-control and 
Pep-4.44-control contained scramble-displayed sequence of DC4.25 and DC4.44 phage, 
respectively. 
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7.2 Determination of binding ability of biotinylated peptides towards iDC 
The synthetic biotinylated peptides were dissolved in DMSO as stock and stored 
at -20°C. Fresh working stocks were prepared by dilution with PBS in every experiment.  
Firstly, in order to determine the ability of the monomeric peptides to bind to iDC, 
the cells were incubated with various concentration of the peptides ranging from 10 nM to 
1000 nM for 2 hours at 4°C. The samples were then centrifuged to remove the 
supernatant. The cell pellets were re-suspended and incubated with 10 µM of streptavidin 
conjugated with Alexa Fluor® 488 (strep488) at 4°C for 20 minutes. The cells were 
centrifuged, the supernatant were removed and the cell pellets were re-suspended in PBS 
prior to flow cytometric analysis. 
Figure 7.2(A) shows the mean fluorescence intensity (MFI) of each sample. When 
the cells were incubated with the monomeric peptides in the range between 10 and 800 
nM concentrations, the MFI of the samples were between 12 and 16. This low MFI 
indicates no peptide binding to the cells. There is an increase in the MFI in all samples 
including control when 1000 nM peptides were used, suggesting a non-specific binding of 
the peptides towards the cells.  
The experiment was then repeated using higher concentration of peptides, in µM 
range. iDC were incubated with increasing concentration of peptides, ranging from 10 to 
1000 µM. The cells were treated exactly as mentioned in the above experiment.  
Figure 7.2(B) shows the MFI of each sample where iDC were incubated with 
monomeric peptides in µM concentration range. In samples with peptides concentration 
ranging from 10 to 800 µM, there is no evidence of peptide binding to the cells, indicated 
by the low MFI, which are between 7 and 13. There seemed to be a slight increase in the 
MFI of all samples when 1000 µM peptides were used, including the scramble control 
peptides, indicating a non-specific binding of the peptides towards iDC. 
These two experiments pointed out that single/monomeric biotinylated peptides 
are unable to bind to iDC. It was considered that this might be because of the low affinity 
of the peptides towards the cells. Thus, the next strategy was to make peptide-strep488 
complexes in effort to increase the avidity of the interaction. 
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Figure 7.2: The binding of biotinylated peptides to iDC in (A) nM and (B) µM range 
concentrations. The peptides were incubated with iDC for 2 hours at 4°C. The cell pellets were 
then re-suspended and incubated with streptavidin conjugated with Alexa Fluor® 488 
(strep488) at 4°C for 20 minutes. iDC were incubated with strep488 alone as control samples 
and the binding was analysed using flow cytometry analysis. There is no evidence of peptide 
binding when the concentration of peptide used was between 10 and 800 nM as well as 
between 10 and 800 µM. When the highest amount of peptides was used in both experiments, 
there is a slight increase in the MFI, indicating a non-specific binding of the peptides.  
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 As streptavidin is a tetramer and each subunit binds biotin with equal affinity, the 
next strategy was to create peptide-strep488 complexes to increase the binding avidity of 
the peptides to the target cell. Each peptide was mixed with strep488 in 4 to 1 molar ratio 
concentration at room temperature for 30 minutes, on a roller to ensure complete mixing. 
The complexes were kept on ice until use. Assuming optimum conjugation had taken 
place, the final concentration of the complexes was 15 µM. iDC were then incubated with 
increasing concentration of the cooled complexes at 4°C for 45 minutes. After 
centrifugation to remove the supernatant, the cell pellets were re-suspended with PBS 
and analysed using flow cytometry.  
 Figure 7.3 shows the MFI value of each peptide-strep488 complex binding to iDC. 
There seemed to be an increase in the MFI of the samples, i.e. from around 50 to 300, 
suggesting an increase in the binding of the complex to iDC in dose-dependent manner. 
However, the fact that the control peptides are also binding in the exact same pattern 
shows that the binding is non-specific. Furthermore, iDC alone when stained with 5 µM of 
strep-488 has an MFI of 259 suggested that the fluorescence signal obtained in the 
experiment might be due to non-specific binding of strep488 to iDC.  
 
7.3 Controls experiment to ascertain non-specific binding of strep488 to 
iDC 
7.3.1  To investigate whether strep488 binds iDC through biotin binding sites 
Control experiments were carried out to investigate whether the binding of the 
peptides to iDC was a result of streptavidin binding non-specifically to the cells and that to 
some extent masking the real binding of the peptides to the cells. 
The first experiment was carried out by saturating streptavidin with free 
unconjugated biotin prior to binding to iDC. In this experiment, 2.5 µM strep488 was 
saturated with excess free biotin (10, 20, 50 and 100 µM) at room temperature on a roller 
for 30 minutes. The complex were kept at 4°C until use. 2 x 105 iDC were then mixed with 
the cooled complexes and incubated at 4°C for 45 minutes. As a control, iDC were also 
incubated with 2.5 µM strep488 alone. The samples were centrifuged, re-suspended in 
PBS and analysed immediately using flow cytometry.  
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Figure 7.3: The binding of biotinylated peptide-strep488 complex to iDC. The complex was 
made by mixing peptide with strep488 in 4 to 1 ratio, incubated with the cells at 4°C for 45 
minutes and analysed using flow cytometry. MFI of all samples increases in complex 
concentration dose dependent manner, suggesting a non-specific binding of the complex to 
iDC had taken place. 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
300
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 
Biotinylated peptide‐streptavidin488 complex (µM) 
Pep‐4.25
Pep‐4.25‐control
Pep‐4.44
Pep‐4.44‐control
     
  119 
Figure 7.4 shows the flow cytometric analysis of the experiment. The fluorescence 
signal obtained from samples with biotin-saturated strep488 was equivalent to that of iDC 
stained with strep488 alone. This indicates that the non-specific binding of strep488 
towards iDC does not happen through the sites on the iDC that bind to the biotin binding 
sites of streptavidin. 
 
7.3.2  To determine whether endogenous biotin in iDC bind strep488 
 As all living cells contain endogenous biotin, the next step was to determine 
whether the high, non-specific background signal was due to strep488 binding to the 
endogenous biotin in iDC. Therefore, the cells were pre-incubated with unlabelled 
streptavidin to block any streptavidin binding sites on biotin or biotin-like molecules in the 
cells. 
 iDC were pre-incubated with 10 µM unlabelled streptavidin for half an hour at 4C, 
washed with PBS and various concentration of strep488 was added to each samples. The 
cells were further incubated at 4C for 45 minutes, and then centrifuged. The cells were 
re-suspended in ice-cold PBS for immediate flow cytometric analysis. 
 The flow cytometric analysis of the experiment in Figure 7.5 clearly shows that 
there is no difference in the fluorescence signal between cells that had been pre-
incubated with unlabelled streptavidin with those untreated.  This signifies that the non-
specific binding of strep488 towards iDC does not happen through streptavidin binding 
sites on biotin or biotin-like molecules on iDC.  
 In addition, both experiments in Section 7.3.1 and 7.3.2 also fail to demonstrate a 
method for reducing undesired non-specific binding of strep488 to iDC. 
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Figure 7.4: Binding of biotin-saturated streptavidin to iDC. Streptavidin was saturated with 
different concentration of excess biotin, incubated with iDC and the samples were analysed 
using flow cytometry. The fluorescence signal of iDC stained with biotin-saturated streptavidin 
(for all different biotin concentration used) is equivalent to that of iDC stained with strep488 
alone. This indicates that the binding of strep488 to iDC is not at the biotin binding sites on the 
cells. 
 
   
   
Figure 7.5 The effect of endogenous biotin in the binding of iDC to strep488. iDC were pre-
incubated with unlabelled streptavidin for half an hour at 4C before the addition of various 
concentration of strep488. The cells were incubated at 4C for 45 minutes and analysed using 
flow cytometry. There is no difference in the fluorescence signal between cells that had been 
pre-incubated with unlabelled streptavidin with those untreated, suggesting that the non-
specific binding of strep488 towards iDC does not happen through streptavidin binding sites.  
 iDC alone 
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7.3.3  To investigate whether longer incubation of strep488 with iDC increase non­
specific binding 
 So far, it has been shown that the non-specific binding of strep488 towards iDC 
does not happen through the biotin binding sites or the streptavidin binding sites on the 
cells. Another control experiment was set up to investigate whether longer incubation of 
strep488 with iDC could increase the non-specific binding. Two concentration of strep488 
were tested to see whether higher concentration of strep488 would produce higher non-
specific binding.  
 iDC were incubated with 5 µM and 10 µM strep488 at 4C with different time 
incubation. The cells were washed with PBS and re-suspended in PBS prior to flow 
cytometric analysis. The MFI value of strep488 binding to iDC is as shown in Figure 7.6. 
The MFI value of the samples increased as the incubation time increased. This pattern 
can be seen in both strep488 concentration used, although in samples where 10 µM 
strep488 was used, the MFI value is relatively higher. This indicates that longer incubation 
of strep488 with iDC increases binding non-specifically. 
 
7.4 Establishing the optimum ratio of biotinylated peptide to strep488 in 
making binding complex using HABA-Avidin  
 HABA-Avidin has been widely used as a standard assay to determine the level of 
biotin incorporated into a protein. The assay is based on the ability of the HABA dye to 
bind to avidin and of biotin to displace the dye. Free HABA dye (4'-hydroxyazobenzene-2-
carboxylic acid) has an absorption peak at 348 nm. When HABA binds to avidin, a yellow-
orange colored complex is produced, which has a strong absorption at 500 nm. Biotin 
binds non-covalently to avidin with high affinity (Kd=1x10-15 M). Since the affinity between 
HABA and avidin is relatively weak (Kd=5.8x10-6 M) compared to the affinity between 
biotin and avidin, biotin can easily displace HABA from the HABA-Avidin complex. This 
results in a decrease of absorption at 500 nm and this change is directly proportional to 
the level of biotin in the sample. 
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Figure 7.6 The effect of longer incubation of strep488 with iDC in non-specific binding. iDC 
were incubated with 5 µM and 10 µM strep488 at 4C with different time incubation. The cells 
were washed and re-suspended in PBS prior to flow cytometric analysis. The MFI value of the 
samples increased as the incubation time increased in both strep488 concentrations, although 
relatively higher in samples where 10 µM strep488 was used. This indicates that longer 
incubation of strep488 with iDC increases binding non-specifically. 
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 By using this method, not only could the level of biotinylation of each peptide could 
be estimated, more importantly, the ratio of peptide to strep488 needed in making binding 
complex could be established optimally. This could also prevent excess free strep488 in 
binding experiment, which would lead to a higher non-specific fluorescence signal. Avidin 
was used instead of strep488 to simulate the complex making because Alexa 488 
fluorophore conjugated to the streptavidin (also yellow in colour) interfered with the 
absorption readings at 500 nm. 
 In this experiment, 20 mL HABA-Avidin solution was prepared by adding 10 mg 
Avidin to 600 µL HABA solution (10 mM) and PBS. The concentration of avidin in this 
complex solution is 7.4 µM and was considered as 1 ratio concentration (all ratio in this 
experiment was with respect to this ratio concentration). The free unconjugated biotin was 
added to HABA-Avidin complex in increasing fold-concentration with respect to avidin as 
a control to determine that the assay was functionally working. Figure 7.7 shows that 
there is a dose dependent displacement of HABA by biotin. The maximum displacement 
happened when 4 ratio concentration of biotin was added to the complex, i.e. 4 to 1 ratio 
of biotin to avidin. This is expected as avidin is tetrameric and can bind 4 biotin with high 
affinity. However, when the biotinylated peptides were added in to displace HABA in 
HABA-Avidin complex, the displacement of HABA was minimal, even at the highest ratio 
concentration used i.e. 10 to 1 of peptides to Avidin.  
 The experiment was repeated using higher concentration of biotinylated peptides 
to displace HABA from the complex, starting from 10 to 1, to 200 to 1 of peptide to avidin 
ratio concentration. Free unconjugated biotin was also included as a positive control. 
Figure 7.8(A) shows the complete displacement of HABA by biotin at 4 to 1 ratio 
concentration indicating that the assay worked as previously shown. Figure 7.8(B) shows 
a slight decrease in the absorption readings of OD 500 nm in all peptide samples, 
including when DMSO of equivalent concentrations was used. This indicates that the 
change in the readings is due to DMSO (used as solvent for the biotinylated peptide) and 
that there is no functional biotin present on these peptides. 
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Figure 7.7: Displacement of HABA in HABA-Avidin complex using biotinylated peptides. 
HABA-Avidin solution was prepared and the amount of avidin used was considered as 1 ratio 
concentration. Biotin and biotinylated peptides of increasing ratio concentration were used to 
displace HABA in the complex. There was a maximum displacement of HABA when biotin to 
avidin ratio concentration is 4 to 1. There was a minimum displacement of HABA by the 
peptides, even at the highest ratio of 10 to 1 of peptides to avidin.  
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Figure 7.8: Displacement of HABA in HABA-Avidin complex using higher concentration of 
biotinylated peptides. HABA-Avidin solution was prepared and the amount of avidin used was 
considered as 1 ratio concentration. Biotin and biotinylated peptides of increasing ratio 
concentration were used to displace HABA in the complex. (A) shows a maximum 
displacement of HABA when biotin to avidin ratio concentration is 4 to 1, indicates the assay 
worked. (B) shows that there was a decrease in the absorption readings when biotinylated 
peptides were added into the complex. However, the displacement of HABA is due the effect 
of DMSO used as solvent. This clearly shows that there is no functional biotin present in the 
peptides. 
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7.5 HABA-Avidin assay on newly synthesised peptides 
Having shown that the biotinylated peptides are non-functional, second set of 
biotinylated peptides were made. HABA-Avidin assay was carried out on the newly 
synthesised peptides to ensure that functional biotin is attached and also to determine the 
optimum ratio of peptides to strep488. Again, avidin was used to simulate the complex 
making because the yellow colour of strep488 (due to Alexa Fluor® 488 fluorophore) 
interfered with the absorption readings at 500 nm. The procedure is as described in 
section 2.10 and section 7.4. 
In this experiment, biotinylated peptides were added to HABA-Avidin complexes in 
increasing fold-concentration with respect to Avidin. Free unconjugated biotin and DMSO 
were included as positive and solvent controls, respectively. Figure 7.9 shows that there 
is the expected dose dependent displacement of HABA by biotin with maximum 
displacement happened at 1 to 4 ratio of Avidin to biotin. Maximum displacement of HABA 
by Pep-DC4.25, Pep-DC4.25-control and Pep-DC4.44-control happened when slightly 
more than 4:1 of peptides:Avidin ratio was used. Pep-DC4.44 displaced HABA maximally 
at 6:1 ratio of peptides:Avidin, whereas the displacement of HABA by DMSO solvent 
control was minimal.  
From this experiment, it is deduced that the optimum ratio for peptide-strep488 is 
6 to 1 of peptides to strep488. Furthermore, it shows that the new batch of peptides was 
synthesised and biotinylated properly, although they may not be perfect (as the ratio for 
peptide-strep488 is 6:1 instead of 4:1). 
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Figure 7.9 Displacement of HABA in HABA-Avidin complex using newly synthesised 
biotinylated peptides. HABA-Avidin solution was prepared and the amount of avidin used was 
considered as 1 ratio concentration. The biotinylated peptides of increasing ratio concentration 
were used to displace HABA in the complex, while free unconjugated biotin and DMSO were 
included as positive and solvent controls, respectively. Maximum displacement of HABA by 
biotin happened at 1 to 4 ratio of Avidin to biotin. Maximum displacement of HABA by Pep-
DC4.25, Pep-DC4.25-control and Pep-DC4.44-control happened when slightly more than 4:1 
ratio of peptides:Avidin was used. 6:1 ratio of Pep-DC4.44:Avidin displaced HABA maximally 
whereas the displacement of HABA by DMSO solvent control was minimal. From this 
experiment, it is deduced that the optimum ratio for peptide-strep488 is 6 to 1 of peptides to 
strep488.   
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7.6 Determination of peptides binding to iDC 
In order to identify the binding ability of the peptides to iDC, the peptides were first 
mixed with strep488 using the 6:1 ratio identified in section 7.5. The mixture were 
incubated for half an hour at room temperature and kept cooled until use. The complex 
ability to bind iDC was tested by incubating various concentrations of complexes with iDC 
at 4C for 45 minutes. The cells were washed with PBS and re-suspended in PBS prior to 
flow cytometric analysis. 
Figure 7.10 shows the MFI value of the complexes binding to iDC. There is an 
increase  in  the MFI  value of all peptide complexes with  the  increase of  the complexes’ 
concentration. However, the MFI value of the biotin-strep488 complexes also increases in 
a similar manner indicating that all binding was non-specific. It has been thought that the 
experimental approach might not be sensitive enough to detect any real binding signal. 
Therefore, another experiment was carried out to determine the binding ability of the 
peptide complexes by using HRP conjugated streptavidin to amplify any positive signal. 
 
7.7 Determination of peptides binding to iDC using strepHRP 
 In order to increase the sensitivity of the binding assay, streptavidin conjugated 
with horseradish peroxidase (strepHRP) was used to replace strep488 in the binding 
complexes. The peptide-strepHRP complexes were made using ratio identified in section 
7.5. The ratio of peptide to strepHRP and biotin to strepHRP are 6 to 1 and 4 to 1, 
respectively. 
 The cooled peptide-strepHRP complexes were incubated with iDC at 4C for 45 
minutes in a 96-well plate. After washing twice with PBS, the pellets were resuspended in 
TMB solution. Once the desired blue signal was acquired, the reaction was stopped using 
stop solution. The plate was centrifuged to pellet the cells and 100 µl of the supernatant 
were transferred into a new plate and the plate was read at 450 nm. Biotin-strepHRP 
complexes were included as control. 
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 The binding of the complexes to iDC is shown in Figure 7.11. There is binding of 
complexes to iDC as indicated by the increased value of OD 450 nm. The biotin-
strepHRP complexes have the lowest OD 450 nm value in all sample concentrations. 
Pep-DC4.25, Pep-DC4.44 and Pep-DC4.44-control have similar binding pattern over 
different concentrations of complexes added. Pep-DC4.25-control, however, has more 
binding than the rest of the peptides. Since Pep-DC4.25-control is a scrambled peptide of 
Pep-DC4.25 and served as a control peptide, this result further confirmed that the 
peptides bind non-specifically to iDC. 
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Figure 7.10 The MFI value of the peptide/biotin complexes binding to iDC. The complexes 
were made according to the ratio determined previously. The complexes were incubated with 
iDC at 4C for 45 minutes, washed and analysed using flow cytometry. The MFI value of all 
complexes increased over increased concentration of peptide/biotin complexes. However, the 
binding pattern of biotin-strep488 complexes suggests that the binding of the complexes to 
iDC is non-specific. 
 
 
Figure 7.11 Binding of peptide/biotin-strepHRP complexes to iDC. The complexes were made 
using ratio determined in section 7.5. The complexes were incubated with iDC at 4C for 45 
minutes. The complexes that had been washed were re-suspended with TMB solution before 
addition of Stop Solution to stop the reaction and the plate was read at 450 nm. There is an 
increase in the OD 450 nm value in all samples as more complexes were used in the binding 
assay. However, the highest binder among the complexes was Pep-DC4.25-control-
strepHRP. This further confirms that the binding of the peptides to iDC is non-specific. 
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8.0  DISCUSSION 
8.1 Phage display 
 Phage display is a powerful tool for selecting peptides, proteins or antibodies 
based on their binding affinity and specificity. According to Brown (Brown, 2000), there 
are three ways of selecting cell-specific targeting peptides by using phage display, i.e. the 
selection could be carried out against purified cell-surface markers, by in vitro selection 
using whole cells or in vivo selection of tissues in animals. Our previous study has given 
us the experience in phage display techniques. In particular, phage display has been 
employed in identifying homing peptides specific for human synovial microvascular 
endothelium (MVE). Such peptides could be used as targeting tools for drug delivery to 
human joints in the treatment of arthritic conditions (Lee et al., 2002). 
The Ph.D.-C7C phage library used in this study consists of randomised 7-mer 
peptides, each flanked by a pair of cysteine residues. The library contains 3.7 x 109 
independent clones, theoretically sufficient to encode all of the 207 = 1.28 x 109 possible 
7-residue sequences. Early work in this study involved the isolation of peptide phage 
specific for a known target in an attempt to test the ability of the library to isolate peptide 
with specific motif. Purified streptavidin was used as a target and the selection was aimed 
at isolating streptavidin-binding peptides through specific biotin interaction site. Peptide 
sequence analysis revealed that out of 10 clones selected after 3 rounds of panning, 3 
phage clones contain HPQ motif and 4 other clones has HPM motif in the deduced 
peptide sequence. While the HPQ motif is the most commonly identified sequence when 
using streptavidin as a target (Devlin et al., 1990), HPM is another consensus sequence 
that is commonly seen (Lam et al., 1991). ELISA results showed that all three peptide 
phage clones bearing HPQ motif were indeed specific for streptavidin and one of the 
clones, i.e. 2strep clone was used later in this study as control phage. The success of 
isolating peptide phage with HPQ and HPM motifs proved that the library is capable of 
isolating peptide with specific motif. 
The next validation of the phage library and its system was carried out by selection 
against cell line expressing αVβ3 integrin, MCF7-αVβ3. This was to test whether phage 
bearing specific binding motifs with specificity to the target could be selected in vitro using 
whole cells as target. There have been many reports on panning selection using peptide 
phage display library against cell lines in culture. For example, Lo and co workers have 
identified a novel peptide (SP94), when phage displayed random peptide libraries were 
used to pan against human hepatocellular carcinoma lines (Lo et al., 2008). Using ELISA 
and flow cytometry analysis, the phage clone PC94 was shown to bind to these cell lines 
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while in vivo study in severe combined immunodeficient mice bearing human 
hepatocellular carcinoma xenografts has shown that PC94 homed specifically to tumor 
tissues but not to normal visceral organs, suggesting the specificity of the peptide 
isolated.  
 Other work has also reported the use of phage displayed random peptide libraries 
to identify peptides with specific binding to Rhabdomyosarcoma (RMS) tumour cells (Witt 
et al., 2009). By screening such libraries on RMS cell line RD, two novel peptides, RMS-I 
and RMS-II were identified to bind to RMS and other tumour cell lines, but not to 
fibroblasts and normal skeletal muscle cells. Interestingly, the group has characterised 
these two peptides and found out that RMS-I (CQQSNRGDRKRC) contained the RGD 
motif and an antibody against αVβ3 integrin, which is expressed on the RMS cell line RD, 
blocked its binding to the cells. 
  αVβ3 integrin is a member of the integrin superfamily of adhesion molecules. It is a 
non-covalently formed heterodimer consists of a 125 kDa alpha V subunit and a 105 kDa 
beta 3 subunit (Wilder, 2002). It was originally isolated as the vitronectin receptor but also 
interacts with other ECM proteins including fibronectin, fibrinogen, osteopontin, 
thrombospondin, von Willebrand factor and others (van der Flier and Sonnenberg, 2001). 
It is highly expressed in osteoclasts, upregulated at inflammatory sites and tumors 
including ovarian and breast cancer. The expression of αVβ3 is at low level in most normal 
tissues including platelets, kidney, endothelium, intestinal, vascular, and smooth muscle 
cells (Horton, 1997; Wilder, 2002).  
  αVβ3 mediates cell adhesion to a broad range of ECM ligands by recognising the 
conserved Arg-Gly-Asp (RGD) sequence. Peptides containing RGD motif were one of the 
first targeted peptides discovered via biopanning. It has been demonstrated that phage 
selected from a phage display library against the αVβ3 (Healy et al., 1995) and  αVβ5  
(Koivunen et al., 1995) predominantly contain the RGD peptides. The residues flanking 
the RGD motif however were quite heterogenous (Healy et al., 1995), proving the 
capability of the  αVβ3 in recognising broad range of peptides.  
 RGD containing peptides have been used in gene delivery research. For example, 
Colin et al. (Colin et al., 1998) investigated the use of RGD-oligolysine ([K]16RGD) cyclic 
peptide in gene delivery into non-cystic ﬁbrosis and cystic ﬁbrosis human tracheal cells. 
They reported an increase in the transgene expression in the cells when using the peptide 
and further increase in the gene transfer efficiency when the peptide was combined with 
the liposome lipofectamine. One of the most extensively used RGD peptides to date is the 
peptide CDCRGDDCFC (RGD-4C), which was isolated from selection of phage library on 
     
  133 
purified αVβ5 immobilised on a solid support. This peptide has been shown to be a potent 
inhibitor of αVβ5- and  αVβ3 -mediated cell attachment to vitronectin (Koivunen et al., 1995) 
and has since been used in many research area including for targeting, imaging and 
treating tumors (Wang et al., 2008).   
 It has been demonstrated that the upregulation of αVβ3 and αVβ5 on human 
monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery by 
promoting the binding of penton base protein through the RGD motifs (Huang et al., 
1995). This is interesting as the ultimate goal of this study is to target DC for gene 
delivery; thus, any peptide selected against MCF7-αVβ3 cells could also be used to target 
monocytes, which in turn could be differentiated into DC.  
 Phage library panning against MCF7-αVβ3 cells yielded a complex mixture of 
peptides. This observation was expected, as a cell type have thousands of different 
receptors and each capable, in theory, of pulling a ligand out of the library. Interestingly, 
out of 20 clones selected, two clear consensus motifs of SS and VGY are present in nine 
clones and two other clones, respectively. These peptide phage clones however, have 
different binding ability towards the cells. ELISA and flow cytometry analysis have shown 
that only 4p clone, which has peptide sequence of CLSSPALLC, has a high binding ability 
to the cells compared to other clones and streptavidin control clone.  
 The binding specificity of 4p phage was tested using other cell lines. Anti-αVβ3 
antibody staining and flow cytometric analysis showed that there is a low level of αVβ3 
expression on the surface of HEK293 cells but no detectable level on U-937 and THP-1 
cells. Previous reports have demonstrated low level of αVβ3 expression in HEK293 cells 
(Bodary and McLean, 1990), but not in THP-1 cells (Wang and Fu, 2001) and U-937 cells 
(Dou et al., 1997). However, there are also contradicting reports on THP-1 cells (Reyes-
Reyes et al., 2002) and U-937 cells (Buckley et al., 1996) having low level of αVβ3 
expression. Flow cytometry analysis and confocal microscopy carried out showed that the 
MCF7 cells (MCF7-control cells) in our acquisition have a low expression level of αVβ3 
integrin. Published reports have demonstrated contradict findings on the level of αVβ3 on 
MCF7 cell lines. Lord and colleagues reported a very high level of αVβ3 integrin 
expression in MCF7 cells (Lord et al., 2006), whereas others revealed that MCF7 cells do 
not express αVβ3 integrin (Doerr and Jones, 1996; Wong et al., 1998; Deryugina et al., 
2000; Morozevich et al., 2004; Xiong et al., 2006). 
 Flow cytometry analysis has shown that 4p phage can bind MCF7-αVβ3 cells but 
not HEK, U-937 and THP-1 cells, suggesting that the binding of 4p phage towards MCF7-
αVβ3 could be due to the highly expressed αVβ3 on the cells surface. However, there is 
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also a possibility that 4p phage is not reactive to the αVβ3 integrin and that the binding of 
4p phage to the cells is due to interaction with other molecules on the cells surface or 
other receptors which expression may have also been upregulated during the stably 
transfection of the wild type MCF7 with the integrin. The best way to investigate whether 
the binding of 4p phage is through the interaction with the αVβ3 integrin or not, is to use 
purified αVβ3 protein in a flow cytometric assay.  
 When targeting a specific receptor of interest, the best strategy is to elute bound 
phage with a known ligand or to carry out subtractive panning with cells that do not 
express the receptor (Palmer et al., 1997). The latter strategy can ideally be 
accomplished by having two cell lines, identical except for the presence or absence of the 
receptor of interest. Subtractive panning involves a depletion step, which is followed 
subsequently by a selection step. The phage are incubated first with cells without the 
receptor of interest (depletion step). The cells and the bound phage are separated from 
the non-bound phage and removed by centrifugation. The supernatant, which contain the 
non-bound phage are collected and added onto the cells that express the receptor 
(selection step). Phage that bind to this cells are eluted and used in the next round of 
panning.  
 As discussed previously, the MCF7-control cells in our acquisition demonstrated 
low expression level of αVβ3 integrin. Panning of RGD peptide phage contaminated with 
an irrelevant phage against these two cell lines had proven that the MCF7-control cells 
were also capable of pulling out the RGD peptide phage (data not shown). In this 
particular experiment, the RGD peptide phage were contaminated with helper phage and 
the mixture were used as input phage panned against both MCF7-αVβ3 and MCF7-control 
cells. The bound phage were eluted using 0.2 M Glycine-HCl (pH 2.2) buffer and the 
eluted phage were titrated and plated on IPTG/XGal plates. The RGD peptide phage 
formed blue plaques while the helper phage formed colourless plaque on the plates. In 
addition, ELISA (data not shown) as well as single phage clone panning experiment also 
showed that the RGD peptide phage bind to the MCF7-control cells, although with a lower 
binding ability compared to the MCF7-αVβ3 cells. Therefore, the best approach in 
performing subtractive panning is against a control cell line lacking αVβ3 such as M21L 
cells.  
 At present, DC-targeting gene delivery strategies are hindered by the lack of DC-
specific target molecules. We, therefore, aim to isolate and identify new ligands that bind 
to immature DC, and not other cells, and that bind molecules capable of internalising on 
iDC, as such peptides are likely to be more efficient in gene delivery.  
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 There have been several reports on the identification of peptide specific to antigen 
presenting cells (APC), particularly dendritic cells by using phage display approach. 
Richards and colleagues (Richards et al., 2003) have identified linear peptides with 
potential applications for antigen delivery to CD40-positive APC. The peptides contained 
a novel FPGN/S consensus sequence that binds to murine CD40. In their study, these 
peptides were found to improve phage binding to a purified murine CD40-immunoglobulin 
fusion protein (CD40-Ig), but not to Ig alone. In addition, Curiel and co workers have 
identified small peptides of 12-mer that specifically bound to human DC (Curiel et al., 
2004). They have further shown that these DC-binding peptides, i.e. peptide 3 
(FYPSYHSTPQRP), peptide 12 (AYYKTASLAPAE) and peptide 18 (SLSLLTMPGNAS), 
bound to distinct, saturable DC surface epitopes without modulating the phenotype and 
function of these cells.   
 In phage display selection aiming at isolating DC phage, two subtractive pannings 
were carried out using PBMC and subsequently CD14+ cells prior to selection against 
iDC. Peptide analysis of all clones selected after panning revealed a diversity of peptides 
with no consensus sequence. Flow cytometry analysis of nine unique peptide phage 
clones showed that two clones, DC4.25 (CFPPTFPAC) and DC4.44 (CTPLLSPFC) have 
the highest binding ability towards iDC. These two clones has very little binding towards 
CD14+ cells and do not bind to PBMC, two monocytic cell lines THP-1 and U-937, 
HEK293 and MCF7-αVβ3 cells. In addition, single phage clone panning experiment 
showed that DC4.44 phage eluted is 2 times more than that of DC4.25 phage and that 
only a small fraction of streptavidin clone were eluted, indicating the binding ability of both 
DC phage clones towards iDC with DC4.44 having superior ability than DC4.25.  
 Peptide sequence comparison analysis of DC4.25 and DC4.44 with that of 
published by Curiel and co workers revealed similar motif of PA shared between DC4.25 
and peptide 12. On the other hand, DC4.44 shared motif TP with peptide 3 and motifs LL 
and LS with peptide 18. On the other hand, DC4.25 contain the first two motif of the novel 
consensus sequence revealed by Richard and his group, i.e. motif FP. 
 Phage display-derived peptides have been demonstrated to increased efficiency of 
gene transfer into dendritic cells (Writer et al., 2003). Peptides that bind immature 
monocyte-derived human dendritic cells were selected from a random constrained 7-mer 
peptide phage display library. The peptides were synthesised in the form 
[K]16GACRRETAWACG and were used in lipopolyplex vectors. The authors have 
demonstrated that when human dendritic cell line was transfected using this vectors, the 
peptides improved the percentage of cells transfected by approximately 1.5 times from 
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that seen with a vector bearing an integrin-binding peptide. Although there is no similar 
motif shared between this published peptide with either DC4.25 or DC4.44, it indicates the 
feasibility of using peptides identified using phage display in gene delivery vector. 
 
8.2 Internalisation of phage into target cells 
Cellular uptake can be assessed by using different methods (Madani et al., 2011). 
Often, a combination of several methods and techniques are required before any 
conclusion can be made, as there is no particular method that can provide a definitive 
answer. 
Flow cytometry is one of the methods that have been used to study internalisation. 
Using this method, phage or peptides are stained or conjugated with a fluorophore and 
the fluorescence signal is determined. However, the surface bound phage must be 
removed, as fluorescence analysis cannot discriminate between surface bound and 
internalised signals, and will give rise to false positive if the surface bound signals are not 
properly stripped.  
The same principle applies when the recovery of phage from within the cells is 
used as a measurement of internalisation. This method involves the use of a stripping 
buffer to remove surface bound phage and subsequently of a lysis buffer to enable the 
recovery of the endocytosed phage.  Therefore, a very good stripping buffer and lysis 
buffer are essential when using this method in assessing internalisation. Ideally, a 
stripping buffer must be able to remove at least 90% of the total surface bound phage and 
a lysis buffer must be able to lyse cells without causing any significant phage death. 
 Temperature is vital when measuring internalisation as it may affect the binding 
and the cell uptake of a ligand. Some ligands will not bind well at low temperatures. 
Others will bind, but not be taken in. Reports have demonstrated the differences in cell 
uptake rate when different temperatures were used. It has been demonstrated that the 
cellular uptake of R8 (octa-arginine) and DR8 (octamer of D-arginine) peptides was 
significantly reduced when incubated at 4°C as compared to at 37°C (Nakase et al., 
2004). In addition, it has been reported that the internalisation of surface-bound 125I-
Man46-BSA by alveolar macrophages was absent at 10C or below, while a maximal 
internalisation of 60-70% of the ligand occurred at 35C (Tomoda et al., 1989). Moreover, 
the uptake of (Arg)9 and Tat peptides were shown to be severely impaired by incubation 
of cells at 4°C (Richard et al., 2003). It has been generally accepted that the process of 
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cell uptake is either slowed down or prohibited at 4°C, although does not apply to all 
ligands. 
 In this study, phage bound to target cells have been shown to be taken up by the 
cells and can be recovered in infectious form from within the cells. At 37C, the highest 
percentage of phage internalised by MCF7-αVβ3 cells was the RGD peptide phage 
followed by the 4p phage and the streptavidin phage. This is expected as the RGD 
peptide phage contain the RGD motif that is well recognised by the αVβ3 integrin for 
specific binding. In iDC, the most endocytosed phage was the DC4.25 phage, followed by 
the DC4.44 phage and the streptavidin phage. At 4C, the percentage of internalisation of 
phage is below 10% in both MCF7-αVβ3 cells and iDC.  
 As the efficiency of the stripping buffer used in this study could not be measured 
quantitatively accurate, there is a possibility that the phage fraction that was recovered 
from within the cells (cell lysate fractions) contain some surface bound phage. Therefore, 
another method was utilised to assess the internalisation of the phage by the target cells. 
 Confocal microscopy is another widely used method in assessing internalisation.  
By using this method, intracellular localisation of a ligand that has been taken up by the 
cells can be monitored. The extracellular and internalised phage can also be 
discriminated, using different fluorophores and markers. However, confocal microscopy 
has its limitation when it comes to statistical analysis, due to small number of cells being 
assessed (Madani et al., 2011).  
 Confocal microscopy images showed that the presence of the phage in the cytosol 
was more evident when the cells were incubated at 37C compared to at 4C, suggesting 
that there is more cell uptake at 37°C than at 4°C. Interestingly, in iDC the phage were 
more concentrated around the cells at 4°C but appeared to be more spread out all over 
the cytosol at 37°C, insinuating more phage remained bound to the plasma membrane 
cell than be internalised at 4°C.  
 Confocal microscopy images also showed that the internalised 4p phage and DC 
phage co-localised with the endosomes in the cytosol, judging by the overlapping of some 
green fluorescence representing the phage with the red punctate staining pattern 
consistent with the cytoplasmic distribution of the endosomes. 
 Co-localisation of phage and endosomes has been widely used as an evidence of 
endocytosis of phage selected from phage libraries by target cells. For example, Hart and 
co workers created hybrid fdRGD phage using high affinity, integrin-binding cyclic peptide 
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sequence GGCRGDMFGC and demonstrated that the hybrid phage bound to and were 
internalised by HEp-2 tissue cultured cells (Hart et al., 1994). They found out that the 
hybrid phage also localised within vesicles and that the vesicles containing phage were 
seen near those containing transferrin receptor, which is recycled between the endosomal 
compartment and the cell surface, but not with the surface marker. Other group has 
shown that phage displaying anti-ErbB2 antibody fragments have been internalised 
specifically by ErbB2 expressing SKBR3 cells and localised at the endosomes (Becerril et 
al., 1999).  
 It has been reported that cell fixation, even in mild conditions, affects intracellular 
distribution of peptides (Richard et al., 2003). Richard and his group investigated the 
cellular uptake of Tat and (Arg)9 peptides in fixed and unfixed HeLa and CHO cells. The 
cells were fixed using 3.7% (v/v) formaldehyde in NaCl/Pi for 5 min at room temperature. 
They found out that fixation changed the distribution of the peptides, resulting in apparent 
nuclear localisation. However, in assessing phage internalisation in this study, the cells 
used must be fixed and permeabilised in order for anti-M13 antibody staining of the 
internalised phage to be carried out. Therefore, it is worthy to repeat confocal microscopy 
experiments using soluble peptides conjugated with a fluorophore such as Alexa-488, 
which will not require any fixation. 
 
8.3 Binding of the biotinylated peptides to iDC 
The experimental findings that both DC4.25 (CFPPTFPAC) and DC4.44 
(CTPLLSPFC) phage could bind to, and be internalised by the target cells, iDC, 
demonstrated great potential of both sequences to be developed into targeting molecules 
for gene delivery. Soluble biotinylated peptides, which contain the encoded peptide 
sequences, were synthesised along with the scramble-displayed sequence control 
peptides.  
 The ability of the peptides to bind to iDC was first tested at monomeric level. Flow 
cytometric analysis detected non-specific binding of the monomeric peptides to iDC when 
used at high concentration. In an effort to increase the binding avidity of the peptides to 
iDC, the biotinylated peptides were coupled with Streptavidin conjugated with Alexa-488® 
flurophore. A modified HABA/Avidin assay was carried out, initially to determine the 
optimum ratio of biotinylated peptides to streptavidin for the formation of the complexes. 
However, the assay indicated that the first batch of biotinylated peptides synthesised were 
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defective, although the mass spectrophotometry analysis data showed that the peptides 
were correctly synthesised (data not shown).  
 The second batch of biotinylated peptides synthesised were functional as 
indicated by the HABA/Avidin assay. Peptides-streptavidin complexes were made using 
ratio identified using HABA/Avidin assay. However, flow cytometric analysis revealed that 
the complexes also bound non-specifically to iDC, as binding was also seen in control 
peptides.  
It is then thought that the peptides may actually bind to iDC but to a very low 
density target molecules that cannot be seen or detected by flow cytometry. Therefore, 
Streptavidin conjugated with horseradish peroxidase (HRP) was then used to form 
complexes with the peptides, in order to increase the sensitivity of the binding assay. The 
HRP enzyme, which is found in horseradish, is used extensively in biochemistry 
applications primarily for its ability to amplify a weak signal and increase detectability of a 
target molecule. In the presence of a substrate, the HRP enzyme produces a detectable 
signal, which can be quantified (reviewed in (Veitch, 2004). However, the results 
corroborated the previous findings, which showed that the peptides bound iDC non-
specifically. 
 Several investigations were carried out in order to elucidate ways of reducing the 
undesired non-specific binding of streptavidin to iDC, but all failed to resolve the problem. 
The non-specific binding did not happened through interaction with biotin or biotin-like 
molecules on iDC, suggesting that streptavidin binds to other molecules on iDC. Reports 
have demonstrated that streptavidin contains an Arg-Tyr-Asp (RYD) sequence, which 
exhibits structural homology to the Arg-Gly-Asp (RGD) cell adhesion domain of fibronectin 
(Alon et al., 1990). It was also reported that this binding is enhanced in the presence of 
biotin (Alon et al., 1992). Cell-bound streptavidin can be displaced by fibronectin, as well 
as by RGD- and RYD-containing peptides, indicating that streptavidin binds to cells via 
this site and that the binding is independent of biotin recognition (Alon et al., 1992; Alon et 
al., 1993a; Alon et al., 1993b). Therefore, proper controls are important when setting up 
binding experiments involving biotin-streptavidin interaction to avoid artifacts of false 
positive.  
The failure of the synthetic peptides to bind to iDC might be due to a number of 
reasons. It could be that the peptides are not specific to iDC. It could also be that the 
sequences that are essential and accountable for the binding are insufficiently 
incorporated into the synthetic peptides, causing failure to bind to iDC. Furthermore, it 
could be that the peptides synthesised fail to retain the cyclised conformation, such that 
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they no longer resemble the binding site for interaction like in phage. As each peptide in 
the library is being constrained in a disulfide loop, maintaining the loop structure may be 
essential for the binding. 
Another approach that can be used to further examine the ability of the peptides to 
bind iDC is by competition experiment using respective phage isolated against iDC. In this 
experiment, iDC will be incubated with the biotinylated peptides for 1 hour at 4°C to allow 
binding. Phage will then be added to the cells and incubated for another 1 hour at 4°C. 
Anti-M13 antibody conjugated to a fluorophore will be used to stain the phage and the 
fluorescence signal will be detected using flow cytometry. Control samples would be cells 
incubated with phage alone, without peptides pre-incubation. The fluorescence signal 
amplified from anti-M13 antibody staining is greater than the signal of biotinylated 
peptides. In addition, the phage have been proven to bind iDC, as demonstrated in the 
previous results chapters. Therefore, it is more advantageous that the cells are pre-
incubated with the peptides and not with the phage. 
Several conclusions can be deduced from this inhibitive experiment. If the binding 
of the synthetic peptides were specific to iDC, the fluorescence signal or the MFI of the 
samples with peptides pre-incubation would be less compared to that of the control 
samples. This is because, the binding sites on iDC have been occupied by the peptides. 
Conversely, should the fluorescence signal or the MFI of the samples pre-incubated with 
the peptides equals to that of the control cells, it suggests that the peptides do not bind 
the same sites on iDC. 
 Although the end experiment in this study demonstrated non-specificity of the 
peptides identified to the target cells, this approach does offer the possibility of identifying 
cell binding peptides that may allow delivery of genes and other therapeutic or imaging 
agents. 
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